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Summary
Blood platelets are small, anucleate cells which circulate 
freely in the cardiovascular system. One of their major 
physiological functions is concerned with haemostasis - the 
cessation of bleeding. However, platelets are also involved 
in the pathological counterpart of haemostasis - thrombosis. 
Platelets are derived from megakaryocytes which are large 
nucleated cells located in the bone marrow.
In view of the contribution of platelets towards thrombosis 
(predominantly arterial thrombosis) for many years the search 
for novel antithrombotic agents has centred largely on drugs 
that impair platelet function. However, evidence now exists 
suggesting, that besides acting at the level of the platelet, 
some potential antithrombotic drugs, such as aspirin, act 
elsewhere in the body since the duration of action of aspirin 
long outlasts the time after this drug would be removed from 
the body. In addition the duration of aspirins inhibitory 
effect on platelet icosanoid biosynthesis exceeds the platelet 
lifespan. This further implies that aspirin can influence 
platelet reactivity by effects other than on the platelet 
per se, presumably by acting at the platelet progenitor cell, 
the megakaryocyte.
In order to exert an effect, drugs, per se, must interact 
with some receptor or influence the component processes 
triggered by receptor occupancy which lead to cellular activation. 
If antithrombotic drugs are in fact able to act at the level 
of the megakaryocyte as well as the blood platelet, then
- X V l l l  -
similar receptors or component processes must exist in both 
these cell types* This thesis attempted to address this 
possibility by investigating the nature of the transduction 
processes in both rat platelets and RPM, a cell line resembling 
normal rat promegakaryoblasts.
Much evidence has accumulated in recent years suggesting 
that the transduction process operating in a number of different 
cell types, including human platelets, involves the agonist- 
induced metabolism of inositol phospholipids - especially 
Ptdlns(4,5)^2 “ with the consequent formation of 1,2-diacyl- 
glycerol and Ins(l,4,5)P3• Both 1,2-diacylglycerol and 
Ins(l,4,5)P3 are believed to act as synergistic second 
messengers - the former by activating protein kinase (resulting 
in the phosphorylation of a 4OK protein, the latter by mobilizing 
Ca^ **" from intracellular stores.
The transduction processes or receptor mechanisms existing 
in both rat platelets and RPM were investigated using Thrombin 
and a range of purines. Metabolism of inositol phospholipids 
was assessed principally as L^^p3 PtdA formation or dis­
appearance of Ptdlns(4,5)P^> in cells prelabelled with
32^1 _ . . .P^ or as the accumulation of inositol phosphates
in cells prelabelled with inositol. Agonist-induced
changes in cytosolic free calcium, Ca^^ were monitored 
using Quin 2. Using this approach, the major findings and 
conclusions reached were;-
(1) In rat platelets. Thrombin »ADP elicited, in a concentration 
dependent manner, the metabolism of inositol phospholipids.
- XIX -
as monitored by PtdA formation and elevation in[ca^t]^,
as monitored by Quin 2. As the extent of PtdA formation
and elevation of  ^ induced by Thrombin exceeded that
evoked by ADP, it can be concluded that Thrombin was a more 
potent and more efficacious agonist than ADP.
(2) In RPM, ADP > Thrombin elicited, in a concentration-dependent 
manner, the metabolism of inositol phospholipids as monitored
by fp^P^ PtdA and elevation of as monitored by Quin 2.
As the extent of PtdA formation and elevation of |^Ca^^ ^
induced by ADP exceeded that elicited by Thrombin, in this 
system ADP is the more efficacious agonist.
(3) In rat platelets, but not RPM, both Thrombin and ADP 
elicited the rapid disappearance of Ptdlns (4,3)P2* 1^
RPM, but not rat platelets, both Thrombin and ADP induced a 
significant accumulation of inositol phosphates.
(4) ¥hile attempting to characterise the nature of the "purino- 
receptor” on rat platelets and RPM it was found that the rank 
order of potency (EC^^) of a range of purines at eliciting 
inositol phospholipid metabolism and elevation in [.Ca^^ J
in both rat platelets and RPM was ADP > ATP »  AMP > Adenosine 
= 0. In rat platelets ATP was a partial agonist when agonist- 
induced i^^P^ PtdA formation or elevation of were
monitored, whereas both ADP and ATP are full agonists in RPM. 
Consequently the possibility exists that a distinct and separate 
receptor for purines exists on rat platelets and RPM.
- XX -
These results would indicate that receptors for both 
Thrombin and ADP (ergo purines) are expressed on both rat 
platelets and RPM. When occupied these receptors are coupled 
to the metabolism of inositol phospholipids and elevation of 
The rank order of potency for purines acting on 
the ’’purinoreceptor” appears to be ADP > ATP »  AMP > Adenosine 
= 0. Since ATP is an antagonist at the ADP receptor on human 
platelets, the possibility exists that the rat platelet and 
RPM ’’purinoreceptors” is distinct from the receptor on human 
platelets.
TO MY MOTHER AND FATHER
— 1 —
1. INTRODUCTION
1.1 Blood Platelets
Blood platelets are small, anucleate cells which circulate 
freely within the cardiovascular system. Many scientists, 
throughout the ages, were intrigued by blood coagulation and 
thrombosis and the nature of cells purported to be involved 
in such processes. However, it was not until 1881 that 
Bizzozero demonstrated, that the corpuscular element involved 
in thrombosis was related neither to the red cell nor the 
white cell but was of independent origin. He designated 
this cell a platelet. Almost a hundred years later Born (1962) 
described a turbidometric technique for measuring platelet 
reactivity in the laboratory which heralded a flood of 
investigation into platelet biochemistry, physiology and 
pharmacology.
Platelets from most species circulate in blood as biconvex 
discs approximately 2-3 P- diameter. They are derived 
from large, nucleated cells named megakaryocytes which are 
located in bone marrow. Their derivation from megakaryocytes 
was demonstrated by Wright in I9IO and is the topic of the 
following section (Section 1.2). Platelet count, rate of 
production and life span vary with animal species. For
g
example, the platelet count in human whole blood is 2-4 x 10 /ml, 
while in rat blood it is approximately 1-2 x 10^/ml. The 
normal turnover rate of human platelets is about 3*5 x 10 /ml/ 
day (Barker and Finch, 1969)* Smaller mammals such as mice 
and rats usually have a faster turnover. Finally the life
— 2 —
span of platelets in man is about 10 days, while in rats 
it is approximately 4-5 days. Platelets are removed from 
the circulation either by involvement in haemostatic plug 
formation or when senescent by sequestration in the liver 
or reticuloendothelial system in the spleen. The spleen also 
contains a pool of viable platelets that can be released into 
the circulation.
1.1.1 Platelet Morphology
Although conventional optical microscopy revealed that 
platelets underwent a morphological transformation in their 
conversion from the quiescent to activated state, the advent 
of electron microscopic techniques allowed the identification 
of the "machinery" involved in the platelet activation process. 
Figure 1 illustrates the major structural features of the 
platelet. The platelet plasma membrane is rich in glycoproteins, 
which when stained with lanthanum, gives a characteristic 
fuzzy appearance to the platelet surface coat or "glycocalyx".
The glycocalyx is associated with the outer surface of the 
plasma membrane, the latter having a typical trilaminar lipid 
structure.
Subjacent to the plasma membrane, in the equatorial plane 
of the resting cell is a bundle of microtubules which forms 
a peripheral ring round the platelet. This microtubule band 
appears to be a flexible cytoskeleton exerting tension outward, 
producing the typical * discoid* shape of the platelet (White 
and Gerrard, 1979)» Consistent with this, selective
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depolymerization of microtubules converts the cell to a more 
spherical form. When platelets are activated, the peripheral 
microtubule band becomes constricted, and microtubules can 
also be visualized within pseudopodia (White and Gerrard,
1979) (vide infra). Other elements of the platelet structural 
and contractile apparatus include actin and myosin (see 
Crawford, I983) which are important for pseudopod formation, 
internal contraction, granule labilization and secretion, and 
clot retraction (Cohen aJ^ . , 1979)»
Within the cytoplasm of the platelet various granular 
organelles exist. The main types include the*dense granules* 
and the *a-granules*. Dense granules from human platelets 
contain calcium, pyrophosphate, ADP, ATP, serotonin and possibly 
antiplasmin (Holmsen, 1975; Joist ejk aJ. , 1976). About 65^ 
of human platelet ADP and ATP is stored in dense granules.
This is known as the * storage pool* of adenine nucleotides 
and may be secreted during platelet activation, but does not 
exchange readily with the remaining 359^  of adenine nucleotides 
which form the cytoplasmic "metabolic pool" (Holmsen and Weiss, 
1979)" Based on the observation that enzyme systems removing 
ADP, such as pyruvate kinase/phosphoenolpyruvate can inhibit 
aggregation induced by certain agents (Haslam, 1964) a role 
for released ADP in mediating platelet activation induced by 
other platelet agonists has been proposed. However, while 
release of ADP clearly can be demonstrated during platelet 
activation induced by Thrombin or Adrenaline (Mills et al.,
1968; Grette, I962) the observation that ADP is not detected
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during the first phase of aggregation induced by the same 
agents, but is detected during the second phase (Mills et al., 
1968; Hardeÿty e_fc ad., 1970) is incompatible with a universal 
role for ADP in platelet aggregation. Nevertheless, agonist- 
induced release of ADP probably is important in recruiting 
additional platelets to an aggregate thus perpetuating 
platelet aggregation (See Holmsen, 1977)* The other main 
constituents of dense granules (Ca^* and 3HT) probably 
subserve a similar role in perpetuating platelet activation. 
Secreted calcium, for instance, may provide a high local 
concentration immediately extracellularly to facilitate 
platelet-platelet cohesion (see Gerrard ejfc a^., I98I). Platelets 
do not synthesise 5HT, but actively scavenge it from plasma. 
Secreted 5HT could possibly recruit the activity of additional 
platelets during haemostasis by acting on cell surface receptors.
The other main type of storage organelle whose constituents 
are secreted when platelets are stimulated are known as the 
a-granules. The contents of these granules are largely protein 
in nature and it appears that they may be heterogenous with 
respect to their capabilities to store different proteins 
(Holmsen and Weiss, 1979)* Two of the constituents of a- 
granules, namely platelet factor four (PP4) and to a lesser 
extent be ta-thrombo globulin (I^ TG) have antiheparin activity.
The role of these secretable proteins in hemostasis is largely 
unknown, but Walsh ejfc ad. (1974) have suggested they might 
promote plasmatic coagulation around platelet hemostatic plugs 
by neutralising heparin locally. Platelet derived growth 
factor (pDGF), another constituent of a-granules, is a low
— 6 —
molecular weight basic protein and has been implicated as 
causative in promoting atherosclerosis (Packham and Mustard, 
1986; see Section
Other constituents of the a-granules include certain 
coagulation factors including factor V and fibrinogen. (Pifer 
et ad., 1977; James ^  ^ .  , 1977; Kaplan ejb ad., 1979a).
Factor V is believed to be an essential cofactor in the 
generation of thrombin from prothrombin in the presence of 
.factor Xa (Nesheim ejfc ad., I980) and thus plays an integral 
role in blood coagulation. Besides generating fibrin strands, 
which help consolidate haemostatic plug formation (see Section 
1:1:4), fibrinogen is thought to play an important role in 
blood coagulation by promoting platelet-platelet attachment 
during platelet aggregation (Bennett and Vilaire, 1979;
Mustard ejt ad., 1978; Marguerie ejb ad. , I985) an event crucial 
to the development of haemostatic plug formation. Addition of 
platelet agonists is thought to induce a single class of 
fibrinogen receptor on the surface of platelets (Marguerie 
et al., 1983)* Although direct evidence of the nature of the 
fibrinogen receptor has yet to be demonstrated, there is reason 
to believe that glycoproteins G P U  b and G P U  la constitute the 
binding site for fibrinogen (Marguerie ejt ad., I983). Thrombo- 
spondin (tSP), a large glycoprotein, is also found in a-granules 
(McLaren, I983; Hagen, 1973)* Much evidence exists suggesting 
that this compound serves to stabilize fibrinogen binding to 
the activated platelet surface and reinforces the strength 
of interplatelet interactions (Leung, 1984; Silverstein ejb ad. ,
1986).
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Other types of granules located in the cytoplasm are 
lysosomes and glycogen granules. The former contain a number 
of degradative enzymes including cathepsins and other proteases 
and hydrolases (Ehrlich and Gordon, 1976). These degradative 
enzymes may be of importance in platelet phagocytic processes, 
and perhaps also in platelet interactions with subendothelial 
surfaces (Ehrlich and Gordon, 1976). The smallest and most 
numerous granules in platelets are the glycogen granules; 
their abundance contrasts with the paucity of platelet 
mitochondria, and this distribution is consistent with the 
platelets* metabolic energy being derived mainly by glycolysis 
rather than oxidative phosphorylation. However, platelet 
mitochondria can help in providing synthesis of ATP which is 
essential for most platelet functions (Holmsen, 1977a).
Two other important structures are the surface-connected 
canalicular system (SCCS) and the network of dense tubules.
The SCCS is an invagation of the plasma membrane and in 
transverse sections may give the appearance of vesicles rather 
than invagations. It appears to serve as a conduit through 
which secreted granule contents pass to the cell exterior 
(white, 1974). The dense tubular system, a smooth endoplasmic 
reticulum, is strongly implicated as a major site of sequestration 
of calcium within platelets and may be analogous to the 
sarcoplasmic reticulum of muscle (White, 1972; Dean and 
Sullivan, 1982; Cutler ejfc al. , 1978; Menashi aJL. , I982).
The dense tubular system is also the major site of platelet 
prostaglandin and thromboxane synthesis (Gerrard ejt aJL. , 1976; 
Hammarstrom and Falareteau, 1977)* Since the dense tubular
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system probably is the major source of intracellular calcium 
used during platelet activation, it is conceivable that these 
icosanoids could be involved in mobilizing this store of 
calcium. Such a role was ascribed to thromboxane by 
Gerrard and coworkers (1978). However, this claim has been 
disputed (see Menashi et al., 1984).
1.1.2 Platelet energy metabolism
Platelets are anucleate cells that do not perform many 
energy requiring anabolic processes, but utilize large amounts 
of energy during execution of their agonist—induced responses 
(Akkerman, 1979; Holmsen, I982). These cells contain a well 
developed glycolytic system for ATP production (Holmsen, 1972) 
and although glucose is the preferred substrate, other sugars 
such as manose, fructose and galactose can be utilized, but 
ten times less effectively than glucose. That ATP was mandatory 
for platelet reactivity was elegantly demonstrated in studies 
where platelets were starved of glucose (Akkermann et al.,
1983)» These experiments revealed that starved platelets 
have low levels of available ATP and do not respond to stimuli : 
refeeding of the starved cells markedly elevates the ATP 
availability with a concerted reappearance of responsiveness. 
Platelets can not synthesize adenine nucleotides de novo, but 
they can synthesize them from adenine, adenosine and hypoxanthine. 
The store of metabolic adenine nucleotides used in platelet 
activation is that located in the cytoplasm.
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1.1.3 Platelet functional responses
In 1962 Born described an optical technique to monitor 
platelet aggregation under experimental conditions. Since then 
numerous techniques have been developed to enable study of a 
variety of platelet functional responses occurring after 
exposure to stimuli. These responses extend to (i) shape 
change; (ii) adhesion; (iii) aggregation; (iv) icosanoid 
synthesis and (v) secretion. Regardless of the initiating 
stimulus, platelet activation appears to follow a similar, 
sequential pattern of response similar to that noted above. 
However, this is not because each depends on the former one 
but because of the order of their dependence on second messenger 
concentration/ATP requirement. Such a pattern of response led 
Holmsen (1974) to propose the hypothesis of "the basic platelet 
reaction”. Simply stated, depending on the initiating stimuli, 
different amounts of second messenger will be formed which 
will independently trigger the different platelet functional 
responses; increasing amounts of ATP will be utilized as 
platelet reactivity continues.
A brief account of the platelet functional responses is 
given below. The nature of the second messenger involved in 
platelet activation is discussed in Sections 1.3*i«3 - 1.3*1*8. 
1.1.3*1 Shape change
Most stimuli, including Thrombin, ADP, calcium ionophore 
A23I87, cause a change in shape. This change involves first 
the formation of very fine (o.l ^m diameter) pseudopodia 
(consisting mostly of actin) from the rim of the disc, followed
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by a general ’'rounding up" of the platelet so that it becomes 
a spiny sphere, often with much broader pseudopodia. In 
human platelets adrenaline fails to initiate shape change 
(Mills, 1973)* Instead small protrusions qualitatively 
dissimilar to those evoked by other platelet agonists is 
observed. The second step in shape change, the change from a 
disc into an irregular sphere, is correlated with the 
phosphorylation of platelet myosin, specifically the 2OK 
light chain (Daniel ^t al., 1984). Shape change, with or 
without secretion, causes the microtubule bundle that lies 
beneath the rim of the disk to become centralised and surround 
the platelet granules, which consequently are concentrated 
toward the center of the platelet (White, 1974). Unlike
2+aggregation, shape change can occur in the absence of Ca
in the bathing medium (McLean and Veloso, I967) suggesting that
2+the internal contractile proteins must utilize Ca from 
internal stores, such as the dense tubular system.
1.1.3*2 Adhesion
Under normal conditions the discoid platelets circulate 
freely within the cardiovascular system and do not readily 
adhere to any surface they may come in contact with such as 
other platelets, other blood components (e.g. red blood cells 
or leucocytes) or vascular endothelial cells. If however a 
blood vessel wall is damaged exposing the subendothelium, 
blood platelets will rapidly accumulate on this surface 
forming a platelet aggregate and initiate the development of 
a haemostatic plug. The component of the subendothelium which
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induces platelets to aggregate has been shown to be fibrillar 
collagen (Zucker and Borelli, 1^62; Hovig, 1963)* At high 
shear rates, von Willebrand factor - a high molecular weight 
portion of coagulation factor VIII - is necessary for platelet 
adhesion to sub endothelium (Weiss ejfc aJL • , 1978)*
1.1.3*3 Aggregation
The term "platelet aggregation* describes the phenomenon 
when platelets cohere to other platelets so that platelet 
clumps are formed. Unlike shape change, aggregation has a 
requirement for fluid phase calcium (or magnesium) (Zucker and 
Grant, 1978) and fibrinogen (Bennett and Vilaire, 1979;
Mustard et al. , 1978; Marguerie ;^t aJL. , I983) * Certain platelet 
agonists, such as ADP or adrenaline, require the presence of 
this protein in the suspension medium, whereas with Thrombin 
or collagen, it is secreted from the a granules (Kaplan ejb al. , 
1979a). It is believed that Ca^^ ions and fibrinogen form 
links between adjacent platelets thereby promoting platelet 
clumping. The nature of these links was investigated by 
Gerrard ejfc al. (198I) (see also Marguerie e_fc al. , I983)* An 
additional requirement for aggregation is that the platelets 
are able to come into contact with each other; experimentally 
this can be achieved by continuously stirring a sample of 
platelets before and after agonist addition. Aggregation, 
like shape change, is usually measured using the turbidometric 
method discovered by Born (1962). With this technique, 
aggregation is measured as the increase in the transmission 
of light (as a result of platelet clumping) passed through 
a suspension of platelets. Two types of aggregatory response
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can be observed; "primary" aggregation, where platelets stick 
together and then dissociate, or "secondary" aggregation 
where platelets stick together irreversibly. The secondary 
wave of platelet aggregation usually is associated with and 
mediated by secretory products which further stimulate the 
cell beyond primary aggregation. Such positive feedback 
mediators may include released ADP, 5HT or metabolites of 
arachidonic acid.
1.1.3*4 Icosanoid synthesis
Platelets are capable of synthesizing an array of compounds 
collectively known as icosanoids (vide infra) which are of 
great importance in platelet reactivity. These compounds, 
which include thromboxanes e.g. thromboxane A^ (TXA^); 
prostaglandins e.g. PGG^ PGH^ and hydroxy acids e.g.
12-HPETE and 12 HETE, are synthesized from arachidonic acid.
The phospholipids of platelets can act as a repository for 
arachidonic acid, in particular the Sn2-position of phospho- 
inositides are especially rich in this fatty acid (Marcus 
et al., 1969). As such these compounds may act as a potential 
source of arachidonic acid for use in icosanoid synthesis.
There is evidence to suggest that in fact the phosphoinositide 
species with the highest arachidonic acid content are selectively 
hydrolysed during platelet activation (Mahadevappa and Holub, 
1983).
Release of arachidonic acid from phospholipids, in 
particular phosphoinositides, may occur by two separate routes. 
Firstly agonist-induced activation of platelets may cause the
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formation of 1,2-diacylglycerol, via the action of a specific 
phospholipase type enzyme (see Section 1.3*1*3)* This entity 
constitutes the fatty acid-containing backbone of the phospho­
lipids. Subsequent and sequential activation of di- and 
monoglyceride lipases release the arachidonic acid (Mauco 
et al. , 1984; Bell ^t al_. , 1979» Prescott and Majenis, I983)*
The second route by which arachidonic acid may be released 
from phospholipids involves the action of a phospholipase 
enzyme (Bills ct aT. , 1977; Broekman e_b al. , I98O; McKean ejfc al. 
I98I; Lapetina, I982). In passing it is prudent to mention 
that although phosphoinositides can provide a source of 
arachidonic acid, it appears that this source represents but 
a small fraction of released arachidonic acid; the majority 
being derived from phosphatidylcholine (Bills aJL. , 1977a).
Following the release of arachidonic acid it is converted 
by a lipoxygenase enzyme to 12-HPFTF and 12-HETE or by a 
cyclo-oxygenase enzyme to two labile endoperoxides, PGG^ 
and PGH^ (Hamberg and Samuelsson, 1974). These compounds are 
not stored in the platelet and are synthesized only after 
platelet activation has been instigated. The physiological 
role of the lipoxygenase products is not clear, although a 
number of physiologic effects of these compounds have been 
described. Both 12-HPETE and 12-HETE have been shown to inhibit 
in vitro (human) platelet aggregation (Aharony ejb al. , I982), 
and 12-HETE inhibits PGH^—induced platelet aggregation 
(Croset and Lagarde, I983; Lagarde ejb al. , I983)* However, 
to date, no single clear-cut function for the 12-lipoxygenase
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products has been noted. The products of cyclo-oxygenase - 
the endoperoxides PGG^ and PGH^- are converted primarily to 
thromboxane by a thromboxane synthetase (Hamberg aT. ,
1975)» or spontaneously to the degradation products 12L— 
hydroxy-5>8,10—hepatadecatrienoic acid (HHT) and malondialdehyde 
(MDA), with small amounts of PGD^, PGE^ and PGF^^ being formed 
by specific synthetases. Thromboxane A^, a very potent 
aggregating agent, has a short half life and is degraded non- 
enzymaticalTy to thromboxane (Hamberg e_t aT. , 1975)* However, 
in plasma TxA^ is more stable and has a half-life of several 
minutes (Smith ejfc aT., 1976). Addition of TxA^ to platelets 
causes shape change, aggregation and secretion (Gerrard and 
White, 1978). Receptors exist for TxA^ on platelets (see 
Jones aJ. , I985 for a review) however Gerrard e_t aJ. (l978a) 
proposed that TxA^ may act as a calcium ionophore in platelets 
and hence may not act at specific receptors. When added to 
platelets both PGG^ and PGH^ are capable of evoking platelet 
aggregation (Hamberg e_t ad., 1974). However, controversy 
exists as to whether PGG^ and PGH^ must be converted to TxA^ 
prior to activating platelets. Some researchers suggest that 
conversion is necessary (Hamberg ad., 1975; Gorman ejb al., 
1977) whereas others have stated facts to the contrary (Raz 
ejb ad., 1977)* The avaidable evidence to date suggests that 
conversion of endoperoxides to TxA^ is not a prerequisite for 
platelet activation. Based on structure-activity-relationship 
studies, and the use of selective antagonists, current evidence 
suggests that the endoperoxides and TxA^ share a common type 
of receptor, namely a TP-receptor (MacIntyre, I985; Coleman
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et al., 1984). In the absence of specific inhibitors, the 
endoperoxides are rapidly metabolised to TxA^ so that in the 
usual situation TxA^ is the major activating agent formed in 
platelets.
Other tissues, besides platelets, are capable of synthesizing 
icosanoids. Of particular importance is the production of 
icosanoids by endothelial cells (Weksler, 1984). Unlike the 
situation observed in platelets where TxA^ is the major active 
agent, endothelial cells preferentially synthesize prostacyclin 
(PGI^)» This compound is one of the most active agents at 
inhibiting platelet reactivity by virtue of elevating levels 
of cyclic AMP in platelets (Moncada et al., 1976; Tateson et al., 
1977; Moncada and Vane, 1979; Moncada and Whittle, 1985)*
PGD^ acts similarly but is less potent and since only trace 
amounts are produced it is probably less significant (Oelz 
et al., 1977)" The production of icosanoids with activating 
and inhibitory actions has led to the concept that a balance 
in production of these compounds may be critical in overall 
hemostatic function (Bunting et al., I983; Moncada and Vane, 
1979a). Imbalances in the production of icosanoids - in 
particular TxA^ and PGI^ - could potentially lead to bleeding 
or thrombotic tendencies. In this context, great use has 
been made of such agents as aspirin and indomethacin. These 
compounds are known as potent antiplatelet (antithrombotic) 
agents by virtue of their ability to inhibit the activity of 
cyclo-oxygenase by acetylating it - the former irreversibly 
(Roth and Majerus, 1975)* As a consequence the production of 
TxA^- and its consequent effects on platelet reactivity - 
are terminated.
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Agonist-induced formation of TxA^ and its subsequent 
release into the suspending medium (or plasma) may act to 
perpetuate platelet aggregation by activating additional 
platelets.(Holmsen, 1977)* However release of icosanoids, 
including TxA^, are not a prerequisite for platelet activation 
induced by all agonists. Detwiler and Huang (1980) proposed 
that two types of agonists exist, weak stimulators (ADP and 
Adrenaline) and strong stimulators (Thrombin) based on their 
susceptibility to inhibition by agents inhibiting cyclo-oxygenase. 
Thus agonists such as Thrombin are capable of eliciting full 
platelet activation in the presence of these compounds, ergo 
in the absence of endoperoxides and TxA^, whilst other agonists 
such as ADP and Adrenaline require their presence (Detwiler 
and Huang, I98O). Nevertheless, by virtue of inhibiting the 
generation of endoperoxides and TxA^, inhibitors of cyclo- 
oxygenase still remain an important group of drugs in anti­
platelet (antithrombàJrîC) therapy (Packham, I983; Weksler, 1984). 
1.1.3*5 Secretion
Secretion of the constituents of dense granules, a granules 
and lysosomes represents the last characteristic feature of 
activated platelets to be discussed. There is extreme selectivity 
in the secretion of constituents from different granules.
Holmsen and Day (l970) demonstrated that, in the secretory 
response evoked by Thrombin release from dense granules preceded 
release of a granule constituents. Consequently it was proposed 
that two phases of degranulation exist, namely release I, which 
involves release from dense granules and release II, which 
involves release from a-granules (see also Holmsen, 1977)*
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It can be demonstrated that weak agonists such as ADP and 
Adrenaline or low concentrations of Thrombin do not induce 
release of a granule contents whereas high concentrations of 
Thrombin can release constituents of both granules (Day and 
Holmsen, 1971). Release of lysosomal granule contents requires 
powerful stimuli in that ADP, Adrenaline and TxA^ fail to 
evoke release of lysosomal hydrolases, whereas Thrombin, 
collagen and A23187 are effective secretagogues. During 
platelet activation granule centralisation occurs (Section 
1.1.3*1)* However, when platelets aggregate, granules move 
to the centre of the aggregate more often than to the centre 
of individual cells (Gerrard et al., 1979)* Actual secretion 
of granule contents occurs at the SCCS which serves as a conduit 
through which secreted granule contents pass to the cell 
exterior (White, 1974). Secretion often accompanies aggregation, 
however aggregation is not a prerequisite as strong stimuli, 
such as Thrombin can induce platelet secretion in the absence 
of aggregate formation (Detwiler and Huang, I980).
1.1.4 Physiological Functions of Platelets
Blood platelets usually circulate freely within the 
cardiovascular system as inert cells. However, in response to 
tissue damage, or wounding, they become highly active and 
participate in haemostasis. This process, of stemming the 
flow of blood, is the major physiological role of blood platelets 
(Gordon and Milner, 1976).
Platelets contribute to haemostasis in two major ways. 
Firstly they form haemostatic plugs at the site of vascular
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injury and secondly they help promote coagulation which 
consolidates the plug with fibrin strands.
Formation of the haemostatic plug incorporates the
previously mentioned platelet functions, namely adhesion,
aggregation and secretion. During damage to the blood vessel
wall the subendothelium is exposed and platelets rapidly form
an adherent layer over the exposed collagen. Such platelets
2+then undergo secretion, releasing ADP, Ca ,5HT and icosanoids 
which can then stimulate and recruit additional platelets 
forming a haemostatic plug at the site of injury. Coincident 
with the initiation of haemostasis is the initiation of 
coagulation. Platelets help promote this process in three 
main ways. Firstly, the procoagulant phospholipid complex 
known as platelet factor 3 is exposed at the surface of activated 
platelets, secondly, platelets secrete procoagulant proteins 
(such as fibrinogen and platelet factor 4) from their a-granules 
when activated, and finally, they carry coagulation Factor XI 
on their plasma membrane, and this factor is activated when 
platelets come into contact with collagen. Factor V, released 
from platelet a-granules, is an essential cofactor in the 
generation of Thrombin from prothrombin during the coagulation 
cascade. Besides being a powerful activator of platelets.
Thrombin is also able to catalyse the polymerization of 
fibrinogen to fibrin thus helping to consolidate the haemostatic 
plug with fibrin strands. After stemming the flow of blood, 
the next process to occur is * repair* of vascular damage.
Certain secreted products, such as PDGF, have mitogenic properties
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and can cause the proliferation of fibroblasts and arterial 
smooth muscle cells maintained in culture (Kaplan ejfc al •, 1979a; 
Ross ejb ad., 1974; see also Ross ejb al,f 1984). This property 
of PGDF, in addition to its ability to stimulate DNA synthesis 
in a variety of confluent cells in culture (Heldin ejb a^. ,
1976; Antoniades ejb , 1979) has led some researchers to 
suggest that it may play an integral role in the development 
of atherosclerosis (Packham and Mustard, 1986; Section 1.1.3)*
Other important properties of platelets include maintaining 
endothelial cell integrity (Johnson, 1971) and clearing 
particles from the blood using pinocytotic and phagocytotic 
mechanisms.
1*1*5 Pathological functions of platelets
Besides playing an essential role in haemostasis, platelets 
also have an integral role in its pathological perversion - 
thrombosis. Other pathological processes in which platelets 
play a fundamental role are atherosclerosis and inflammation.
Stemming the flow of blood after vascular damage, by 
forming a haemostatic plug, is a normal physiological function 
of platelets. However, in certain conditions, haemostatic 
plugs or thrombi can form inside blood vessels in the absence 
of damage severe enough to cause blood loss. Thrombi can form 
in veins, arteries or chambers of the heart. In venous 
thrombosis, packets of platelets aggregate together and adhere 
to the vessel wall, particularly in the neighbourhood of valves. 
Localised coagulation follows and the intercalating strands 
of fibrin so produced form a dense network - a so-called red
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thrombus* Arterial thrombi consist of a larger platelet mass 
with fewer fibrin strands - a so-called white thrombus. The 
difference between the two types of thrombi appears to arise 
partly from the greater blood flow in arteries compared to 
veins* However, common to both types is the possibility of 
a part of the thrombus (embolus) breaking off and being swept 
into the general circulation, later to lodge in the small 
blood vessels of the lung or brain. Such occurrences represent 
perhaps one of the more serious medical complications. The 
causative factor(s) in the development of thrombi are unknown, 
but certain conditions such as immobility, or pregnancy and 
certain social habits such as smoking may predispose an 
individual to developing thrombosis.
Atherosclerosis is a process characterised by focal lesions 
of the arterial intima that consist of plaques containing 
varying amounts of fibrous tissue and lipid. The result of 
the plaque formation is localised thickening of the arterial 
wall with consequent narrowing of the vascular lumen. 
Consequences of this narrowing include cardiac, cerebral or 
peripheral ischemia which in advanced stages, can result in 
death. The aetiology of atherosclerosis is unknown, however 
dietary factors, smoking, hypertension and diabetes have all 
been implicated (Packham and Mustard, I986). The exact role 
of blood platelets in the genesis of atherosclerosis is 
unknown. They may however participate in one of several ways. 
Firstly, mural thrombi may become incorporated into the 
endothelium and develop intimai thickenings similar to 
atherosclerotic plaques. However, studies have shown that
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these plaques differ from atherosclerotic plaques which occur 
spontaneously (Craig _et a^. , 1973); hence the contribution, 
made by platelets, to atherosclerosis, through this mechanism 
is ill-defined. A second, more likely, contribution made by 
platelets to the atherosclerotic process lies in their ability 
to secrete products which may inflict changes on the endothelium. 
Atherosclerotic plaques often occur around bifurcations in the 
vasculature (Murphy et al., I962). Such disturbances in blood 
flow may result in small aggregates of platelets with 
consequent release of their granule contents. Amongst the 
constituents of a-granules are mitogens such as platelet 
derived growth factor and P-transforming growth factor. These 
compounds may be of importance in the development of athero­
sclerosis (Harker ejb aT. , 1978; Packham and Mustard, I986).
For a recent review of the aetiology of atherosclerosis and 
the possible role(s) of platelets in the development of the 
disease, see Packham and Mustard (1986).
Inflammation has been defined as a local reaction to 
injury of the microcirculation and its contents (Spector and 
Willoughby, I968). Acute inflammation is characterised by 
warmth, redness, pain and swelling. Physiologically such 
effects are mediated respectively by vasodilation and increased 
blood flow, activation of sensory nerve endings and increased 
vascular permeability. As already stated, activated platelets, 
as a result of injury, are capable of fomiing icosanoids from 
released arachidonic acid (Section 1.1.3*4). In addition to 
the endoperoxides (PGG^ and PGH^) prostaglandin is also 
formed and this compound increases vascular permeability
- 22 -
(Wallis al•; 1972; Silver et al., 1974). HETE, a substance 
formed by platelet 12-lipooxygenase, has been demonstrated 
to be chemotactic for polymorphonuclear leukocytes (Turner 
et al., 1973) further emphasizing the importance of platelet 
icosanoid formation in inflammation processes. Chronic 
inflammation is associated with tissue degradation. Platelets 
also contain protinases (Ehrlich and Gordon, 1976) and the 
possibility exists that platelet protinases may participate 
in such pathological conditions.
1.2 Megakaryocytes
Although the megakaryocyte was known to Bizzozero, it 
was not identified as the cell of origin of platelets until 
the studies of Wright at the beginning of the century. Using 
histological techniques and observing megakaryocytes vitro, 
Wright (1910) established the megakaryocyte as the source of 
blood platelets. Since then, various more elaborate techniques 
have been used in the study of these cells and in I969 Behnke, 
using electron micrographical techniques, confirmed and 
extended the observations of Wright.
Megakaryocytes are large, nucleated cells that originate 
in the bone marrow. However, the number of these cells in 
human bone marrow is very low, about 0.0379  ^of all cells.
This value is only 10^ of that recorded in bone marrow from 
the guinea pig or rat megakaryocyte (Levine, I98O). As 
technology has advanced there has been a corresponding upsurge 
of interest in these cells. Specific criteria now exist for 
the identification of megakaryocytes (Levine, I98I). They can
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be identified on the basis of (l) size. Typically these large 
cells range from between 10 p,m to 50 )im, (2) nuclear size or 
ploidy level. Unlike most other cells in the body, megakaryocytes 
are capable not only of cytoplasmic division but of : ;
: ' ^ with a resultant increase in nuclear material.
Hence ploidy levels can range from 2N - 64N, where N is the 
diploid number; (3) staining for acetylcholinesterase. Staining 
for this enzyme was once thought to be a specific marker for 
megakaryocytes, especially of the rodent species (Jackson,
1973)* However the discovery that other, non-megakaryocytic 
cells could also stain positive for this enzyme lends the 
fidelity of this as a marker for rodent megakaryocytes doubtful 
(Lepore ejfc al. , 1984). Megakaryocytes have a distinctive 
morphology and this can also be used in their identification 
(Levine, I98I; Williams and Levine, I982). The paucity of 
this cell in bone marrow in no way reflects its biological 
importance. As the precursor of platelets, its relevance to 
haemostasis is fundamental. Besides elaborating blood platelets, 
studies have also demonstrated their capacity to synthesize 
coagulation proteins such as fibrinogen, factor VIII antigen, 
platelet factor 4 and factor V. They can also take up serotonin 
(5HT) from the blood and store it in granules and impart the 
majority of functional properties to the platelet (vide infra; 
see also Schick and Schick (1980) for review on megakaryocyte 
biochemistry). Most studies on megakaryocytes have been 
performed on animal tissue primarily due to the greater numbers
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of cells obtainable from such sources (see Levine (1986) for 
a comparison of cell harvest amongst different species).
However, there is no good evidence available from the present 
literature, to suggest any major difference may exist when 
using human tissue. In order to study these cells, isolation 
from the bone marrow is required. Several techniques now 
exist for isolating and enriching megakaryocytes obtainable 
from both human and non-human sources. (Schick and Schick,
1986). Megakaryocytes also appear in blood (vide infra) and 
Morgan and Brodsky (1983) recently demonstrated the ability 
of a megakaryoblast-like cell, obtained from blood, to be 
maintained in culture, although it did not differentiate 
into a more mature megakaryocyte. Given the scarcity of 
megakaryocytes in human bone marrow, the blood as a convenient 
and ready source of megakaryocytes seems unlikely.
1.2.1 Megakaryocyte Formation
Megakaryocytes are thought to be deriyed from pluripotential 
stem cells (Ebbe, I98I). These stem cells do not seem to be 
in a proliferatiye mode, nor does it appear that homeostatic 
mechanisms regulating megakaryocytopoiesis act at this leyel 
(Ebbe, 1981).
Thus, a more differentiatied cell must therefore respond 
to changes in platelet demand. The earliest detectable 
progeny of these pluripotential stem cells capable of elaborating 
morphologically identifiable megakaryocytes appears to be 
the colony-forming unit megakaryocyte (CFU-M) (Nakeff and 
Daniels-McQueen, 1976). This cell is neither cytochemically
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nor morphologically recognizable, however it is capable of 
forming colonies of morphologically recognizable megakaryocytes# 
When appropriately stimulated, CFU-M begin to proliferate 
(Hoffman ejt , 1975)* They give rise to progeny which have 
less proliferative qualities but more characteristics of the 
mature cell they will eventually become, commonly known as 
transitional cells. Zajicek (1954) demonstrated these cells 
to stain positive for acetylcholinesterase in murine tissue 
and proposed that these cells were precursors for megakaryocytes 
These observations were confirmed by Jackson (l973) (but see 
Lepore ejt aJ. (1984)). Definitive proof that these cells were 
in fact immature megakaryocytes was provided by Long and 
Williams (198I). They found that the small acetylcholinesterase- 
positive cells did not give rise to colonies of megakaryocytes, 
but rather matured into single megakaryocytes. The human 
counterpart of these immature megakaryocytes have proved more 
elusive to identify, however their existence is not disputed. 
These immature megakaryocytes eventually become recognizable 
at the level of the light microscope by increasing their 
ploidy level and state of cytoplasmic maturation (Long ejfc aJ., 
1982). Such cells then routinely pass through various stages 
of maturation distinguishable by difference in nuclear/ 
cytoplasmic ratio, nuclear configuration and size (Williams 
and Levine, I982) (vide infra).
Odell and Jackson (1968) using rat tissue, demonstrated 
that only the most immature megakaryocytes can synthesize DNA 
and that development of polyploidy occurs only in young 
megakaryocytes. These young megakaryocytes were shown to
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exhibit the full range in ploidy levels namely 4N; 8N; 16N;
N. Odell and Jackson postulated that the development of 
polyploidy occurs before cytoplasmic maturation begins and 
that when cytoplasmic maturation commences no more DNA is 
synthesized. In a later study, Levine ejfc aJ. (1982) demonstrated 
that maturation and polyploidy appeared to be linked in that 
low ploidy (4N - 8N) megakaryocytes were immature whereas 
platelet-shedding megakaryocytes were (^N - 32N).
Regulation of megakaryocytopoiesis is believed to be under 
the control of two humoral stimuli, namely, Thrombopoientin 
and megakaryocytic colony stimulating factor. (Williams and 
Levine, 1982; Gewirtz, I986). Not much is known about the 
exact mechanisms of action of these substances, however, with 
respect to regulating platelet formation, it is clear that 
a deficiency of circulating platelets is associated with 
stimulation of megakaryocytopoiesis (Craddock ^t al•; 1955) 
and an excess with its suppression (Cronkite, 1957)*
1.2.2 Megakaryocyte Morphology
Megakaryocytes at all stages of their development have a 
distinct morphology (Williams and Levine, 1982; Levine, I98I) 
and depending upon the author and techniques used their 
development has been postulated to cover 3 (Ebbe and Stohlman, 
1965) to h (Levine ejfc ad., 1982; Williams and Levine, I982) 
separate stages (see also Breton-Gorius and Vainchenker, I986).
According to Ebbe and Stohlman (1965) megakaryocytopoiesis 
in the rat proceeds through three stages. Stage I or mega- 
karyoblast; Stage II or basophilic and Stage III or granular 
megakaryo cyt e.
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stage I represents the earliest identifiable cell by- 
light microscope as belonging to the megakaryocyte series.
Salient features at this stage are a compact nucleus occupying 
most of the cytoplasm; the cytoplasm has a clear, basophilic 
appearance; mitochondria are also present at this stage. In 
their s-tudy Rabellino ejfc ad. (198I) demonstrated the existence 
of specific platelet glycoproteins, platelet factor 4 and 
factor Vlll-antigen occurring in what they termed "early 
megakaryocytes". The appearance of specific organelles, 
including granules have also been detected early in megakaryocyte 
development (Paulus, 1970). Various s-tudies have confirmed 
both the synthesis and localisation of various a-granule 
constituents, including platelet factor 4; factor VIII antigen; 
factor V and fibrinogen in megakaryocytes (Rabellino ejfc ad.,
1979; Ryo ejfc ad., 1983; Nachman ejfc ad., 1977; Chiu ad. ,
1985)* The formation of the dense membrane system (DMS) 
was shown by MacPherson (1972) to be an event, occurring in 
earliest recognizable megakaryocytes. This membraneous system 
is thought to be derived from the megakaryocyte plasma membrane 
and to form^at least in part, the surface coat of fu-ture 
platelets (Behnke, I968). However, elegant freeze-fracture 
studies performed by Zucker-Pranklin and Petursson (1984) 
have shown differences in the plasma membrane constituents 
of platelets and megakaryocytes, suggesting that the surface 
membranes of these two cells differ in origin and structure.
The cells in this stage are present in a range of ploidy classes 
(Odell and Jackson, I968) suggesting that a number of successive 
endomitosis must occur during the transit of cells through 
this stage.
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Stage II cells have a characteristically different 
morphology# These cells have a lower nuclear-cytoplasmic ratio; 
the nucleus is usually lobulated and the cytoplasm has a 
foamy basophilic appearance. The mitochondria are more numerous 
than at the previous stage and scattered throughout the 
cytoplasm. On electron microscopy they exhibit all the cell 
specific organelles present in stage I, but in greater numbers*. 
The smooth endoplasmic-reticulum in these cells has been shown 
by histochemical techniques to be identical with the dense 
tubular systems of the circulating platelet (Breton-Gorious 
and Reyes, 1976). Before this stage is completed, endomitosis 
has ceased and nuclear segmentation increases (Ebbe and Stohlman, 
1963); it is likely that the development of cytoplasmic 
maturation is itself a potent inhibitor of further synthesis 
of DNA, however the exact nature of this inhibitor is unknown.
At this stage of maturation, the full ploidy distribution has 
been attained and cells belonging to each class of ploidy 
mature in parallel (Odel and Jackson, I968) (Contrast this 
with Levine et al. (1982) where they state that a relationship
exists between ploidy level and state of maturation). It is 
probable therefore that platelet production can take place 
in megakaryocytes at several ploidy stages.
Stage III cells possess nuclei which have become condensed 
and centralised in the cell. The cells however continue to 
grow in size. The penultimate phase of megakaryo cyt e maturation 
(stage IV by other authors) includes cells which are capable 
of releasing platelets (vide infra). In rats, the distribution 
between the various stages is 18^ in Stage I; 239° in Stage II 
and 369  ^in Stage III; the average total maturation time of
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rat megakaryocytes was estimated to be approximately 43-73 
hours (Ebbe and Stohlman, I963).
It is clear that throughout megakaryocyte maturation, 
most of the platelet specific proteins and organelles are 
synthesized within the megakaryocyte and it is likely that 
subsequent to platelet release, granule contents are packaged 
within the megakaryocyte.
1.2.3 Megakaryocyte functional responses
Megakaryocytes are thought to be designed specifically 
for elaborating platelets and hence are indirectly involved in 
haemostasis. Nevertheless, under certain conditions, mega­
karyocytes have been shown to exert platelet—like behaviour 
often to a striking degree. These responses include cellular 
shape change or cell spreading (Leven e_t al. , 1983; Leven 
and Nachmas, I98I; Fedorko, 1977; Leven and Nachmas, I982); 
metabolism of arachidonic acid (Walenga ejfc aT., 1984; Miller 
et al., 1982; Levine e_b al. , I983); uptake, storage and release 
of serotonin (3HT) (Fedorko, 1977; Schick and Weinstein, I98I; 
Tranzer e_t al. , 1972) and release of ATP (Miller, 1983)* These 
responses in megakaryocytes can be elicited by a range of 
platelet agonists including Thrombin; ADP; Adrenaline and 
calcium ionophore A23187 (Leven and Nachmias, 1982; Walenga 
et al., 1984; Fedorko, 1977; Miller, I983; Leven ejfc al., 1983; 
Leven and Nachmias, I98I). Because of the difficulty in 
obtaining human tissue, most of the above studies were performed 
using animal tissue. However there is no reason to expect 
any major differences in response were human tissue to be 
used. The significance of these responses to normal megakaryocyte
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function is unknown but serves to demonstrate the similarities 
between them and their progeny.
In response to ADP (l-lOO p,M) and Thrombin (ly,/ml)
Levine and Nachmias (1982) demonstrated the spreading of 
cultured guinea pig megakaryocytes. Such spreading was blocked 
by dibutyryl cyclic AMP or isobutylmethylxanthine but not by 
colchicine indicating the action of actomyosin system rather 
than the microtubular system - similar to the situation observed 
in platelet activation. Mechanistic studies suggested that 
intracellular alkalinization accompanied by an increase in 
intracellular free calcium was required for spreading induced 
by ADP or Thrombin (Nachmias, I983). Whether this holds true 
for other agonists or represents only one mechanism for 
megakaryocyte spreading is unknown. Fedorko (l977)> also 
using guinea pig megakaryocytes, could also observe marked 
changes in megakaryocyte shape with ADP (lO )i,M - 1 mM) ;
Thrombin (l - 100 J - ) ; Adrenaline (lO p,M - ImM) and A23187
(1 - 12 pM). The requirement for a high agonist concentration 
to observe any spreading in the latter study may reflect species 
variations of megakaryocytes and hence an ability to respond 
to stimuli ; additionally during preparation necessary cofactors 
may be washed from the megakaryocyte preparation. One major 
difference between shape change in megakaryocytes and their 
progenitors is, that in the former, shape change occurs over 
a period of minutes rather than seconds as occurs in platelets. 
Additionally, instead of producing filopodia, megakaryocytes 
appear to form ruffles at the leading edge (Nachmias, 1983)*
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Metabolism of arachidonic acid has been demonstrated 
in megakaryocytes from a variety of species* In rat mega­
karyocytes Demers ejfc al. (198O) demonstrated the synthesis 
of significant amounts of prostaglandin E* Also in rat 
megakaryocytes, Worthington and Nakeff (198I) demonstrated 
the synthesis of thromboxane Using guinea pig megakaryocytes
Miller ejt al* (1982) demonstrated the synthesis of thromboxane B^, 
12-hydroxyheptadecatrienac acid (HHT) and 12-hydroxy 
elcosatetraenoic acid (12-HETE). These results suggested that 
megakaryocytes possess the full complement of cyclo-oxygenase 
and lipoxygenase activities found in circulating platelets#
The metabolism of arachidonic acid in platelets can be affected 
by inhibitors of cyclo-oxygenase such as aspirin. Studies 
have demonstrated that in addition to inhibiting platelet 
cyclo-oxygenase, aspirin may also inhibit cyclo-oxygenase in 
megakaryocytes. Using rat megakaryocytes Demers ejfc al. (1980) 
demonstrated that aspirin could abolish the ability of the 
megakaryocytes to synthesize prostaglandin E. Worthington 
and Nakeff (1982) also demonstrated the ability of aspirin 
to inhibit rat megakaryocyte thromboxane synthesis. The 
latter authors demonstrated a lag period occurring between 
aspirin addition and full recovery of cyclo-oxygenase activity 
in platelets. This is thought to represent inhibition of 
cyclooxygenase in megakaryocytes - normal eyelooxygenase 
activity returning after synthesis of new cyclooxygenase in 
the megakaryocyte. Some studies have reported a difference 
in sensitivity of cyclooxygenase in platelets and megakaryocytes 
in response to inhibition by aspirin. Worthington and Nakeff
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(1982) reported that platelets were approximately 25 times 
more sensitive to the effects of aspirin on cyclooxygenase 
as were megakaryocytes# Contrary findings were reported by 
Walenga ejt al. (1984). The difference may be explained by 
species differences in that rat tissue was used in the former 
study and guinea pig tissue in the latter.
Like platelets, megakaryocytes have been demonstrated to 
take up, store and then release 5HT (Fedorko, 1977)* Uptake 
was temperature dependent and thus in part energy dependent; 
uptake was also inhibited by reserpine and imipramine — similar 
to findings using platelets. Release of 5HT was induced by a 
range of known platelet agonists such as ADP, Thrombin and 
Adrenaline. Schick and Weinstein (198I) demonstrated by 
autoradiography, at the level of the light microscope, that 
megakaryocytes appeared to be the only cells in marrow taking 
up 5HT. However, regardless of stage of maturation, similar 
amounts of labelled 5HT had been accumulated into the cells. 
They proposed that 5HT accumulation may be a marker for the 
immature megakaryocyte. 5HT cannot be synthesised in 
megakaryocytes and like platelets these cells must accumulate 
it from the blood. Uptake of 5HT into specific subcellular 
organelles has been demonstrated (Tranzer ejb a^. , 1972), and 
it is possible that these organelles may represent the 
precursors of 5HT storage organelles in platelets.
In response to Thrombin and A23187, Miller (1983) 
demonstrated the release of ATP from guinea pig megakaryocytes. 
However, although one megakaryocyte contains about 200-300 
times as much ATP as does one platelet, the extent of ATP
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release induced from each, megakaryocyte is only about 34 times 
as great as that per platelet when Thrombin is used, or about 
63 times as great when using A23187* This discrepancy in 
amount present in each cell and amount released may be resolved 
by postulating either that the releasable nucleotide pool 
develops late in megakaryocyte life and due to heterogeneous 
population of megakaryocytes, one may get less ATP released 
or, equally likely, ATP may enter a storage pool compartment 
relatively early in megakaryocyte development, but the ability 
of the cell to undergo degranulation - and hence possess 
the machinery to enable it to perform this function - may 
occur late in maturation and hence are incapable of eliciting 
a full response to platelet stimuli.
These studies serve to demonstrate that in addition to 
imparting structural and functional aspects to platelets, 
megakaryocytes are also capable of undergoing several "platelet* 
like" responses subsequent to addition of platelet stimuli, 
thus serving to strengthen further the teleological 
relationship between these two cells.
1.2.4 Physiological Functions
The physiological function of megakaryocytes can be 
seen as maintaining the status quo in terms of platelet 
production. The manner in which the body regulates the 
production of platelets has already been alluded to. This 
section deals with the manner in which platelets are elaborated 
from the mature megakaryocyte and the nature of the released 
platelets.
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Platelet release from the mature megakaryocyte is poorly 
understood and at least three mechanisms have been postulated, 
(i) Megakaryocytes located in the bone marrow have been 
demonstrated to extend pseudopodia from the cell, seeking out 
the marrow sinusoids. These pseudopodia have been shown to 
contain microtubules orientated along their axis thus affording 
rigidity (see Penington, I98I). Once they have passed through 
the walls of the marrow sinusoids the pseudopods fracture 
thus releasing platelets, (ii) Some megakaryocytes may actually 
pass through the sinusoids intact and be carried via the 
venous circulation to the lung. Once lodged in the micro­
circulation of the lung they could fracture and release 
platelets (Kaufman ^t a^., I965; Trowbridge ejfc al., I982);
(iii) Recent studies of Zucker-Franklin and Petursson (19^4)
ixioo RluLU.5; N 9- ^
have suggested that the entire megakaryocyte cytoplasm 
disintegrates in situ and release platelets in this fashion.
It must be emphasized that regardless of the method of release, 
the "platelets” released from the megakaryocyte are not fully 
developed. The transition from these "platelets" to the 
typical discoid platelet probably occurs in the general 
circulation. Additionally, those "platelets" which may be 
formed in the bone marrow are non-adhesive as they pass 
through the marrow sinusoids. They probably develop their 
adhesive capacity by "taking—up" plasma components on to 
their surface (Behnke, 1969)*
Platelets are known to be composed to a heterogenous 
population with respect to their size. Paulus (l975) argued
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that as platelet formation is characterised by a random 
fragmentation of megakaryocyte cytoplasm, each megakaryocyte 
must therefore produce a log normal distribution of platelets, 
including large and small platelets. This postulate was later 
confirmed, on purely mathematical grounds, by Trowbridge ^t al. 
(1982). The number of platelets reportedly produced from 
one megakaryocyte varies but based on ultrastruetural studies, 
it appears that perhaps as many as 3OOO platelets may be 
elaborated from each megakaryocyte (Chemoff ejfc aT. , I980).
1.2.5 Pathological Functions
Megakaryocytes are the progenitor cells of platelets 
and have been shown to contain most of the constituents found 
in platelets. Any derangement in elaboration of platelets 
from the megakaryocyte, or premature release of certain platelet 
constituents from the magekaryocyte may result in the development 
of pathological situations.
Trowbridge ejt aT. (1982) have suggested that all platelets 
are produced by physical fragmentation of megakaryocytes lodged 
in the lung. The same authors (Martin al., 1983a; 1983b) 
have suggested that abnormal platelet production (due either 
to abnormalities in the megakaryocyte itself or in the 
pulmonary vasculature) may be involved in the pathogenesis 
of vascular disease., A correlation between abnormal platelet 
size and reactivity previously has been made (Karpatkin,
1978; see Eldor e_t al. , I982).
During normal platelet production it is possible for 
platelets to be derived from each of the principal ploidy
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classes (8N, 16N and 32N) of megakaryocytes (Odell and 
Jackson, I968). Pen lington jet al. (1976) have suggested 
that platelets produced from each individual class of ploidy 
may elaborate platelets with differences in reactivity. It 
is quite possible that a propensity of any one of these types 
may result in initiation of pathological diseases. Such a 
possibility awaits further investigation into the nature of 
each type of platelet produced by the different megakaryocytes.
Studies have shown that human megakaryocytes contain 
growth factor(s) with similar biological properties to 
platelet derived growth factor (Castro-Malaspina _et al. ,
1981).
It has been suggested that megakaryocytes may play a 
role in the pathogenesis of the marrow fibrosis observed in 
myeloproliferative disorders by stimulating fibroblast 
proliferation and collagen secretion (Gastro-Malaspina e^fc al., 
1981). In myelofibrosis, abnormalities in megakaryocyte 
morphology and ineffective megakaryocytopoiesis are common.
The above authors suggest that this combination may lead 
to excessive concentrations of megakaryocyte derived growth 
factor accumulating with the consequent initiation of 
myeloproliferative disorders.
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1.3 Molecular Mechanisms of Cellular Reactivity
Receipt and transduction of external signals initially 
depends upon surface phenomena and in particular upon -the 
existence of membrane associated * cognitive' elements or 
receptors. In many cases, these have been directly identified 
and partially or completely purified; in other systems 
their existence is entirely hypothetical. Receptor proteins, 
which may be in the form of monomeric or oligomeric subunits 
are assumed, per se, to span the phospholipid bilayer of the 
plasma membrane and contain ligand binding sites, recognizing 
specific ligands, on the outer surface. The mechanism whereby 
ligand-receptor interaction on the cell surface evokes an 
intracellular response involves the action of a 'transduction- 
process*. Activation of these transduction processes elaborate 
intracellular effector molecules or second messengers which 
can then elicit activation (or inhibition) of the cell 
(Berridge, I980). In a variety of different cell types, 
including human platelets, the more common effector molecules 
or second messengers are cyclic 3 ’>5' adenosine monophosphate 
(cyclic AMP) and calcium (Berridge, I98O, I98I). These second 
messengers are the keys to controlling many of the enzymes 
and protein complexes responsible for cellular activation.
The most notable exception to the second messenger theory 
for controlling cellular reactivity is the cholinergic nicotinic 
receptor. This receptor is coupled to a sodium channel whose 
opening leads to a rapid change in membrane potential, the 
extracellular signal being transmitted intracellularly by an 
electrical impulse rather than a chemical messenger.
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The transduction process controlling generation of 
cyclic AMP has been well characterised in a number of different 
cell types however, by comparison the mechanisms controlling 
the generation of Ca^’*’ signals is, at present, highly speculative
1.3*1 The Second Messengers
1.3.1.1 Cyclic AMP (cyclic adenosine-3S5'-monophosphate)
Cyclic AMP was first proposed as an intracellular mediator 
of the effects of glucagon and adrenaline in the liver by 
Sutherland and Rail (1960). Since this discovery innumerable 
studies have addressed the generation of this nucleotide, 
following agonist exposure, and in a plethora of different cell 
types cyclic AMP is now accepted as being a ubiquitous 
regulatory agent in most mammalian tissues (Robison i^b aT. ,
1971; Cramer and Shultz, 1977)*
The enzyme adenylate cyclase, located on the cytoplasmic 
face of the plasma membrane, forms cyclic AMP from ATP in 
the presence of Mg^^. The adenylate cyclase complex exists 
as an oligomeric unit consisting of at least three separate 
components. These include the hormone receptors, which 
discriminate the specificity of the hormone signals ; the 
catalytic subunit, which catalyses the conversion of ATP 
to cyclic AMP} and guanine nucleotide (ATP) binding regulatory 
entities, which are involved in the coupling between the 
agonist receptors and the catalytic subunit (Ross and Gilman, 
1980). It has been shown that the hormone receptors are 
molecularly separate from the rest of the adenylate cyclase 
system (Birnbaumer and Rodbell, 1976; Limbird and Lefkowitz,
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1977) whilst cell fusion experiments have shown that the 
receptors float freely in the plasma membrane (Schram and Orly,
1976). Extensive research on the transduction mechanisms of 
stimulatory and inhibitory agonists has provided strong evidence 
that two GTP-binding proteins, termed Ng and N^, are involved 
in the coupling between stimulatory and inhibitory agonist 
receptors respectively, and the catalytic subunit. Ng mediates 
the agonist-induced stimulation of the adenylate cyclase 
whereas N^  ^ is responsible for the hormone-induced inhibition 
of the adenylate cyclase (Ross and Gilman, I98O; Jakobs et al., 
1984). The guanine nucleotide-binding regulatory units are 
oligomeric proteins composed of three non-identical subunits, 
termed an a-, 1^- and a ^  -subunit (Northup _ejt al. , I98O; Godina 
et al., 1984; Hi 1 deb rand t ejb al. , 1983)* There appears 
homogeneity in the size of the 1^- and ^  sub-units, however the 
a-subunit - the source of high affinity binding sites for GTP 
appears to vary somewhat in its molecular size.
Following agonist-receptor interaction, the receptor 
associates with Ng, facilitating the release of GDP and 
binding of GTP to the a subunit, which then dissociates into 
its a and 1^ subunits (Gilman, 1984; Schram and Selinger, 1984; 
Jacobs et al., I986; Taylor and Merritt, I986). The subunits 
remain dissociated for as long as GTP is bound to the a subunit; 
it is the dissociated subunit which stimulates adenylate 
adenylate cyclase activtiy and hence elevates cytoplasmic 
levels of cyclic AMP. Agonists exhibiting a negative effect 
on the accumulation of cyclic AMP bind to separate receptors 
which preferentially combine with N^, however the mechanism
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whereby dissociation of leads to inhibition of adenylate
cyclase is not entirely clear; it may involve the inactivation
of Ng(a^) by the released P subunit (Gilman, 1984; Smigel
et al., 1984). Mechanisms exist to terminate the effects on
adenylate cyclase of stimulatory or inhibitory ligands. This
is understood to be performed by GTPase's catalysing the
conversion of GTP to GDP thereby promoting reassociation of
the subunits and hence termination of the response. Evidence
exists that the GTPase activity is an intrinsic feature of
GTP-binding proteins (Ross and Gilman, I98O; Cassel and
Selinger, 1976; Brandt et al., I983; Jakobs et al., I985;
Birnbaumer et al., I985; Jakobs et al., I986) in particular
with the a-subunit. The structural and functional identification
of both N and N. owes a considerable amount to two bacterial s 1
exotoxins, cholera toxin and pertussis toxin (lAP). The
former toxin causes the NAD^-dependent ADP-ribosylation of
the a-subunit of (Van Heyningen, 19775 Gilman, 1984). This
process also depends upon GTP and leads to the activation and
dissociation of N into its constituent subunits. It iss
believed that cholera toxin inhibits an inherent GTP-ase 
activity associated with a-N^, hence allowing it to remain 
activated. In contrast, lAP ADP-ribosylates the a-subunit 
of but, in this instance, it blocks the dissociation and 
activation of this regulatory protein and this obliterates 
inhibitory responses (Gilman, 1984; Jakobs e_t al. , 1984;
Ui, 1984). In this fashion, both these compounds can regulate 
the levels of cellular cyclic AMP. Both compounds however
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need to gain access to platelets, being inactive in intact 
preparations. Nevertheless, cholera toxin and lAP should 
prove useful tools in delineating further the mechanism of 
action of the adenylate cyclase system in future studies.
As mechanisms exist to terminate the activity of 
adenylate c y c l a s e , mechanisms must likewise exist to terminate 
the actions of its product, the second messenger cyclic AMP.
In the case of cyclic AMP this is achieved by selective cyclic 
AMP phosphodiesterases which hydrolyse any cyclic AMP formed 
to the inactive 3' AMP. In human platelets three different 
types of cyclic nucleotide phosphodiesterases have been isolated 
(Hidaka and Asano, 1976). Rat platelets contain two forms, 
one is a cyclic GMP-binding phosphodiesterase, which hydrolyses 
cyclic AMP but acts preferentially on cyclic GMP and the 
other is specific for cyclic AMP (Coquil et al., I98O).
In platelets an elevation of cyclic AMP is associated 
with inhibition of reactivity (Moncada and Whittle, I983;
Haslam et al., 1978). Agents known to elevate cytoplasmic 
levels of cyclic AMP are the most powerful known inhibitors 
of platelet function (Packham, I983) and include the following;- 
Prostaglandins such as PGI^» PGE^ and PGD^; Adenosine, 
diterpenes such as forskolin; and non-specific phosphodiesterase 
inhibitors such as isobutyl methyl xanthine.
Platelets contain high affinity binding sites for PGI^»
PGE^ and PGD^ (reviewed by MacIntyre, 1983)» Studies (Whittle 
et al., 1978) have shown that PGI^ and PGE^ share a common 
receptor on the surface of platelets from various species, 
whilst PGD^ acts at a distinct receptor (Mills and MacFarlane,
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1974; Whittle ^  al•» I983). Studies examining the effects 
of prostaglandins on the ■ elevation of cyclic
AMP in rat platelets have revealed that, even at relatively 
high concentrations, PGD^ is unable to inhibit agonist-induced 
aggregation (Hwang, I980) implying that rat platelets lack 
receptor sites for PGD^"
Adenosine is also known to elevate cyclic AMP levels and 
inhibit platelet reactivity in both human and rat platelets 
(Michel al. , 1976). However, it appears that rat platelets 
are less sensitive to the inhibitory effects of adenosine 
compared to human platelets, an effect shown to be quantitative 
rather than qualitative (Michel et al., 1976).
The diterpene forskolin, isolated from the roots of Coleus 
forskolii, has proved immensely useful in probing the adenylate 
cyclase system in a variety of different cell types. This 
compound can bypass the system at the receptor level and act 
directly on the catalytic unit of the enzyme (Seamon and Daly,
1981) and/or on the stimulatory GTP-binding protein,
(Durf1er et al., I982) thus elevating levels of cyclic AMP. 
Forskolin is a potent stimulant of platelet cyclic AMP formation 
and inhibitor of ADP induced platelet aggregation (Siegl 
et al., 1982). In human platelets, incubated with Quin 2,
Sage and Rink (1983) demonstrated forskolin to elevate 
cytoplasmic levels of cyclic AMP with a concomitant inhibition 
agonist-induced aggregation and rises in cytoplasmic free 
calcium, the latter believed to be one of the mechanisms by 
which elevation of cyclic AMP inhibits platelet reactivity 
(vide infra).
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Lastly, inhibition of* the cyclic AMP phosphodiesterase 
is another mechanism by which cytosolic levels of cyclic AMP 
can be elevated. The non-specific phosphodiesterase inhibitors 
such as isobutyl methyl xanthine can inhibit platelet reactivity 
by elevating cyclic AMP levels. However several compounds 
exist which are allegedly specific for platelet cyclic AMP 
phosphodiesterase. One such compound is Trequinsin (Ruppert 
and Weithmann, I982). These researchers found this compound 
to be at least 100 times more active as an inhibitor of 
arachidonic acid-induced platelet aggregation compared to 
PGI^» a compound previously thought to be amongst the most 
active compounds at inhibiting platelet activation (Moncada 
and Vane, 1979; Moncada and Whittle, 1985)* Another compound 
shown to completely inhibit cyclic AMP phosphodiesterase 
in platelets is R0-15-204l, an analogue of anagrelide 
(Hoick et al., 1984).
So far the effects of agents elevating levels of cyclic 
AMP and their ability to inhibit platelet reactivity subsequent 
to agonist addition has been discussed. What is not known is 
whether or not inhibition of adenylate cyclase and hence 
reduction in cyclic AMP levels plays any part in platelet 
reactivity. Several known pro-aggregatory agents are known 
to exert a negative effect on accumulation of cyclic AMP. 
Adrenaline and ADP have been demonstrated to reduce the 
concentration of cyclic AMP which has been previously elevated 
by adenylate cyclase stimulants (Mills, 1974). They can also 
inhibit basal and hormone-stimulated adenylate cyclase 
activity in platelet particulate fractions (Jakobs et al., 1978;
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Cooper and Rodbell, 1979)* The inhibition of adenylate cyclase 
by agents such as adrenaline involves the participation of the 
regulatoary protein and requires GTP (Jakobs et al. , 1978)* 
Other pro-aggregatory agents e.g. ADP (Mellwig and Jakobs,
1980); platelet-activating factor (PAP-acether) (Williams ^t al.,
1983) and Thrombin (Aktories and Jakobs, 1984) have also 
demonstrated, to varying degrees, the inhibition of adenylate 
cyclase and decrease in levels of cyclic AMP in (human) platelets 
- this effect is observed only in platelet lysates when either 
Thrombin or PAF-acether are used. While these pro-aggregatory 
compounds have been shown to decrease levels of cyclic AMP 
in their various studies, what is not known is the physiological 
significance of the effect. Haslam et al. (1978a) suggested
that the inhibition of adenylate cyclase is only physiologically 
significant in the context of reducing the stimulation of the 
enzyme by positive agonists such as PGI^ and adenosine.
1.3»1*2 Mechanisms of action of cyclic AMP
Elevated levels of cyclic AMP elicit a wide range of 
responses in the eukaryotic cell from stimulating glycogenolysis 
in the liver, to water readsorption in the kidney to insulin 
secretion in the pancreas (Sutherland and Robinson, I966; 
Sutherland e_t aJ^ . , I968; Rasmussen, 1970). Cyclic AMP mediates 
these diverse responses by stimulating the structural 
modification of pre-existing proteins within its target tissue 
(Kuo and Greengard, I969). The nature of this modification 
is the formation of a phosphate ester linkage within the 
hydroxyl groups of specific serine and threonine residues of
- 43 -
a protein substrate using ATP as a donor. The specific
phosphorylation of certain platelet proteins has been observed
after elevation of cyclic AMP and are mediated by cyclic AMP-
dependent protein kinases. Several membrane proteins are
phosphorylated (Steiner, 1973; Apitz-Castro al., 1976)
and one of these, a protein with an apparent mass greater than
400K, shows enhanced incorporation of labelled phosphate
accompanying an elevated cyclic AMP (Apitz-Castro and Murcian,
1978). Haslam and coworkers (1979» I980) observed that elevation
of cyclic AMP led to the rapid phosphorylation of proteins
with apparent molecular weight 24K and 3OK and slower
phosphorylation of several other proteins, including one of
22K. It thus appears that potentially many proteins can be
phosphorylated in the presence of elevated levels of cyclic
AMP. However, it is the steady state level or the rate and
direction of change of these phosphoproteins which is more
directly related to cellular reactivity. Déphosphorylation
of the protein, by hydrolysis of the phosphate ester, is
catalysed by protein phosphatases. Acting through these, as
yet, largely unidentified protein substrates, elevated levels
of cyclic AMP are able to inhibit or terminate cellular
reactivity. Potential mechanisms by which cyclic AMP may
inhibit platelet reactivity are outlined below.
(i) Inhibition of Ca^ "*" availability; One of the mechanisms
by which cyclic AMP regulates platelet functions is by controlling
2+the level of Ca in the cytosol. Although this has long 
been assumed to be so, no direct evidence was available until
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the introduction of Quin 2 made such experiments feasible
(see Section 2.2.9.2). In Quin 2 loaded platelets, the elevation
in cytoplasmic free calcium elicited by Thrombin is inhibited
by prior exposure to PGD^; PGE^ or forskolin (Peinstein ^t al.,
1983a; Sage and Rink, I983). When added at the peak response
in Quin 2 fluorescence, either of the above compounds or the
membrane permeant cyclic AMP derivative, 8—bromo—cAMP resulted
in a rapid fall in Quin 2 fluorescence (Peinstein e_fc al., 1983a;
MacIntyre ejt al., 1983a). Finally Sage and Rink (1983) also
demonstrated that forskolin could inhibit, with equal potency,
2+the Ca influx and mobilization induced by hrombin or platelet
activating factor. These results strongly suggest that cyclic
24-amp is able to regulate Ca availability in intact platelets.
However, resting levels of Ca^* do not appear to be regulated
by cyclic AMP, since agents known to elevate cytoplasmic levels
24-of cyclic AMP e.g. PGI^ and PGD^, do not affect resting Ca .
(MacIntyre jet al. , 1983a). Additionally, since platelet
stimulatory agonists do not elicit cyclic AMP formation to any
great extent, it is unlikely that unless exposed to an adenylate
cyclase stimulant, endogenous cyclic AMP would subserve a
physiological role in regulating Ca^ "*" availability. Platelets
are thought to contain systems controlling calcium transport.
Such transportation of CEilcium may be stimulated by platelet
cyclic AMP-dependent protein kinases. Kaser-Glanzman and
co-workers (1977> 1979) demonstrated that cyclic AMP could
24-stimulate the active sequestration of Ca into purified 
platelet intracellular membranes, thought to correspond to
24-the dense tubular system, an organelle thought to store Ca 
(white, 1972). Interestingly, using cytochemical techniques.
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the existence of adenylate cyclase has been demonstrated in
the dense tubular system (Cutler ejk a^« , I983)* However,
studies by Menashi ejk al. (1982) have failed to demonstrate a
2+cyclic AMP-dependent accumulation of Ca into intracellular 
platelet membrane fractions.
(ii) Inhibiting the generation of putative second messengers; 
The metabolism of inositol phospholipids, in particular
phosphatidyl inositol(4,5)^2 ^Ptdins(4,3)P^^ is believed to
be involved in the generation of second messengers, in particular, 
1,2 diacylglycerol (the endogenous activator of protein kinase 
C) and inositol(1,4,5)trisphosphate (thought to be involved 
in the elevation of cytosolic free calcium) (see Section 1.3.1.6 
and 1.3*1*8).
Phospholipase C, a phosphodiesterase type enzyme is 
believed to catalyse the metabolism of inositol phospholipids.
The finding that dibutyrlcAMP, a membrane permeant derivative 
of cyclic AMP can inhibit phospholipase C action in platelets 
(Rittenhouse-Simmons, 1979; Lapetina eJb a^. , 1977) is 
consistent with the idea that cyclic AMP may act by inhibiting 
the availability of calcium. Furthermore, numerous studies 
have demonstrated that agents elevating cytoplasmic levels 
of cyclic AMP can inhibit the metabolism of P t d l n s (4,5)^2 
(Feinstein ejt al. , I985) and reduce the formation of Ins(l,4,3)P^ 
(Watson ejt al., 1984). Interestingly cyclic AMP has also been 
demonstrated to stimulate the formation of PtdIns(4)P in 
intact platelets (de Chaffoy de Courcelles et al., I986).
Besides being a precursor for the formation of P t d l n s (4,5)P2* 
PtdIns(4)P has also been implicated in Ca^* transport
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(Varsanyi ejt al • , I983; Choquette ejt a^. , 1984). The possible 
Ptdlns(4)P-induced depression of cytoplasmic levels of calcium 
might evidently contribute to the inhibitory effects observed 
with elevated levels of cyclic AMP.
(iii) Inhibition of protein phosphorylation: The phosphoryl­
ation of a wide, and varied collection of proteins occurs 
subsequent to agonist addition in platelets and is monitored 
using platelets prelabelled with L^^P*^ P^. Lyons e_t al. (l975) 
were the first to demonstrate that there were two major proteins 
phosphorylated on stimulation of platelets with thrombin. The 
first was a protein of molecular weight 40K, now known to be 
47K (depending upon techniques used this protein can range 
from 40-47K)• The second was a protein of molecular weight 20K. 
The identity of the latter protein was established by Daniel 
et al. (1981) as being myosin light chain. The former protein 
has been isolated by Imaoka al. (1983) however its precise 
function in platelet reactivity is not clearly established. 
Recently it has been suggested that it may be a lipocortin- 
like entity, capable of inhibiting phospholipase A^ (Touqui 
et al., 1986). Upon agonist-induced phosphorylation of the 40K 
protein by protein kinase C, the inhibitory activity is 
suppressed and may possibly represent the mechanism underlying 
mobilization of arachidonic acid in platelets (see Section 
1.1.3*4). In a separate study Connolly and Majerus (1986) 
proposed that the 4OK protein may act as Ins(l,4,3)P^ phosphatase, 
cleaving the 3 phosphate from Ins(l,4,3)P^• Feinstein al. 
(1983b) demonstrated that PGD^ or forskolin could reverse the 
the Thrombin-induced phosphorylation of both the 20K, and 4OK
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proteins. In the presence of agents elevating cyclic AMP, 
phosphorylation of both proteins was again inhibited (Lyons 
e t ^ . ,  1975; Fox et ^., 1978).
Both myosin light chain and the 40K protein are believed 
to be intrinsically involved in platelet activation; 40K 
protein phosphorylation has been correlated with serotoni# 
secretion, and 1,2-diacylglycerol formation (leysan ejfc al.,
1982; Sano ^  ^ .  , 1983; Kawahara £t ^ .  , 1983); phosphorylation 
of myosin light chain is correlated with secretion and clot 
retraction (Daniel ^t al., 1977)*
Although potentially many other mechanisms may be 
regulated by elevated levels of cyclic AMP the exact biochemical 
consequences of an increase in cytoplasmic cyclic AMP remains 
to be ascertained.
1.3*1*3 Calcium
In 1883; the British physiologist Sidney Ringer demonstrated 
that the calcium ion was required in the bathing medium to 
sustain contraction of an isolated frog heart. Almost a 
hundred years later, it was demonstrated that 'skinned* muscle 
fibres could be induced to contract following application of 
external ions (Natori, 1954). Within a few years considerable 
evidence accumulated in support of the concept that calcium 
ions play a critical role in excitation-contraction coupling, 
a term introduced by Sandow (1952). In I96I, Douglas and 
Rubin emphasized the importance of free ionized calcium as 
a ubiquitous intracellular coupling agent by showing that it 
was an essential component in the acetycholine-induced
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release of catecholamines from the adrenal medulla. From 
this study the term "stimulus-secretion coupling" was derived 
to characterise stimulated exocytosis of honnones and secretory 
products. Since this time many events have been shown to be 
dependent on the presence of free ionized calcium ions and 
its role as a ubiquitous mediator of cellular reactivity is 
not disputed (Rasmussen and Barret, 1984; Rubin, I982). Blood 
platelets can be stimulated by a wide range of chemically 
different compounds such as Thrombin (a proteolytic enzyme); 
collagen (a macromolecular complex); low molecular weight 
compounds such as ADP and thromboxane A^ and vasoactive amines 
such as adrenaline. Nonetheless the response generated e.g. 
shape change, aggregation, secretion and icosanoid synthesis, 
seems virtually indifferent of the agonist used. This implies 
that a common "effector system" is operating. The role of 
cytosolic free calcium in platelet function has been extensively 
investigated and is generally accepted as the intracellular 
effector molecule in platelets (for reviews, see Detwiler et al., 
1978; Feinstein, 1978; Gerrard je_t aT. , I98I). While the 
evidence for this is partly circumstantial and indirect, the 
essential evidence to indicate that calcium plays some regulatory 
role is available. The earliest evidence for a role in platelets 
was the work of ésrette (1962) who demonstrated in porcine 
platelets a requirement for external Ca^ "*" for hrombin-induced 
secretion at 13°C, but Ca^ "*" was not required at higher 
temperatures. Murer (1972) confirmed these findings using 
human and porcine platelets. The increased requirement for 
Ca^ "*" at the lower temperatures was explained by the reduction
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in effectiveness of an activator at this temperature. Indirect
evidence of an essential role of Ca^^ in platelet activation
derives from the following (i) Calcium ionophores;-
The demonstration that the calcium ionophore A23187 could elicit
the full platelet response e.g. shape change, aggregation,
secretion and icosanoid synthesis (Feinman and Detwiler, 1974;
White et al., 1974; Massini and Luscher, 1974) in a manner
similar to that elicited by agonists interacting at specific
platelet receptors proved to be amongst the first in a long
2+line of indirect evidence expounding a role for Ca in platelet 
activation. One notable difference in its effects on platelets 
appears to be its less efficacious nature of eliciting the 
metabolism of inositol phospholipids - a characteristic feature 
of many platelet agonists. The mechanism of action of iono- 
phores, in particular A23187; is believed to involve the 
formation of a 'cage* by the combination of A23187 with Ca^*. 
This 'cage* is lipophilic thus facilitating the transport of 
Ca^* across membranes. However various workers (Holmsen and 
Dangelmaier, I98I; Lages and Kruger, I983) have reported that 
only free A23187> and not divalent complexes, could activate 
platelets, (ii) ^^Ca^^ ;— The use of this entity to measure 
Ca^^ fluxes in a variety of cells is hampered by the difficulty 
in interpreting data obtained from such studies. However,
Brass (l984a,b) has recently used this probe to investigate 
Ca^ **" homeostasis in human platelets providing useful information 
concerning intracellular stores of this ion.
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(iii) Chlortetracycline CTC;- CTC can be used to measure
mobilisation of membrane-associated divalent ions such as Ca^^
(Caswell and Hutchison, 1971a; Caswell and Hutchison, 1971h;
Caswell, 1972). This compound forms a fluorescent complex 
2+with Ca ion, the intensity being 20-100 times more intense
2+in a nonpolar environment. Upon releasing Ca the intensity 
of fluorescence decreases. Ffeinstein (1980) was the first to 
demonstrate release of intracellular Ca^^ in platelets using 
this compound. Upon Thrombin addition, release of intracellular 
Ca^ "*" occurred with a time-course consistent with its proposed 
role in activation-secretion coupling. Later studies by 
Thompson and Scrutton (1985) confirmed these observations. 
However as a probe for measuring intracellular Ca^* they 
concluded, from their studies, that it was not possible to 
define which membrane site(s) were involved. Additionally, 
quantification of the CTC fluorescence signal is difficult.
(iv) Calcium antagonists e.g. TMB-8;- Studies by Malagodi and 
Chiou (1974; 1974a) demonstrated that 8-(N,N-diethylamino)octyl 
3>4,5“trimethoxybenzoate (TMB-8) was a potent inhibitor of the 
contractility of both smooth and skeletal muscle. Subsequent 
studies demonstrated that a possible mechanism of action of 
TMB-8 could be to reduce Ca^^—availability by stabilizing Ca^^ 
binding to cellular Ca^^ stores and thereby inhibiting its 
release upon agonist addition (Chiou and Malagodi, 1975)*
By analogy in platelets, it is believed that TMB-8 acts as an 
intracellular Ca^’*’-ant agonist inhibiting the agonist-induced 
mobilization of Ca^* (Charo et al., 1976). Several groups
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have used this compound to investigate activation processes in
platelets (Charo ejfc a^«, 1976; Mnrer and Siojo, 1982; MacIntyre
and Shaw, 1983)» However, several effects of TMB-8 in platelets
24-have been shown not to be entirely attributable to Ca
antagonism e.g. TMB-8 interferes with formation of thromboxane,
apparently by inhibiting cyclooxygénase (Shaw, I98I). Additionally
Simpson et al. (1984) demonstrated TMB-8 to be less effective
24-at inhibiting Thrombin-induced Ca flux or internal release 
in human platelets, but more effective at inhibiting the 
secretory response evoked by phorbol esters at basal Ca^ "*".
Phorbol esters are known activators of protein kinase-C, 
an enzyme thought to be involved in platelet reactivity (see 
Section 1.3*1»8.3)« Hence, the use of TMB-8 in probing Ca^* 
ion in platelets is debatable.
(v) Permeabilized platelets;- By rendering platelets permeable
to Ca-EGTA (and other small molecules) using high-voltage
electrical fields, the role of intracellular calcium in platelet
activation can be examined (Knight and Scrutton, I98O; Knight
et al., 1982). The addition of buffered micromolar concentrations
of Ca^”*", without an agonist was sufficient to induce dense
granule secretion (Knight and Scrutton, I980). Results
obtained using permeabilized platelets are plagued by the fact
that such procedures allow entry of other low molecular weight
compounds and the attendent possibility of internal damage.
Nonetheless, they represent a valuable model for studying 
24.
the role of Ca ions in platelet activation.
- 34 -
(vi) Intracellular indicators;- Within the past couple
of years the development of indicator dyes whose fluorescence
changes upon chelation with Ca^* ions has contributed vastly
2+towards our understanding of the role of Ca ions in platelet
activation. In particular the custom built fluorescent probe
Quin 2 (Tsien, I98I) has been of considerable value. This dye
is introduced into cells in an ester form, Quin 2 AM. The
hydrolysed form. Quin 2, reports intracellular levels of free
Ca^* (Tsien ejfc al., 1982a, 1984; 1983; see also Section 2.2.9*2)
Using this technique, in human platelets. Rink et al. (1982)
demonstrated that Thrombin or ionomycin caused a very rapid
increase in fluorescence, indicating an increase in cytosolic
calcium ion activity. Since then numerous workers have shown
similar results with a variety of different agonists (see
MacIntyre ejb al. , 1983b, for a recent review).
It is clear from the above citations that a number of
2+techniques are available to us for probing the role of Ca 
in platelet activation. To date the most explicit information 
has come from using Quin 2 (however newer and better Ca^*- 
indicator dyes have been developed and are discussed in 
Section 2.2.9*2). Using this technique, in human platelets.
Rink and Coworkers (198I) recorded basal cytoplasmic free 
calcium concentrations Ca^* , to be approximately 100 nM.
In a subsequent study. Rink and coworkers (1982) recorded the 
threshold levels of Ca^* , required for shape change, 3HT 
secretion and aggregation induced by A23I87* They were 0.3 pM; 
0.8 p,M and 2 ]iM respectively. In the same study however they
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demonstrated the ability of Thrombin to evoke shape change
2+and secretion at resting Ca levels. They suggested that 
alternative pathways must exist for platelet activation other 
than elevation of Ca^* . Similar conclusions were drawn by 
Knight e_fc aJ^ . (1982) using permeabilised platelets. They 
observed that different concentrations of"Thrombin were required 
to elicit dense granule and lysosomal release whereas a similar 
concentration of Ca^* could elicit both processes, implying an 
additional pathway regulating platelet reactivity.
Assuming that platelet activation is mediated, at least 
in part, by calcium ions then a ready supply of these ions 
must be obtained, possible sources being either intracellular 
or extracellular in nature.
The homeostasis of calcium in human platelets has recently 
been subject to detailed analysis (Brass, 1^84a,b,c). With 
respect to possible intracellular sources of Ca^ "*", Brass 
demonstrated the existence of two pools of Ca^* in human platelets 
one cytosolic in nature and the other possibly the dense 
tubular system. The cytosolic pool appeared to more rapidly 
exchanging pool with a t.l/2 of Ca^* exchange approximately 
17 min. All of the ^^Ca^* that had entered this pool could 
be released by digitonin. However, the possibility exists 
that the calcium released acrued from a number of separate 
pools of calcium, the existence of which has been postulated 
by Johnson et al. (1985)* For many years the dense tubular
system in platelets has been proposed to subserve a similar role 
in storing calcium as does the sarcoplasmic reticulum of muscle 
cells (white, 1972). Various studies using intracellular
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membrane fractions derived from human platelets - thought to 
correspond to the dense tubular system - have demonstrated the 
accumulation of Ca^* in the presence of ATP (Kaser—Glanzmann 
et al.> 1977; 1978; 1979» Menashi ejfc al.» 1982; Menashi ^  al.» 
1984). Other histological (Cutler ejfc al.» 1978) and immuno­
logical (Dean and Sullivan, I982) evidence also support the 
existence of an ATP-dependent Ca^* sequestrating activity in 
human platelet membranes, supposedly corresponding to the 
dense tubular system. In Brass's study, the second, more slowly 
exchanging pool (t.l/2 of several hundred minutes) was assumed 
to be the dense tubular system and acted to 'buffer* the size 
of the rapidly exchanging pool by helping to remove Ca^ "*’ from 
the cytosol. The studies of Brass and those of Kaser-Glanzman 
et al. (1977; 1978; 1979) and Menashi and colleagues (1982;
1984) help confirm that the dense tubular system probably does 
represent the most important intracellular store for calcium. 
Other possible intracellular Ca^^-stores in platelets are 
membrane-associated calcium mitochondria or dense granules. 
Membrane associated calcium has been demonstrated using the 
CTO fluorescence technique and may play an essential part in 
regulating Ca^*- availability after receptor occupation. 
Platelets contain many mitochondria and by analogy with other 
cells presumably accumulate calcium. However studies using
inhibitors of mitochondrial respiration suggest they play no
2+significant role in generating availability of Ca for platelet 
reactivity (Friedman and Detwiler, 1975)* In human platelets 
up to 60^ of platelet Ca^* is stored in dense granules (Murer, 
1969; Skaer, 1975) (although this figure is questioned by
Feinstein (1978) in a secretory pool that is not in equilibrium
with the cytosol and that presumably plays no role as a
second messenger.
In plasma the free extracellular concentration of Ca^* is
approximately 1 mM and hence represents a potential source of
calcium required for platelet reactivity. Mechanisms governing 
2+influx of Ca into platelets are ill-defined. However, one
2+possible mechanism by which Ca could gain entry to the cell 
is through a calcium 'gate* or 'channel*. To date a few studies 
have been performed which suggest the existence of a calcium 
channel in the platelet plasma membrane. In his study. Brass 
(l984a) demonstrated that Ca^* influx was maximal at free Ca^* 
concentrations 20-fold less than in plasma and inhibited by
moderate concentrations of Gd^* and La^* (< 100 pM). He
2+ 2+ concluded that Ca influx occurs through a selective Ca
channel. In a separate study Hal lam and Rink (1985a)
demonstrated that when added to Quin 2 loaded platelets, the
divalent cation Mn^^ quenched the fluorescence signal as a
result of its well known property to bind avidly to Quin 2
(Arslan et al., 1985)* They postulated that Mn^^ and Ca^^
2+enter through some sort of Ca -channel in the plasma membrane.
Like most cells, platelets possess mechanisms which maintain 
levels of I^Ca^^^ , within defined limits as well as restoring 
agonist-induced elevation of Ca^* ^. In other cells both 
Ca^^-sequestration and extrusion processes operate (Rasmussen 
and Barett, 1984). Similar processes may operate in platelets. 
While there appears to be good evidence for a Ca^ /^Mg^ "*"
ATPase existing in the dense tubular system, acting to sequester
Ca^ "*" (Cutler et al « , 1978; Menashi et al » , 1982; 1984;
2+Dean and Sullivan, I982), the mechanisms governing Ca 
extrusion from platelets is less well understood. The mechanism 
does not appear to be a Na-Ca or Ca-Ca exchange process since 
in his studies Brass (l984a,b) could not demonstrate a
dependency on either Ca^^ influx or transmembrane Na"*" gradient
2+ 2+ for Ca efflux. The existence of an ATP - d ep end en t Ca
sequestrating mechanism acting in platelet membrane lysates
has been demonstrated (Cutler et al•, 1978; Dean and Sullivan,
1982). However, histochemical studies have failed to demonstrate
the enzyme in the platelet plasma membrane (Cutler et al., 1978).
Finally, Brass (1984c) has recently suggested that glycoproteins
llb/llla may be involved in Ca^* efflux in platelets. These
proteins span the platelet plasma membrane and may form a
2+ 2 +Ca -channel. It is clear that the mechanisms regulating Ca
availability in platelets are complex and that a variety of
mechanisms exist by which agonists may perturb the homeostatic
mechanisms generating Ca^ "*" availability required for platelet
activation.
2+1.3.1.4 Mechanism of action of cytosolic free calcium, Ca ^
The targets for a regulatory increase in cytoplasmic free 
c a l c i u m , a r e  calcium receptor proteins. These proteins 
bind Ca^* with high affinity (kd 10  ^- 10 ^M) and thus undergo 
a conformational change, which leads either to a change in 
function or a change in ability to interact with other proteins= 
to change their functions. There are two classes of Ca^ "*" 
receptor protein (i) true Ca^* receptor proteins such as
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calmodulin which is present in all cells in a membrane-bound
and soluble form and troponin—C and parvalbumin, proteins found
in muscle cells, and (ii) calcium-activated enzymes with no
specific calcium receptor subunit such as calcium-activated.,
phospholipid-dependent protein kinase (Rasmussen and Barrett,
1984). The calcium target for which best evidence exists in
platelets is calmodulin (for a recent review of the role of
calmodulin in platelets, see Feinstein, I982). Calmodulin
has been identified in platelets (White ejfc a^. , I98I) and is
a low molecular weight calcium binding protein that mediates
Ca^ "*" regulation of many processes (Cheung, I98O ). It occurs in
both the cytosol and bound to membranes and undergoes a
2+conformational change upon the binding of 1-4 Ca atoms per 
molecule which renders it capable of activating a wide range 
of enzymes. Processes which are believed to be Ca^"*"-calmodulin 
activated in platelets include (i) stimulation of glycogenolvsis. 
Large amounts of ATP are consumed during platelet activation.
The levels of ATP are redressed by stimulation of cellular 
metabolism. Ca^^-calmodulin activates phosphorylase kinase 
which in turn activates phosphorylase-b to phosphorylase-a, 
the latter catalysing glycogen breakdown to glucose. Glucose 
formed in this manner can then synthesize ATP via glycolysis 
and the citric acid cycle, (ii) Activation of platelet actomyosin. 
Platelet myosin light chain kinase has been isolated, and shows 
a requirement for calmodulin (Dabrowska and Hartshorne, 1978; 
Hathaway and Adelstein, 1979)* Phosphorylation of myosin chains 
allows them to interact with actin filaments and ATP-dependent 
actomyosin contraction can take place which is involved in
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platelet activation and clot retraction (Pollard ejk a^. , 1977;
White and Gerrard, 1979; Cohen, 1979)* Although potentially 
many Ca-calmodulin activated processes do exist, the only 
direct and convincing evidence for calmodulin regulating 
platelet enzymes is for the above cited case, (iii) Regulation 
of platelet protein phosphorylation. Various proteins are 
phosphorylated by platelet agonists such as Thrombin, collagen, 
and A23I87 in cells prelabelled with P^  ^ (Lyons ejfc al. ,
1975; Haslam and Lynham, 1977)» The demonstration that the 
calcium ionophore A23187» at low concentrations, can preferentially 
phosphorylate the 20K protein (Yamanishi et al., I983) which 
corresponds to myosin li^t chain is definitive proof of an 
involvement of Ca^ "*" in protein phosphorylation. Other evidence 
originates from the use of purported calmodulin antagonists 
such as trifluoperazene (Weiss and Wallace, I980). Feinstein 
and Hadjian (198I) demonstrated the inhibition of phosphorylation 
of a polypeptide of molecular weight 2OK as well as one with 
molecular weight of 47K using trifluoperazine.
2+Another process thought to be regulated by Ca -calmodulin 
in platelets include activation of phospholipase A^ which is 
involved in release of arachidonic acid from certain platelet 
phospholipids (Wong and Cheung, 1979)»
Given the high concentrations of calmodulin present in 
eukaryote cells, including platelets, it is primarily the 
intracellular level of free Ca^* and its distribution that 
will be responsible for controlling platelet reactivity.
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1.3.1.5 Metabolic pathways of inositol phospholipids
Before discussing the role of inositol lipid metabolism 
in stimulus-response coupling it is pertinent to consider the 
metabolic pathways of inositol phospholipids. The recognized 
pathways of inositol phospholipid metabolism are detailed in 
Figures 2a and 2b. The inositol phospholipids, comprising of 
phosphatidyl inositol (Ptdlns); phosphatidyl (inositol-4- 
phosphate (PtdIns(4)P) and phosphatidyl i n o s i t o l - 4 , 5-^2 (Ftdlns 
(4,5)^2) located in the inner leaflet of the plasma membrane
and are in a state of perpetual turnover. Two different types 
of enzymes are involved in inositol phospholipid metabolism, 
namely phosphomonoesterases and phosphodiesterase(s) e.g. 
phospholipase C. The phosphomonosterases selectively remove 
phosphate from positions 4 and 5 of the inositol ring and
convert P t d l n s (4,5)P2 Ptdlns(4)P and the latter to Ptdlns.
Together with Ptdlns and Ptdlns(4)P kinases these enzymes
are responsible for the turnover of the phosphate in the 4 and
3 positions of the inositol ring, without affecting the mass 
of these inositol lipids in the steady state. There is some 
evidence that Ptdlns kinase and Ptdlns(4)P kinase may be 
controlled by receptor occupancy (Drummond ejfc al., 1984), 
perhaps through the actions of protein kinase (since phorbol 
esters and synthetic 1,2-diacylglycerols can affect the 
synthesis and levels of the polyphosphoinositides (de Chaffoy 
de Coürcelles ^  ^ . , 1984a,b). Relief of kinases from 
product inhibition, as demonstrated for Ptdlns(4)P kinase 
(Van Rooijen ejt , I983), may also account for an increase 
of flux through the kinases relative to metabolism by the
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InsPg
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#
lns(1,3‘,4,5)P4
lns(1,2-cyc,4,5)P3
Ptdlns4P
lns(1,2-cyc)P
lns4Plns1P
Free Inositol ^
lns(1,3,4)Pg
Other routes of 
dephosphorylation?
Figure 2b; Proposed metabolism and interconversion of inositol 
phospholipids and inositol phosphates.
Some of the known (bold line) and probable (broken line) inter­
conversions of inositol phospholipids and inositol phosphates 
are depicted.
After Michell, 1986
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phosphomonosterases. An important point to note is that a 
dynamic equilibrium exists between the three main inositol 
phorpholipids and that the kinases and phosphomonoesterases 
maintaining this equilibrium are amongst the most active enzymes 
in the cell (Hawthorne and Pickard, 1979)* Any change in the 
level of one of the inositol phospholipids will be rapidly 
"buffered” by compensatory changes in the levels of other 
inositol lipid species.
Phosphodiesteratic attack, by phospholipase C, causes 
the metabolism of all three inositol phospholipids, with the 
concomitant generation of the water soluble inositol phosphates, 
InslP, Ins(l,4)P2 and Ins(l,4 , from Ptdlns, PtdIns(4)P 
and Ptdlns(4,3)^2 respectively, which are then released into 
the cytosol. Various phosphatases are responsible for 
metabolising Ins(l,4,3)P^ to Ins(l,4)P2> Ins(l,4)P2 to InslP 
and InslP to Inositol (Segfred e^ aZ. , 1984; Storey ejb al. ,
1984; Joseph and Williams, 1983 and Connolly et al., 1983)»
The sequential metabolism of the inositol phosphates is probably 
responsible for the appearance of Ins(l)P since, in a variety 
of studies, agonist-induced formation of Ins(l)P lags behind 
formation of Ins(l,4,3)P^ (Berridge, 1983; Norten, 1983;
Rebecchi and Gershengorn, 1983)» The addition of lithium has 
been shown to inhibit the Ins(l)P and Ins(l,4)P2 phosphatases 
not the Ins(l,4,3)P^ phosphatase (Storey jet al. , 1984). The 
consequence of this step is to convert an otherwise complex . 
cycle into one with one accumulating end product e.g. Ins(l)P, 
thus allowing easier interpretation of agonist-induced effects 
on inositol phospholipid metabolism (Berridge et al., 1982).
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Recent evidence has been presented demonstrating the 
existence of a novel inositol trisphosphate, Ins(l,3>^)P^
(Irvine ejt , 1984a; figure 2b). The metabolism and kinetics 
of Ins(l,3>4)P^ are entirely different from those of Ins(l,4,3)P^ 
which is formed immediately following agonist exposure; 
Ins(l,3>4)P^ formation tends to be somewhat delayed as its 
decline on removal of the agonist (Irvine et al., I983;
Burgess jet a^. , 1983)* Although it is conceivable that 
Ins(l,3;4)P^ does subserve some second messenger function, 
only Ins(l,4,3)P^ has been demonstrated to mobilize intra­
cellular Ca^* (Streb ejfc a^., 1983; Irvine e_t aJ^ . , 1984b;
Burgess ejt al. , 1984a). Evidence has also been provided for 
the existence of a higher phosphorylated derivative of inositol 
phosphates, designated inositol 1,3>4,3-tetratrisphosphate 
(lns(l,3»4,3)P^ > iu rat brain slices (Batty jejfc al., 1983)» 
hepatocytes (Hansen e_t a^. , I986) and GH^ pituitary cells 
(Heslop jejt al. , 1983)* With very long prelabelling periods 
even higher phosphorylated derivatives, designated InsP^ and 
InsP^, have been isolated (Heslop ejt ad., I983; Figure 2b).
However their potential role in cellular reactivity is unknown.
The source of Tns(l,3;4,3}F^ is of crucial significance to its 
possible role in receptor mechanisms. One possibility is a 
receptor-linked phospholipase G-induced hydrolysis of an 
appropriate phospholipid, phosphatidylinositol 3>4,3-trisphosphate 
Ptdlns(3>4,3) .  Although preliminary evidence for its 
existence of this phospholipid in animal cells has been 
presented (Santiago—Galvo et al., I963) others have failed to 
confirm this finding. An alternative source could be that
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derived from Ins(l,4,5)P^* Evidence for an active and specific 
Ins(l;4,3)P^-3-kinase has been presented (Irvine et al.> I986). 
The same authors (irvine jejfc aT. , I986) propose that formation 
of Ins(1,3» 4, 5)P^ and subsequent degradation to Ins(l,3>^P^ 
(via a 5“dephosphorylation of Ins(l,3;4,3)P^; see Batty al. , 
1983) may provide an alternative route of metabolism of 
Ins(1,4,3)P^ rather than the acclaimed dephosphorylation route. 
Although it seems quite likely that Ins(l,3;4)P^ and/or 
Ins(1, 3 > 4 , 3 will turn out to have intracellular messenger 
functions of their own, this idea remains to be tested because 
so far the compounds have only been obtained in trace amounts. 
Concomitant with the formation of inositol phosphates is the 
production of 1,2-diacylglycerol, which remains in the plasma 
membrane. In most cells, 1,2-diacylglycerol is metabolised 
primarily to phosphatidic acid (PtdA) by diacylglycerol kinase. 
Carrier proteins exist which transfer the formed PtdA to the 
endoplasmic reticulum (or analogous membrane in platelets) 
where it interacts with CTP to form cytidine diphosphate 
diacylglycerol. The latter compound combines with inositol 
to form Ptdlns which is then carried back to the plasma 
membrane by carrier proteins thus completing the cycle. It 
is important to note that, regardless of the parent compound,
1,2-diacylglycerol and hence PtdA will be formed. As such 
PtdA formation is often used as an index of inositol phospho­
lipid metabolism. 1,2-diacylglycerol may also be attacked 
sequentially by diacylglycerol lipase and monoacylglycerol 
lipase thus producing free arachidonate. Mauco et al. (1984)
calculated that as much as 60^ of 1,2—diacylglycerol may be
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consumed in this fashion, the remaining hO^ c returning to the 
metabolism of inositol phospholipids, forming a common backbone 
to all inositol phospholipids. Subsequent studies (Mahadevappa 
and Holub, I986) have proposed that the diacyl/monoacylglycerol 
lipase pathway is a minor source of released arachidonate.
In passing, a special mention for phospholipase C is apt 
since, as the wealth of information suggests, this is perhaps 
the major enzyme regulating agonist induced metabolism of 
inositol phospholipids. Various studies have demonstrated that 
the phospholipase C enzyme is capable of metabolising not only 
Ptdlns (Mauco ad., 1979; Rittenhouse-Simmons, 1979;
Stess and Lapetina, I983) but also Ptdlns (4)P (Rittenhouse,
1983; Graff ^t al*, 1984) and P t d l n s (4,5)^2 (Agranoff ejfc al., 
1983; Rittenhouse, 1983)* One difficulty that had to be resolved 
was how the inositol phospholipids, located in the inner leaflet 
of the plasma membrane, could be attacked by a cytosolic enzyme. 
One possibility is that upon combining with the receptor the 
agonists induce a conformational change in it which in turn 
perturbs the membrane sufficiently to make the inositol phospho­
lipids accessible to the phosphodiesterase (irvine ad., 1984). 
An alternative proposal is that the phosphodiesterase may also 
be controlled by coupling of receptors to the enzyme through a 
GTP-binding protein in an analogous manner to the adenylate 
cyclase system (Gomperts, I983; Gilman, 1984). An early clue 
to this came with the demonstration that GTP reduced the affinity 
of noradrenaline for a^-receptors (Goodhardt e_t ad., I982), 
carbachol for muscarinic receptors (Plorio and Sternweiss, 1985)» 
and chemotactic peptides to neutrophil membranes (K o o  a d . ,
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1983)» More definitive evidence indicating an involvement of 
GTP-binding proteins in metabolism of inositol phospholipids 
has been obtained by observing the effects of introducing non- 
hydrolysable analogues of GTP into the cells. Cockcroft and 
Gomperts (1985) have shown that metabolically stable GTP 
analogues stimulate polyphosphoinositide metabolism in neutrophil 
plasma membranes. Using platelets that had been made permeable 
to small molecules, Haslam and Davidson (1984) demonstrated that 
GTP-analogous promote 1,2-diacylglycerol formation and the 
secretion of serotonin. Similar results have been obtained in 
homogenates and plasma membrane preparations from insect 
salivary glands (Litosh et al., 1985)» hepatocytes (Wallace and 
Fain, I985) and GH^ pituitary cells (Lucas ejfc al., 1985)» This 
data suggests that a novel GTP-binding protein may be involved 
in coupling receptors to phospholipase 0. However the identity 
of this GTP-binding protein has not yet been ascertained.
Numerous GTP-binding proteins probably exist, the best 
characterised being and from the adenylate cyclase system. 
Addition of pertussis toxin inhibits the activity of by 
catalysing the ADP-ribosylation of the 4lK a-subunit of this 
protein (Katada and Ui, I982). Addition of pertussis toxin to 
mast cells (Nakamura and Ui, I983), neutrophils (Verghese 
et al. , 1983) and human leukemic HL60 cells (Brandt ejt al. ,
1983; Krause et al., I983) inhibited agonist-induced cellular 
activation, including amongst, other things, metabolism of 
inositol phospholipids, suggesting that the GTP-binding protein 
may be N^. However, addition of pertussis toxin to 3T3 
fibroblasts (Murayama and Ui, I983), pituitary GH^ cells
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(Sch-legel et al « > I985) and hepatocytes (Pobin er et al. ,
1985) with concentrations that apparently cause a complete 
ADP—ribosylation of and prevention of its inhibitory effects 
on adenylate cyclase, do not prevent agonist—induced increases 
of polyphosphoinositide breakdown or Ca^* mobilization. Hence 
the exact identity of the GTP-binding protein coupled to 
phospholipase G remains elusive. However, the possibility of 
a GTP-binding protein that differs from in its susceptability 
to ribosylation and inactivation by pertussis toxin in 
different cells, but which uniquely couples to phospholipase 0 
in all cells may hold true.
Finally, the dependency of phospholipase 0 on Ca^* has
been the subject of much discussion. Various studies (Simon
et al., 1984; Chap al., I985) have demonstrated, using Quin 2
loaded platelets, the ability of thrombin to induce platelet
activation at resting levels of cytoplasmic Ca^*. In a separate
study Wilson and colleagues (1984) demonstrated, using purified
phospholipase 0 reconstituted along with radiolabelled inositol
lipid substrates into phospholipid vesicles, that whereas Ca^*
stimulated the breakdown of all three inositol phospholipids,
only the polyphosphoinositides were hydrolysed in the presence
of EGTA. Nevertheless, one must be cautious when stating
2+the dependency of an enzyme on the presence of Ca since it 
may simply require the presence of Ca^* for activation (see 
Michell ^  al., I98I).
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1.3*1.6 Metabolism of inositol phospholipids — their role in
stimulus-response coupling
The major unanswered question in cells which use Ca^ '*’
ions to elicit their response is how the Ca^* ions are made
available to the cell. Unlike the adenylate cyclase system,
where receptors are coupled in either a stimulatory or inhibitory
manner thus regulating the intracellular second messenger
2+cyclic AMP, the mechanism regulating Ca availability is
unknown or at least speculative.
Where cells depend upon the extracellular medium for their
source of Ca^^ ions the immediate problem is to overcome the
penetration of the plasma membrane. This problem can be overcome
2+by the opening of Ca "channels" in the plasma membrane
allowing Ca^^ ions to flood in down its concentration gradient.
There may be as many as three such channels (Reuter, 1983)*
The two major ones are the receptor—operated channels or 'ROC’s
and voltage—operated channels or *VOC*s. Receptor mediated
cellular activation in the absence of a change in membrane
potential, as is the case with platelets (MacIntyre and Rink,
1982), suggests that platelets rely on ROCs for gating
extracellular Ca^ "**. As outlined in Section 1.3*1*3 the
2+existence of a specific Ca channel in platelets has been 
proposed. Whether these channels represent the ROC's is 
unknown.
Mobilization of intracellular Ca^* as a consequence of
cell surface receptor occupation demands the presence of
2+intracellular mediators capable of releasing stored Ca . These 
mediators may or may not be involved in the influx of extra
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cellular Ca^* through the plasma membrane.
Over the past years, the search for these mediators has
centred primarily on the stimulated metabolism of inositol
phospholipids. These are rather minor components of the plasma
membrane, representing 3”10% of the total phospholipids, but
are the most metabolically active. The one present in the
largest amounts is phosphatidyl inositol (Ptdlns) while the
phosphorylated derivatives, phosphatidyl inositol-4-phosphate
(Ptdlns(4)P^  and phosphatidylinositol 4,3-bisphosphate (Ptdlns
(4,3)P2) each contain about 1% of the total inositol lipid
(see Figure 2c). Stimulated inositol phospholipid metabolism
was discovered by Hokin and Hokin (l953)> who demonstrated
that the incorporation of into phospholipids in pancreas
was stimulated by acetylcholine. Metabolism of the poly-
phosphoinosotides was first demonstrated by Durell ejt al.
(1969) who suggested that this stimulated metabolism may be
a part of receptor function. The first indication of an
involvement between agonist--stimulated metabolism of inositol
phospholipids and elevation of cytoplasmic free calcium was
cited by Michell in 1973* He demonstrated that occupation of
receptors which elicited the elevation of cytoplasmic free
calcium also brought about the metabolism of Ptdlns giving rise
to the phrase the "Ptdlns response". Although the hypothesis
was generally accepted there were some points of contention
such as the apparent calcium-dependency of the "Ptdlns response"
in neutrophils (Cockcroft ejfc al., 1980a,b; Cockcroft, I98I;
see also Hawthorne, 1982; Michell, I982 for critical appraisal).
Nevertheless, substantial - be it circumstantial - evidence now
exists leading to the widespread acknowledgement that changes 
in cytoplasmic free calcium concentration and inositol
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-  73 -
phospholipid metabolism are closely linked. Some of the
earliest data pertaining to this association included the work
of Fain and Berridge (Fain and Berridge, 1979» 1979a; Berridge
and Fain, 1979)* Using ^owfly salivary glands they demonstrated
that upon prolonged stimulation with 3HT, the tissue was unable
to transport Ca^^ (Berridge and Fain, 1979)* This effect
was associated with an inability to resynthesize Ptdlns (due
2+to an apparent Ca -dependent block in the synthetic pathway 
between Ptdlns and PtdA) (Berridge and Fain, 1979)* Addition 
of inositol to the preparation restored the ability of 3HT to 
elicit Ca^"*"-transport (Berridge and Fain, 1979; Fain and 
Berridge, 1979a), thus reinforcing the proposed link between 
inositol phospholipid metabolism and Ca^* mobilization. Other 
evidence includes the many coincidences between calcium- 
mobilizing agonists and stimulated inositolphospholipid 
turnover (Michell and Kirk, I98I) and equally important numerous 
negative controls (that is, receptors which do not mobilize 
calcium do not stimulate the metabolism of inositol phospho­
lipids). Many studies have demonstrated a strong correlation 
between occupation of specific receptors, metabolism of inositol 
phospholipids and elevation of cytoplasmic free calcium 
(Michell £t al. , 1976; Kirk ejb al. , I98I; Evans al. , I983) 
suggesting that the phenomenon is a receptor operated event 
and not a non-specific action at the plasma membrane.
Recent evidence suggests however that it is not the 
metabolism of Ptdlns that is the initial event occurring after 
agonist-receptor interaction but rather the metabolism of the
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phosphorylated derivatives namely Ptdlns(4)P and Ptdlns(4,3)P2*
In rat hepatocytes, Michell e_t al. (198I) demonstrated that
addition of vasopressin resulted in a decrease in P t d l n s (4,3) P2
which preceded any changes in Ptdlns and was largely independent
of extracellular calcium. Purthennore, the demonstration
that the formation of Ins(l, 4 , 3 >  the water soluble product
of P t d l n s ( 4 , 3 )P2 metabolism, precedes that of Ins(l)P (the
water soluble product of Ptdlns metabolism) in insect salivary
glands (Berridge, I983; Berridge eJb ^ .  , 1984a) and GH^ pituitary
tumor cells (Rebecchi and Gershengorn, I983; Martin, I983)
provides additional evidence that P t d l n s (4,3)P2 fact
the primary substrate in agonist stimulated metabolism of
inositol phospholipids. Perhaps the most tantalizing evidence 
2+linking Ca fluxes and metabolism of inositol phospholipids, 
especially P t d l n s  (4,3 )l*2 originates from studies where levels 
of polyphosphoinositides have been depleted by lowering levels 
of cellular ATP. Under these conditions, agonist addition is 
unable to exert effects on intracellular Ca^^ levels (Poggioli 
et al., 1983)* However, an alternative interpretation of 
this particular data could be that by lowering intracellular 
levels of ATP one is interfering with an ATP-dependent 
mechanism regulating Ca^ '*’ availability. This ATP-dependent 
mechanism may or may not be dependent on the absolute levels 
of the polyphosphoinositides. In simplistic terms, depletion 
of cellular ATP levels may merely interfere with energy 
dependent processes leading to an inability of the cell to 
respond to external stimuli (Akkermann ^t al., I983)*
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Nevertheless, there are now many studies supporting the
notion that the metabolism of P t d l n s (4,5)P2 ^ common
response in a variety of different cell types using primarily 
2+Ca ion to elicit their responses (see Berridge, 1984 for 
comprehensive list).
1.3.1.7 Agonist-induced metabolism of inositol phospholipids
The first evidence for the metabolism of inositol phospho-r 
lipids in platelets was reported as early as the 1970's by 
jjoyd and coworkers. They demonstrated the incorporation of
Pj^ into PtdA, Ptdlns, Ptdlns (4)P and Ptdlns (4,5 )P2 
rabbit platelets exposed to ADP (Lloyd jet al. , 1972, 1973) 
and collagen and Thrombin (Lloyd and Mustard, 1974). Later a 
rapid but transient Thrombin-induced increase in 1,2-diacyl- 
glycerol and decrease in Ptdlns was reported (Ri11enhouse- 
Simmons, 1979» Bell and Majgrus, I980). Metabolism of Ptdlns 
and a concomitant formation of PtdA was demonstrated in human 
platelets by Broekman _ejt a^. (1980) . As described previously
(Section 1.3*1*6) the initial event in agonist-induced metabolism 
of inositol phospholipids is believed to be the metabolism of 
Ptdlns(4,5)P^* Consequently many studies have demonstrated a 
rapid and transient agonist-induced decreases in labelled 
polyphosphoinositides. In human platelets using ^ hrombin, a 
decrease in labelled Ptdlns(4,5)P2 followed by an increase 
has been demonstrated (imai ^t al., I983» Agranoff, I983)* 
Measuring the mass of inositol phospholipids, Vickers 
et al. (1982) in rabbit platelets demonstrated a decrease in
both mass and radiolabelled phosphorous of Ptdlns(4,5)P2 
platelets activated by ADP. Using Thrombin, in human platelets.
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Broekman (1984) similarly demonstrated a decrease in mass 
of P t d l n s (4 j3 )P2 followed by an increase in this inositol 
lipid* As would be expected a concomitant production of 
inositol phosphates can be demonstrated in platelets labelled 
either with P^ or^I^inositol. Agranoff et al. (1983)
demonstrated a very rapid increase in (p^P^labelled Ins(l,4,3)P^ 
within seconds after thrombin stimulation. Thrombin-induced 
formation of [Pl^labelled Ins(l,4)P2 lns(l,4,3)P^ have been
detected before significant accumulation of InslP in human 
platelets (Watson et al., 1984) and rabbit platelets (Vickers 
et al.9 1984). The above citations support the concept that 
metabolism of P t d l n s ( 4 , 3 ) B2 amongst the initial events 
that follow receptor occupation and inherent in this theory 
(as expounded by Michell ejb al. , I98I) disappearance of Ptdlns 
occurs as a result of compensatory resynthesis of depleted 
polyphosphoinositides.
However recent data suggests that the metabolism of 
inositol phospholipids, at least in platelets, may not be as 
straightforward as first seems. Wilson ejb al. (1983) demonstrated 
using non-equilibrium labelling techniques, that the flux or 
rate of conversion of Ptdlns to Ptdlns(4P) and P t d l n s (4,3) P2 
in human platelets stimulated with thrombin was not fast 
enough to explain the decrease in Ptdlns. They proposed that 
all three (i.e. Ptdlns, PtdIns(4)P and PtdIns(4,3)P2^ be 
metabolised. However, this proposal is inconsistent with the 
fact that no significant amounts of [^ H^^  InslP are produced 
in platelets labelled with inositol soon after agonist
addition (Seiss, 1983)*
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1.3*1*8 Metabolism of inositol phospholipids and generation of 
effectors or second messengers 
While there appears little doubt that the metabolism of 
inositol phospholipids is a recurrent feature of receptors 
acting predominantly through calcium, the exact nature of the 
mechanisms governing cellular reactivity in these cells is just 
beginning to unfold. It now appears that roles for most of the 
intermediaries in the inositol phospholipid metabolic cycle 
exi s t.
1.3*1*8.1 Role of Ptdlns(4,5)P2> Ptdlns and PtdA
Ptdlns(4,5)?£ Insides being a substrate for phospholipase C, 
may also be a potential source of Ca^^ required for cellular 
reactivity. Ptdlns(4,5)P2 known to bind Ca^^ with high 
affinity (Dawson and Hauser, 1970) and it is possible that upon 
its metabolism it may release its source of Ca^^ (Billah and 
Lapetina, 1982). The original hypothesis put forward by 
Michell (1975) envisaged that metabolism of Ptdlns in some way 
resulted in the opening of a calcium channel in the plasma 
membrane thus allowing an influx of Ca^^. Subsequent theories 
included an ionophoric effect for PtdA (Putney et al., I98O).
Lyso PtdA (produced from PtdA by the action of phospholipase A^) 
was also proposed as an ionophore in platelets (Lapetina ejfc al., 
1981a). However the discovery by Holmes and Yoss (1983) that 
neither PtdA nor lysoPtdA could translocate Ca^* across the 
membranes of purified phosphatidyl choline vesicles suggested 
they might not be important regulators of calcium flux. The 
possible role of inositol phospholipid metabolism in mediating
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2+Ca influx is, at present, unknown, however recent evidence 
suggests that Ins(l,3,4)P^ or indeed Ins (l,3 > 4,3 )Pji^ may play 
a role in Ca^ "*" influx through the plasma membrane (see Section
1.3.1.8.2).
1.3*1*8.2 Role of inositol phosphates
While there still remains some doubt as to the nature of 
the relationship between the metabolism of inositol phospho­
lipids and the influx of Ca^^, there appears little doubt, 
from the now copious literature, that the link between such 
metabolism and mobilization of Ca^^ from intracellular stores 
is Ins(l,4,3)P^ - the water soluble product from metabolism 
of PtdIns(4,3)P2*
The first suggestion that this may be the case was put 
forward by Berridge and colleagues (1983» 1984). They observed, 
in insect salivary glands, that upon addition of serotonin,
accumulation of Ins(l,4,3)P^ occurred with no apparent lag,
2+however the physiological Ca -dependent response was delayed 
by approximately 7s. They concluded that Ins(l,4,3)P^ may 
act to mobilize intracellular calcium. Increases in Ins(l,4,3)P^ 
following cell stimulation also precede physiological responses 
in liver (Thomas ejt al. , 1984) and GH^ pituitary tumor cells 
(Drummond e_t a^. , I983) thus confirming their proposal. The 
finding that Ins(l,4,3)P^ was metabolised equally quickly 
suggested that it may in fact be the effector or second messenger 
which could mobilize intracellular Ca^*.
In 1983 Streb and coworkers demonstrated the ability of 
exogenously added Ins(l,4,3)P^ to mobilize intracellular calcium 
in a preparation of leaky rat pancreatic acinar cells. Similar
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observations were later found in a variety of cell preparations 
including liver (Burgess et , 1984; Joseph et , 1984)
GH^ pituitary cells (Gershengorn ^  , 1984) Swiss 3T3 cells
(Berridge et al., 1984) as well as human platelets (O'Rourke 
et £il * > 1985» Authi and Crawford, I983; Adunyah and Dean, 1983)* 
Perhaps the most definitive work demonstrating a second messenger 
role for Ins(l,4,3)P^ is the observation that direct introduction 
of this water-soluble metabolite, by microinjection, into sea 
urchin eggs caused exocytosis of cortical granules and the 
appearance of a fertilization envelope (Whitaker and Irvine, 
1984). Additionally, introduction into intact photoreceptor 
cells of Liraulus evoked a voltage response similar to that 
produced by light (Fein ejfc al•, 1984; Brown ejt al•, 1984).
The store from which Ins(l,4,3)P^ releases Ca^* is most likely 
to be the endoplasmic reticulum (or dense tubular system in 
platelets) since inhibition of mitochondrial function by removing 
metabolic substrates or by adding inhibitors has no effect on 
the ability of Ins(l,4,3)P^ to release calcium (Streb et al.,
1983; Joseph £t ^ .  , 1984; Gershengorn £t ^ . , 1984). This 
conclusion is supported by cell fractionation experiments, 
which demonstrate that Ins(1,4,3)P^ can release calcium from 
microsomes but not from isolated mitochondria (Prentki et al.,
1984).
The mechanism by which Ins(l,4,3)P^ releases intracellular 
Ca^+ is thought to involve its interaction with specific sites 
or receptors on the endoplasmic reticulum. Spat et al. (1986)
have demonstrated that Ins(l,4,3)P^ binds to a specific and 
Saturable site in permeabilized guinea pig hepatocytes and
- 80 -
rabbit neutrophils. The properties of this binding site were 
consistent with it being the physiological receptor for 
Ins(l,4,5)P^" Recent studies by Dawson at ad. (I986) have 
demonstrated that a protein, phosphorylated by GTP, has to bind 
to microsomal membranes before Ins(l,4,5)P^ can stimulate Ca^* 
release. Whether these two mechanisms are mutually exclusive 
remains to be seen. The exact concentrations of Ins(l,4,3)P^ 
that can be attained after cell stimulation is unknown. However, 
several estimates suggest that micromolar levels, which are 
within the levels active on permeabilized cells, can be attained 
(see Berridge and Irvine, 1984). Termination of calcium 
mobilization induced by Ins(l,4,5)P^ apparently involves the 
action of a phosphomonoesterase on Ins(l,4,5)P^ (Authi and 
Crawford, I983; Storey e_fc al., I986). Recently a new dimension 
to the Ca^^-mobilizing role of Ins(l,4,3)P^ has been introduced 
by Putney (1986). He proposed that besides mobilizing Ca^^ 
from intracellular stores, Ins(l,4,3)P^ may also provide a 
mechanism for Ca^^ influx into the cell. Based on a capacitance 
theory, the generation of Ins(l,4,3)P^ facilitates both Ca^* 
mobilization from intracellular stores and Ca^^ influx through 
the plasma membrane. Whether this theory is upheld remains to 
be seen. Preliminary experiments performed in rat liver 
plasma membrane vesicles (Hansen et al., I986) ascribe a similar 
role to the higher phosphorylated derivative Ins(l,3,4,3)P^* 
Again, this observation awaits further confirmation.
In addition to mobilizing Ca^* from intracellular (and 
possibly extracellular) sites Ins(l,4,3)P^ has been demonstrated 
to induce platelet activation (Brass and Joseph, I983) possibly
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vis arachidonic acid metabolites (Authi ^  , I986;
Vatson et al., I986). Ins(l,4,5)P^ has also been demonstrated
to induce phosphorylation of 4OK and 20K proteins (Watson a^.,
1986; Lapetina ejb al. , 1984). Whether or not these effects
2+are mediated directly by Ins(l,4,5)P^ or via released Ca and 
the biochemical/physiological relevance of such effects is not 
known.
In the majority of cases where cells have been demonstrated
to utilize Ca^* as part of their stimulus-response coupling
mechanism, it appears that Ins(l,4,5)P^ is the second messenger
releasing intracellular Ca^^. Possible exceptions could be in
smooth and skeletal muscle where, although Ins(l,4,3)P^ has
2+been demonstrated to induce release of Ca from intracellular 
stores (Volpe e_fc al. , I983; Volpe ad., I986; Yamamoto and 
Breemen, I983)» its involvement here is by no means certain.
Other water soluble products of inositol phospholipid metabolism 
such as inositol l:2-cyclic 4,3-triphosphate also appear to 
have calcium mobilizing activities (Wilson ejb ad., 1983)*
Despite difficulty in isolating this compound, due to its 
rapid metabolism under the acidic conditions used to extract 
inositol phosphates, it appears that this compound is as likely 
as its non-cyclic derivative to subserve a second messenger 
function in stimulated cells (Wilson ejt ad., 1983)»
1.3.1.8.3 Role of 1,2-diacylglycerol
As indicated in Section 1.3*1*3 the addition of the calcium 
ionophore A23187 to platelets results in their activation, thus 
indicating a role for Ca^* ions in platelet reactivity.
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However, the studies by Rink et al. (198I) who demonstrated
that Thrombin could evoke platelet shape change and secretion 
at resting levels of cytoplasmic free calcium and those of 
Knight ejfc ad. (1982) who demonstrated that different concentration 
of Thrombin were required to evoke the same degree of secretion 
from dense granules and lysosomal granules whereas similar 
concentrations of Ca^^ could elicit both processes (see Section 
1.3.1.3) suggested that processes, other than an elevation of 
cytoplasmic free calcium, must operate in platelets resulting 
in their activation. This additional process is believed 
to involve the interaction of 1,2-diacylglycerol and Ca^^- 
dependent, phospholipid-dependent protein kinase C.
Protein kinase C was first isolated by Inoue e_fc al. (l977) 
as a proteolytically-activated protein kinase. Subsequent 
studies demonstrated it to be a Ca-dependent, phospholipid- 
dependent enzyme (Takai ad., 1979)* Experiments carried 
out by Nishizuka and colleagues later demonstrated that the 
lipid 1,2-diacylglycerol could greatly increase the affinity 
of protein kinase C for Ca^* thereby activating it (Takai ejfc a^., 
1979a; Kishimoto e_t al. , I98O; Nishizuka, I980). Very rapid 
and transient increases in 1,2-diacylglycerol are detected 
soon after activation of a variety of cell types, including 
platelets, which previously were assumed to utilize Ca^ "*" alone 
as a second messenger (Rittenhouse-Simmons, 1979)* it is 
believed that 1,2-diacylglycerol produced in activated cells 
plays a physiological role in activating protein kinase C.
This belief originated from the above observation that 1,2- 
diacylglycerol, a product of agonist-induced inositol phospho­
lipid metabolism, could increase the affinity of protein kinase
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for thereby activating it (Kawahara e^ al•> I98O; Takai
et al« > 1982; Nishizuka, 1984). Such observations were enhanced 
by the work of Castagna ejk ad. (1982) and Kaibuchi ejk ad. (1982), 
Castagna e_t ad. (1982) demonstrated that a number of phorbol 
esters could stimulate protein kinase C in a manner analogous 
to 1,2-diacylglycerol. Indeed it can be demonstrated that 
phorbol esters and 1,2-diacylglycerol can compete for binding 
sites on protein kinase C (Sharkey e_t ad. , 1984), and as such 
protein kinase C has been proposed as the receptor for phorbol- 
esters (ergo 1,2-diacylglycerol) (Kikkawa e_t ad., I983;
Nishizuka, 1984). Only biologically active 4P-phorbol esters 
such as TPA, phorbol dibutyrate and phorbol dibenzoate are 
able to activate protein kinase C, while others such as 4a- 
phorbol didecanoate - which is not biologically active - fail 
to affect protein kinase C (Couturier et ad., 1984). Kaibuchi 
et ad. (1982) demonstrated that synthetic mimetics of 1,2- 
diacylglycerol such as l-oleoyl-2-acetyl-sn3-glycerol (GAG) 
can mimic the effects of naturally produced 1,2-diacylglycerol. 
Again this effect proved highly specific since monoacylglycerol 
or triacylglycerol or fatty acids fail to activate the enzyme 
(Castagna e_t ad., 1985)*
That activation of protein kinase C can occur only when 
biologically active phorbol esters and mimetics of 1,2- 
diacylglycerol are used suggests that activation of protein 
kinase C is a highly specific event. Furthermore, addition 
of phorbol esters to samples of platelets does not result in 
either metabolism of inositol phospholipids or formation of 
endogenous 1,2-diacylglycerol (Nishizuka, 1984; Castagna at al.,
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1985; Castagna et al., I982). However, studies have been 
performed which demonstrate that the effects of phorbol esters 
and synthetic analogues of 1,2-diacylglycerol are not directly 
comparable (Ashby at , I985; Kiss and Luo, I986). One 
further dimension to the enzyme protein kinase C, is that 
upon agonist-induced elevation of 1,2-diacylglycerol, the 
enzyme is translocated from the cytosol to the plasma membrane 
(Drust and Martin, 1985)» a phenomenon possibly regulated by 
cytoplasmic levels of calcium (Wolf at al., I983; May at al.,
1985).
The addition of phorbol esters or OAG to human platelets 
results in secretion and aggregation in the absence of changes 
in basal cytoplasmic free calcium levels (Rink ak a^. , I983; 
at least as reported by Quin 2). This independence from 
changes in cytosolic free calcium levels has recently been 
challenged by Ware afc ad. (1983) who suggest that small discrete 
changes in cytosolic free calcium evoked by agents like OAG 
may not be detected using Quin 2, which is diffused throu^out 
the cell, but may be detected using aqueorin which tends to 
report localised changes in cytoplasmic calcium concentration. 
Whether or not phorbol esters or OAG do in fact elicit the 
elevation of cytoplasmic free calcium, the biological (cellular) 
response induced by these agents is qualitatively different 
compared to that evoked by a receptor-directed agonist; 
being delayed and somewhat slowed (Rink ejk ad., 1983; Rink and 
Hallam, 1984). Subsequent studies demonstrated that low 
concentrations of calcium ionophore or OAG which alone could 
induce very little secretion can produce a full secretory
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response when added in combination with each other (Kaibuchi 
et al« > 1982; 1983; Rink ejfc ad., I983; Rink and Hadlam, 1984). 
The synergistic effect of the calcium-dependent pathway 
(mediated by elevation of Ca^*) and the calcium-independent 
pathway (mediated by 1,2-diacylglycerol activated protein 
kinase C) represents a bifurcating signal pathway. Such a 
system can provide the versatility necessary to introduce 
subtle variations in the control mechanism and is observed 
not only in platelets, but in a variety of other cells 
including lymphocytes (Mastro and Smith, I983) and adrenal 
glomerulosa cells (Kojima ejb ad. , I983) to name but two.
(See also Nishizuka, 1984).
The degree to which individual agonists utilize each 
pathway is unknown. However, in human platelets, some way 
towards understanding the mode of action of physiological 
agonists such as collagen. Thrombin and ADP was carried out 
by Rink and Hallam (l984). They envisaged collagen acting 
primarily through the 1,2-diacylglycerol-protein kinase C 
pathway, ADP through the Ca^^-dependent pathway and Thrombin 
acting through both, thus possibly accounting for the fact 
that Thrombin is one of the most efficacious platelet 
agonists known. However such observations - at least with 
respect to collagen and ADP - diverge from the widely held 
belief that an integral aspect of agonist-receptor interaction 
in a variety of different cell types is in fact the synergistic 
action of Ins(l,4,3)P^ - ergo mobilization of Ca^* - and
1,2-diacylglycerol - ergo activation of protein kinase C.
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Collagen has been demonstrated to elicit the formation of
1,2-diacylglycerol at basal levels of (Rink ejb al^ . , I983).
One possible explanation for such an effect, as proposed by
Rink and Sanchez(l984) could be that collagen preferentially
hydrolyses a compound other than Ptdlns(4,5)^2’ possibly
Ptdlns, such that no formation of Ins(l,4,5)P^ occurs but still
allows formation of 1,2-diacylglycerol. However, Watson at al.
(1983a) since demonstrated the formation of lns(l,4,3)P^ in
collagen treated (human) platelets. Nevertheless, these
authors could find no detectable mobilization of Ca^* as
monitored by Quin 2. The possibility remains that as an
2+indicator of small, localised transients of Ca , that Quin 2
may not be the most sensitive probe to use (see Section 2.2.9*2).
Hence whether or not collagen can induce elevation of cytosolic 
Ca^* remains to be ascertained. Using ADP as the agonist, a 
number of workers have demonstrated that this agonist elicits 
an elevation in cytosolic Ca^* without the concomitant metabolism 
of inositol phospholipids - ergo Ins(l,4,3)P^ and 1,2- 
diacylglycerol formation (MacMillan al. , 1984; MacIntyre 
et al. , 1983c; Fisher ejfc , I983)* Recent studies 
demonstrated that the response to ADP, in human platelets, 
was not voltage dependent (Hallam and Rink, I983)* Hence the 
mechanism whereby ADP elevates cytosolic Ca^* remains an enigma.
Addition of Thrombin (Kawahara ejt al • , I980) , collagen 
(Sano e_t al. , I983) or platelet activating factor (leyasau 
et al., 1982) to platelets results in the phosphorylation of 
two proteins of molecular mass 2OK and 40K. In intact platelets
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one of the major substrates for protein kinase C appears 
to be the 40K protein (leyasau ^  al. , 1982; Sano al. , 1983)*
Phosphorylation of the 40K protein has been associated with 
platelet secretion (leysau ejb al. , 1982; Sano ejk al. , 1983; 
see also Nishizuka, 1984). However the exact relationship 
between phosphorylation and secretion is not clear since an 
increase in 40-47K protein phosphorylation can be shown to occur 
in the absence of secretion if permeabilized platelets are 
challenged with 1,2-diacylglycerol in the presence of 0.01 tiM 
Ca^* (Knight ejfc al., 1984; Haslam and Davidson, 1984). The 
effects of protein kinase 0 has been demonstrated to be 
suppressed by the addition of trifluoperazine, chlorpromazine 
(Sanchez ejt al . , I983) or 1-(3-isoquinoline-sulfonyl )-2- 
methylpiperazine (H7) (inagaki jet al. , 1984). The use of 
such compounds, especially the latter, will be useful in 
discerning whether or not activation of protein kinase C by
1,2-diacylglycerol does fulfil any physiological role in 
cellular activation.
Besides exhibiting synergism with Ca^* ions, activation
of protein kinase C, by 1,2-diacylglycerol, is now thought to
be involved in inhibitory feedback mechanisms in a number of
different cell types. Lagast ^  (1984) demonstrated, in
neutrophils, that phorbol esters could suppress agonist-
induced elevation of cytoplasmic free calcium and attributed
2+it to an activation of a Ca -extrusion process. Prior 
addition of phorbol esters to human platelets was also shown 
to suppress the increase in cytoplasmic free calcium induced
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by platelet agonists such as Thrombin (MacIntyre et al., 1983d; 
Zavoico et al., 1983)» However, since basal cytoplasmic 
concentrations of Ca^* were not affected, this effect of phorbol 
esters in human platelets can not be attributed to the activation 
of an extrusion process. Addition of phorbol esters at the 
peak of agonist-induced elevation of cytoplasmic free calcium 
has been demonstrated to accelerate the decline in Quin 2 
fluorescence (MacIntyre ejt al. , 1983a; MacIntyre ejfc ad. , 1983b) 
and a number of other cells including GH^ pituitary tumor cells 
(Drummond, I983)» rat basophilic leukemic cells (Sagi—Eisenberg 
et ad. , 1983) and PC 12 cells (Vincintini ejt ad., 1983)*
Addition of agonist to a sample of platelets (MacIntyre ejb al. , 
1983a) or GH^ pituitary tumor cells (Drummond, I983) pre­
incubated with Quin 2 often exhibit an increasing rate of decline 
as the agonist concentration is increased. This suggests that 
the cells are limiting their response to high concentrations of 
agonists by activating an intracellular negative feedback 
mechanism. In view of the ability of phorbol esters to alter 
or reduce agonist-induced changes in cytoplasmic free calcium 
consequently, it was postulated (Drummond and MacIntyre, I983); 
that such a regulatory mechanism may operate vis activation 
of protein kinase C.
Not only are agonist-induced changes in cytoplasmic free 
calcium attenuated or inhibited by addition of phorbol esters, 
but the metabolism of inositol phospholipids also seems to be 
affected by these compounds. In platelets, thrombin, vasopressin, 
and PAF induced metabolism of inositol phospholipids, monitored 
as L^^p3 -PtdA formation, was impaired by phorbol esters
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(MacIntyre et al., 1983d; Zavoico ejfc ad., 1983)* Such, effects 
on inositol phospholipid metabolism are observed in a number 
of other cell types including neutrophils (Naccache et al.,
1983) PC12 cells (Vinientini aJ^ . , I983) and GH^ Pituitary 
tumor cells (Drummond, 1983)» In their study MacIntyre et al. 
(1983d) suggested that the mechanism by which activated protein 
kinase G results in the inhibition of inositol phospholipid 
metabolism could be attributed to an inhibitor of phospholipase 
C. However, the design of their experiments could not preclude 
alternative actions e.g. on 1,2-diacylglycerol kinase or 
Ptdlns(4)P phosphomonoesterase. Subsequent studies by Rittenhouse 
and Sasson (1983) demonstrated that phorbol esters attenuated 
Thrombin-induced formation of Ins(l,4,3)P^ - an effect consistent 
with inhibition of phospholipase 0. Given the proposed link 
between Ins(l,4,3)P^ and Ca^* mobilization, inhibition of inositol 
phospholipid metabolism by activated protein kinase C may 
represent a mechanism by which agonist-induced changes in 
cytoplasmic free Ca^ "*" are attenuated or inhibited.
The possibility that an intermediary in agonist-induced 
metabolism of inositol phospholipids e.g. 1,2-daiacyglycerol 
could both facilitate and inhibit cellular reactivity led to 
the concept that protein kinase C may subserve a bidirectional 
role in cellular activation (Drummond and MacIntyre, 1983)*
One interesting divergence from this concept is the observation 
made by Krishnamurthi jejfc aT. (1986) who demonstrated that OAG 
could potentiate the actions of Thrombin in human platelets, 
but observed no inhibitory effect with this compound. OAG is 
a synthetic analogue of 1,2-diacylglycerol and, like its
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endogenous counterpart, is rapidly metabolised. Consequently, 
studies utilizing this compound may prove more physiologically 
relevant than those using phorbol esters. The ability of 
synthetic mimetics of 1,2-diacylglycerol and phorbol esters 
to stimulate the formation of polyphosphoinositides (de 
Chaffoy de Courcelles ejb ad., 1984a,b; Halenda and Feinstein, 
1984; Taylor ejb ad., d984), apparently by increasing the 
activity of Ptdlns and Ptdlns(4)P kinase by an unknown mechanism, 
represents another divergence from the proposed bidirectional 
control of cellular reactivity by protein kinase C. By 
stimulating the formation of polyphosphoinositides - rather 
than inhibiting cellular reactivity as inherent in the bi­
directional control proposal - this effect of protein kinase C 
could conceivably act as a positive feedback mechanism by 
generating and/or maintaining a supply of inositol phospho­
lipids ergo generation of second messengers. However no 
convincable evidence has been presented to suggest that 
increased levels of polyphosphoinositides have any effect on 
the levels of second messengers. Additionally, the ability 
to stimulate formation of polyphosphoinositides has been 
demonstrated only in platelets (de Chaffoy de Courcelles,
1984a,b; Halenda and Feinstein, 1984) and thymocytes (Taylor 
et al., 1984).
Other effects of 1,2-diacylglycerol, presumably acting 
through protein kinase C, include modulation of adenylate 
cyclase activity and receptor regulation. In platelets, using 
phorbol ester-activated protein kinase C, both stimulation 
and inhibition of cyclic AMP formation has been demonstrated.
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The former may result from phosphorylation of the regulatory 
unit (Katada _et , 1983; Watanabe et , I983) and latter 
from phosphorylation of receptors that mediate an increase 
in cyclic AMP (Bushfield âi.* > I986).
Modulation of receptors by phorbol ester-activated protein 
kinase C has also been demonstrated. In some cells agonist 
binding is inhibited. This may be a direct consequence of 
phosphorylation of the receptors by protein kinase C since 
receptors for somatomedin, insulin, EGF, transferin and his tone 
have been shown to be substrates for the enzyme (Anderson 
et al., 1983)* Internalisation of receptors for EGF and 
transferin (Beguinot ejt al. , I983) has also been demonstrated. 
Protein kinase C activation may be involved in receptor 
internalisation or desensitization as a general phenomenon 
for termination of agonist-mediated transduction processes 
(Macara, 1983)»
Because the biological effects of activated protein kinase 
C have been evaluated mainly using phorbol esters or synthetic 
analogues of 1,2-diacylglycerol, which may not act in a 
similar fashion to endogenously produced 1,2-diacylglycerol 
and the doubt as to whether sufficient 1,2-diacylglycerol is 
produced in cells with physiological agonists to fully activate 
protein kinase C, much more investigation is required before 
à complete understanding of the role of protein kinase C in 
cellular activation is attained.
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1.3.1.9 Inositol phospholipid metabolism and generation of 
arachidonic acid and cyclic GMP
In addition to metabolising inositol phospholipids and 
elevating cytoplasmic free calcium, receptors which act 
predominantly through calcium generate significant amounts of 
arachidonic acid and elevate cytoplasmic levels of cyclic GMP 
(Berridge, 198I).
Inositol phospholipids are enriched in the Sn-2 position 
with arachidonic acid, but oleate or linoleate can also be 
detected, albeit in significantly lower amounts. During 
agonist-induced metabolism of inositol phospholipids there 
appears a preferential degradation of molecules such that the
1,2-diacylglycerol and subsequently the PtdA, produced by the 
receptor mechanism predominantly carriers of arachidonic acid 
in the Sn-2 position (Bell e_t al^ . , 1979» Mahadevappa and 
Holub, 1983)» The release of arachidonic acid from inositol 
phospholipids and its subsequent metabolism to icosanoids 
has been outlined (Section 1.1.3*4). Released arachidonic 
acid and/or its metabolites has been demonstrated to activate 
guanylate cyclase (Graff ejb al. , 1978; Craven and DeRubert, 
I98O; Gruetter and Ignarro, 1979)* The role of cyclic GMP 
in cellular reactivity, unlike the role of cyclic AMP is 
widely contested. None more so in platelets. Addition of 
membrane-permeant derivatives of cyclic GMP such as 8-bromo- 
cGMP results in the inhibition of thrombin-induced inositol 
phospholipid metabolism, elevation of cytoplasmic free calcium, 
and secretion of serotonin (Nakashima ejt al. , I986). Addition
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of sodium nitroprusside, which elevates levels of cyclic GMP 
selectively, at the peak of the Quin 2 fluorescence signal 
induced by platelet activating factor in human platelets 
resulted in an accelerated decrease in fluorescence signal 
(MacIntyre ejt ad. , 1985a) suggesting that cyclic GMP may play 
a role in calcium mobilization. Certain platelet stimulatory 
agonists have been reported to cause cyclic GMP formation, 
this occurs relatively late after agonist addition and may 
represent a mechanism by which platelets can regulate their 
reactivity (Haslam et al., I980). However, data exists which 
demonstrates that an increase in cyclic GMP is ineffective 
(Weiss ejfc al. , 1978) or that its addition may actually enhance 
platelet reactivity (Chiang ejk al •, 1976).
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2. MATERIALS AND METHODS
2.1 Materials
The following materials from the indicated sources were 
used in the undertaking of this project. Unless otherwise 
stated, all drugs were dissolved in distilled water to give 
stock solutions in the mM concentration range with subsequent 
dilutions being carried out in 0.9^ saline.
2.1.1 Drugs and reagents
Bovine thrombin, adenosine, adenosine 3 *-monophosphate 
acid (a m p ); Adenosine 5 *-diphosphate (ADP); Adenosine 5*- 
triphosphate (ATP); Prostaglandin E^ (PGE^) and Digitonin 
were purchased from Sigma (U.K.).
Hirudin; Adrenaline-tartrate and Adenosin-5 ' -0-|]3- 
thiotriphosphatej (ATP^S) were purchased from Serva, Heidelberg; 
Koch-Light Laboratories (U.K.) and Boehringer Corporation 
(London) respectively. Both prostaglandin I^ (PGI^) and 
9,11-epoxymethane prostaglandin H^ (u44069) were donated by 
Dr J.E. Pike (Upjohn, U.S.A.). PGI^ was dissolved in Tris-HCl 
buffer, pH 9.2. Other prostaglandins were dissolved initially 
in ethanol and diluted to 3*3 mM stock by addition of 9 vol. 
Na2C0^(3 mM) with subsequent dilutions in saline. Quin-2- 
acetoxy methyl ester (Quin 2 AM), purchased from Lancaster 
synthesis (Morecambe), was dissolved in dimethyl-sulphoxide 
(DMSG).
Bovine serum albumin; HEPES; phospholipid standards 
trichloro-acetic acid (TCA); ethylene glycol bis-(P-aminoethyl 
ether)N,N,N*-tetraacetic acid (eGTA); trypan blue and Dowex 
1 X  8(Cl” form, 100-200 mesh) were purchased from Sigma (U.K.)o
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All compounds used in tissue culture (Dubecco's modified 
eagles medium (DME); Hanks balanced salt solution HESS ; 
foetal calf serum (FCS); Penicillin-Streptomycin (5OOO p,/ml) 
and Neomycin (10,000 ^g/ml) were purchased from Gibco-Europe.
Rat promegakaryoblasts (RPM) were a gift from Drs R. Weinstein 
and T. Maciag, Harvard Medical School, Boston, U.S.A. ‘ =
TLC plate macherney Nagel "Polygram Silica G" 
precoated glass plates (Camlab, Cambridge, U.K.) and Merck 
Silica Gel 60 HP-TLC plates (Macfarlane Robson Ltd., Glasgow,
U.K.) were purchased. The following compounds were also 
purchased; Folin and Gocaltean's phenol reagent (BDH Chemicals 
Ltd.); triton X-100 and scintol 2 (Koch-Light Laboratories Ltd.); 
Ecoscint (National Diagnostics, New Jersey); X-ray developer 
and fixer (Agfa Ltd.). All organic solvents and other
laboratory reagents were of analytical grade.
2.1.2 Radiochemicals
Carrier-free i orthophosphate (P\) was kindly supplied,
gratis, by the regional isotope dispensary (Western Infirmary,
Glasgow, U.K.). 5-Hydroxy G-^H tryptamine creatinine sulphate
(17 mCi/mmol); 8-^H Adenine (24 Ci/mmol); myo-(2-^H) inisitol 
(13.8 Ci/mmol) were from Amersham International (Amersham,
U.K.).
2.2 Methods
2.2.1 Rat Platelets
2.2.1.1. Preparation of rat platelets
Blood was obtained from the vena cava of rats of either 
sex under light ether anaesthesia and collected into plastic
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tubes containing 10^  ^(v/v) trisodium citrate (O.IM) and 
centrifuged (800g; 10 min; 15-20°C). The supernatant platelet- 
rich plasma was aspirated into plastic tubes with care taken 
to avoid contamination with red or white blood cells. Platelets 
were then pelleted by centrifugation (2000g; h min, 13-20^0) 
in the presence of PGI^ (lOO hM) to prevent platelet activation 
(Moncada e_t al. , I982). The supernatant plasma was aspirated 
and the platelets suspended in the appropriate buffer depending 
upon the nature of the experiment (vide infra).
2.2.1.2 Radioisotope labelling of washed platelets
Metabolism of inositol phospholipids in rat platelets was 
monitored in cells prelabelled with L^^P^ P^. Rat platelets 
obtained as described (Section 2.2.1.1) were suspended in 
calcium-free, phosphate-free buffer (NaCl, I30 mM; KCl, 4 mM; 
MgCl^» 1 mM; Na-Hepes, 3 mM; dextrose, 10 mM; Bovine serum 
albumin, 0.3?^ ; pH 7.4) at 10^ cells/ml and incubated with
-free Q^^P^ -orthophosphate (30 ]iCi/ml) for 90 min at 
37^C, at which point labelling of PtdA approached steady-
state (equilibrium) conditions (Figure 3)» Platelets were 
then pelleted by centrifugation (2000g, 4 min, 13-20°C) in 
the presence of PGT^ (lOO uM) and resuspended in approximately
1.3 times the original labelling volume of fresh buffer.
2.2.1.3 Measurement of platelet cytosolic free calcium, Cca^t^-
loading with calcium indicator dye Quin 2 AM 
2 +Ca was measured using the fluorescent indicator dye 
Quin-2-acetoxy methylester (Quin 2 AM). Rat platelets obtained 
as described (Section 2.2.1.1) were suspended in a modified
c a m  er 
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Figure 3 ; Incorporation of P Pj into rat platelet 
phospholipids with time.
Rat platelets (v/1 x 10^ cells/ml) were incubated with 
[_32pj PI (30 p.ci/ml) for the times indicated, prior to 
extraction of phospholipids (Section 2.2.3.2.1);- 
phosphatidicacid (O); phosphatidylinositol (O); 
phosphatidylcholine (/^  ) ; phosphatidyl ethanolamine 
(•). Results are expressed as DPM (mean - SO). The 
experiment shown is typical of one other experiment.
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Hepes—buffex'ed tyro des (MaClf X20ib]M; Na^ citrate» 8 * 9n#I;
NaHCO^t 8.9mtî; OExtrose, 5,5mM; Hep es, 5mM; KH^PO^, 0.8mM;
MgCl , 0#84mM; CaCl^, 24mM, pH ?.4) at 10^ cells/ml. Platelets
were iacuTbated with Quin 2AM (20|iM final concentration; 37®C;
10 min) before pelleting by centrifugation (2000g; 4 min; 
15-20°C) in the presence of PGI^ (lOO nM). Quin 2 labelled
platelets were suspended in fresh buffer at a concentration
8of 5 ^ 10 cells/ml, and were kept at room temperature 
throughout the duration of the experiment.
Note that the above procedure 'differs from that used in
human platelets (Rink et al., 1982; Pollock et al.» 1984).
Most importantly, incubation with Quin 2 AM is performed in 
plasma—free suspensions of washed platelets, as opposed to 
platelet rich plasma, because preliminary experiments indicated 
that plasma esterases, or other plasma constituents, interfere 
with the uptake of dye into the cell. Incubation of rat 
platelets with Quin 2 AM resulted in an intracellular 
accumulation of 2.54 — O.39 mmol/litre (mean — SD, n = 4)
Quin 2.
2.2.2 RPM
Rat promegakaiyoblasts, or RPM, are a cell line originally 
obtained by Cicorla and Hempling (I980) from the bone marrow 
of a female bong-Evans rat. They have been characterised, 
both morphologically and biochemically, by Weinstein et al. 
(1981) as being similar to normal rat pr omegakaryobl as ts.
RPM are grown in suspension cultures with Dulbecco's 
Modified Eagles Medium (DME) supplemented with 10^ foetal
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calf serum (PCS) (vide infra). Under these conditions, the 
cells are in a proliferative mode. However, should they be 
grown under conditions of serum deprivation, or exceed a 
cell density of approximately 4 x 10^ cells/ml(approximately 
7 days continuous culture) they stop proliferating and undergo 
a process of maturation, passing through three stages, Stage I 
or promegakaryoblast; Stage II or megakaryoblast and Stage III 
or mature megakaryocyte (Weinstein ejb al. , I98I). During the 
latter stages of Stage III, small vesicular bodies are visible, 
these have been designated Stage IV. Representative 
illustrations of each stage in RPM maturation, using light 
microscopy, are depicted in Figure 4. The following outlines 
the procedures used to maintain RPM in cell culture and their 
preparation for experimentation.
2.2.2.1 Methods of cell culture
Rat promegakaryoblasts (RPM) were grown and maintained 
under conditions essentially as outlined by Weinstein ejb al. 
(1981). RPM were grown in stationary suspension culture stocks 
in 100 mm cell culture dishes (Nunc) in Dulbecco*s Modified 
Eagle’s Medium (DME) and 10^ foetal calf serum (FCS) at 37°C 
in an automatic 00^ incubator (Forma Scientific, Marietta,
Ohio, USA) under a humidified atmosphere of 959^  air/y^ CO^* 
Antibiotics benzyl penicillin (lOO iu/ml) and streptomycin 
(100 p,g/ml) were included to cope with minor bacterial contam­
inations which could have arisen from non-sterile culturing 
techniques. Cells were monitored regularly using a light 
microscope (Labovent, Leitz).
-  _LUU -
#
Figure 4 ; Light microscopy of the RPM cell 
line in various stages of maturation.
Top left: Stage I (promegakaryoblasts); 
middle right: Stage II (immature mega­
karyocytes); middle left: Stage III 
(megakaryocytes); Bottom right: Stage IV 
(vesicular bodies).
After Weinstein al. 
(1981).
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2.2.2.1.1 Maintenance of aseptic conditions
All aseptic manipulations were performed in a vertical 
laminar flow hood (Microflow Ltd., Andover, Hants, U.K.).
Every operation using sterile solutions included the use of 
either 1 ml sterile graduated pastettes (Alpha Labs., Eastleigh, 
England); 5 ml sterile graduated movettes (Nunc, Roskilde,
Denmark); or 10 ml sterile graduated plastic pipettes (Falcon) 
when necessary. Operations with 10 ml pipettes were made 
easier by the use of an automatic "Pipetus" obtained from 
Flow Labs., Irvine, Scotland.
2.2.2.1.2 Passaging of RPM
RPM were seeded at 1 x 10^ cells/lOO mm plastic petri- 
dishes in 10 ml of culture medium unless otherwise stated.
On the day of passaging - usually seven days from previous 
passage and after 4 "doubling times" - the cells from one dish 
were gently aspirated and transferred to individually wrapped 
17 X 100 mm sterile plastic tubes (Falcon) and pelleted (700g;
8 min; 25°C). The resulting cell pellet was suspended in 
fresh DME (lO mis) and 1 ml of cells aliquoted into sterile 
petri dishes containing the complement of medium outlined 
in Section 2.2.2.1.
2.2.2.2 Preparation of RPM
RPM were harvested by centrifugation (700g; 8 min; 25°C) 
and suspended in Hanks Balanced Salt Solution (HBSS) |3 NaCl,
137 mM; KCl, 5.4 mM; MgSO^, 0.4 mM; Na^HPO^, 0.3 mM; NaHCO^,
4.1 mM; KH^PO^, 0.4 mM; MgCl^» 0.49 mM; Glucose, 5«5 mM;
CaCl^, 0.1 mM; pH 7'4^ at a cell concentration of approximately
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6 X 10^/ml. Cell viability, assessed by trypan blue exclusion, 
was routinely approximately 90% in both, treated and untreated 
cells. After suspension cells were ready for immediate use.
The methodology for labelling RPM with [p^p] P^ and inositol
is outlined in the following sections.
2.2.2.3 Radioisotope labelling of RPM with ^^P P^
On day 6 after previous passage RPM were harvested as 
in Section 2.2.2.2 and seeded at a cell concentration of
1.1 X 10^/ml in 260 ml sterile plastic bottles (Nunc) containing 
DME and FCS. The cells were incubated with carrier free t?^P^
(3 p.Ci/ml; 24 hrs; 37°C). RPM were then pelleted by centri­
fugation (yOOg; 8 min, 15-20°C) before suspension in HBSS at 
a cell concentration of approximately 6 x 10^ cells/ml. After 
24 hrs incubation, approached equilibrium conditions
with respect to PtdA, Figure 5*
3
2.2.2.4 Radioisotope labelling of RPM with H Inositol
3 1On day 4 after previous passage inositol (lO p,Ci/dish)
was added to several dishes and allowed to grow as normal for 
a further 3 days. On the seventh day, the cells were harvested 
as before (Section 2.2.2.2) and suspended in HBSS, containing 
10 mM LfCl , at a cell concentration of approximately 6 x 10^ cells 
y^ ml. The inclusion ofU/Cl , prevents the hydrolyses of inositol 
phosphates and thus facilitates their detection (Berridge 
_et ^ .  , 1982; see also Section 1.3.1.5). Incorporation of 
^H inositol into inositol phospholipids was detected, values
being 3IOI76 - 33416 dpm for P t d l n s ( 4 , 5 ) P 2 »  ^9940 - I9696 dpm
for Ptdlns(4)P and 10092 - 3460 dpm for Ptdlns (results means
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P Pj into RPM phospholipidsFigure 5 ; Incorporation of 
with time»
6 32
RPM ( 1 X 10 cells/ml) were incubated with P P^ ^
(1.5 Ci/ml) for the times indicated, prior to extraction
of phospholipids (Section 2.2.3.2.2):- Phosphatidic acid (O);
phosphatidylinositol (□ ); phosphatidyl choline (A ) ;
phosphatidyl ethanolamine (# ). Results are expressed as
DPM (mean - SD). The experiment shown is typical of one
other experiment.
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- SEM> n = 2). Thus accumulation of inositol phosphates
can be assumed to be derived from these inositol phospho­
lipids .
2 +2.2.2.5 Measurement of RPM cytosolic free calcium, Ca -
loading with Quin 2 AM.
RPM prepared as described (Section 2.2.2.2) were suspended 
in HBSS at a cell concentration of approximately 6 x 10^ cells/ml. 
They were incubated (37^C> 35 min) with Quin 2 AM (lO pM, final 
concentration) before pelleting by centrifugation (700g> 8 min,
13-25°C) and washed twice in fresh HBSS to remove unincorporated 
Quin 2 AM before final suspension at a cell concentration of 
approximately 6 x 10^ cells/ml. Under such incubation conditions, 
intracellular accumulation of Quin 2 was O.69 - 0.34 mmol/litre 
(mean - SD, n = 4). RPM were kept at room temperature throughout 
the duration of the experiment.
2.2.3 Phospholipid Studies
The experimental procedure for monitoring inositol 
phospholipid metabolism in cells prelabelled with [p^P^ was
essentially similar for both rat platelets and RPM. The 
experimental technique for monitoring accumulation of inositol 
phosphates is described in Section 2.2.3«^*
2.2.3.1 Metabolism of inositol phospholipids in cells prelabelled 
with D^:^P^
Radiolabelled cells (0.5 ml platelets, containing approximate­
ly 0.94 mg protein; 0.4 ml RPM, containing approximately 0.54 mg 
protein) were dispensed into plastic tubes at 37 C. The maximum
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number of samples in any single experiment was 30 whilst within 
each experiment triplicate determinations for each drug/vehicle 
treatment were performed. Reactions were initiated by the 
additions of agonists (usually 5 pi) in the presence of» or 
subsequent to, the addition of antagonists (usually approximately 
5 pi) or the appropriate vehicle as a control. The design of 
the individual experiments was such that from start to finish 
of each one, a period of approximately 20-30 min had elapsed.
Once the reactions had been terminated, extraction of phospho­
lipids were carried out immediately.
2.2«3'2 Phospholipid Extraction
In order to optimize the efficiency of phospholipid 
extraction from rat platelets and RPM, separate extraction 
procedures for each cell type were utilized.
2.2.3*2.1 Extraction of phospholipids from rat platelets 
Extraction of phospholipids from rat platelets was 
performed essentially as described by Schacht (198I). Reactions 
were terminated by removal of the entire platelet sample into 
a glass test tube containing 1.5 ml of Chloroform;Methanol 
(l;2) (v,v) on ice. Partition of aqueous and organic phases
was facilitated by the addition of 0,5 ml, 2.4N HCl and O.5 ml
chloroform. The lower (organic) phase was then removed to a
clean glass test tube and the upper (aqueous) phase and protein 
interface was washed with 1 ml chloroform. The second lower 
phase was combined with the first and the combined lower phases 
were washed with 2 mis of methanol: IN HCl (l:l) (v/v). Between
each partitioning step of the extraction procedure the tubes
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vortexed briefly and centrifuged (lOOO RPM, 3 min, 3°C). The 
final lower phase was removed into a glass vial, dried at 43°C 
under nitrogen and stored at -20°C until use, usually within 
2k hrs.
2.2.3*2.2 Extraction of phospholipids from RPM
Extraction of phospholipids from RPM was carried out 
essentially as described by Method B of Lloyd et (1972).
Reactions were terminated by removal of the entire sample to 
glass test-tubes containing 2 ml of Chloroform;Methanol; ION HCl 
(l00;200:8, v/v/v) at room temperature. Phospholipids were 
extracted by partitioning of the aqueous and organic phases 
following the addition of 0.623 ml of chloroform and 0.623 ml 
of distilled water. After vortexing the tubes and centrifugation 
(yOOg, 3 min, 13-20°C) the lower (organic) phase was removed 
into a glass vial, dried at 43^0 under nitrogen and stored at 
-20^0 until use, usually within 24 hrs. The above procedure 
was performed when only PtdA and Ptdlns were required to be 
monitored. ¥hen resolution of the polyphosphoinositides e.g. 
Ptdlns(4,3)P^ and PtdIns(4)P were required, the more efficient 
Schacht extraction (Section 2.2.3*2.l) was used.
2.2.3.3 Separation of phospholipids bv thin layer chromatography 
Two techniques were utilized to resolve the phospholipids 
extracted from rat platelets and RPM. When only PtdA and Ptdlns 
Were required to be resolved, the technique described by Yavin 
and Zutra (l977) was used. The technique as outlined by 
Jolies e^ (198I) was performed to resolve the polyphospho­
inositides, namely Ptdlns(4,3)P2» PtdIns(4)P as well as Ptdlns 
and PtdA.
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2.2.3«3»1 Separation by thin-layer chromatography of PtdA and 
Ptdlns
Lipids were dissolved in O.I5 ml of Chloroform;Methanol 
(9:l) (v/v) and spotted on silica-gel t.l.c. plates (lO cm x 
10 cm) (silica Gel, 25; Camlab) for two-dimensional separation 
of phospholipids (Yavin and Zutra, 1977)* This t.l.c. system 
employs a basic solvent in the first dimension - Chloroform; 
Methanol;40^ aqueous methylamine (l3:6;1.5) (v/v/v); diethyletheri 
acetic acid (glacial) (l9:l) (v/v) for the intermediary m n
(through the second dimension) and Chloroform; acetone;methanol; 
acetic acid (glacial);distilled H^O (lO;4;2;3:l) (v/v/v/v/v) 
for the second direction. The glass chromatographic chamber 
was lined at both ends with Whatman I filter paper, and the 
tanks were equilibrated with the solvent mixtures (approximately 
200 mis in total) 2 hrs before commencing the separation. All 
three organic mixtures were freshly prepared and a total of 30 
plates could be run without significant loss of resolution.
Phospholipid samples were applied at the lower left hand 
corner (2 cm in), using a 10 p.1 disposable micro-pipette. The 
solvent was dried in a stream of warm air. A total of 8 plates 
could be run in one batch. After a period of approximately 
25 min in the first solvent, by which time the solvent front 
was within 1 cm from the edge of the plate, the plates were 
removed and dried in a stream of warm air for IO-I5 min whilst 
placed on a tray. Each plate was then exposed to the fumes 
of a concentrated solution of HCl for approximately 5 min.
The plates were then dried in warm air for approximately 5 min, 
then cool air for an additional 3 min. The plates were then
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placed in the second solvent running in the second dimension 
(origin at lower right corner) for a period of 10-13 min. 
Following this ether;acetic acid wash the plates were dried 
for 3—10 min in a stream of cool air before placing in the 
third solvent in the same dimension as that immediately above.
A period of approximately 23 min was needed to allow the solvent 
front to reach within 1 cm of the edge of the plate. At this 
point the plates were removed from the solvent and allowed to 
dry, thoroughly, in a stream of cool air. After drying, the 
phospholipids were visualized by placing the plates in an iodine 
vapour tank. The spots corresponding to PtdAs and Ptdlns (see 
Figure 6) were scraped into polythene scintillation vials and 
counted for radioactivity in a scintillation counter (see 
Section 2.2.6).
2.2.3.3.2 Separation by thin-layer chromatography of polyphospho­
inositides
Lipids were redissolved in 0.13 ml of Chloroform;Methanol 
(9;1, v/v) and spotted as 1.3 cm bands (l.3 cm from edge) on 
potassium oxalate (l^ in Methanol ; distilled v/v))
impregnated HP-TLC plates (Silica Gel, 60; Merck, 20 x 20 cm) 
under a stream of warm air. Prior to spotting the plates were 
’activated' by placing in an oven for 13 min at 110°C. The 
plates were developed, in the longitudinal dimension, in 
Chloroform;acetone ;methanol; glacial acetic acid;distilled 
(40;13;13;12;8; v/v/v/v/v) until the solvent front was 12-14 cm 
from the base line. The solvent was always freshly prepared.
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(1)
Chloroform 
Methanol 
40% Methylamine 
(13:6:1. 5 v /v /v )
(2) Diethyl Ether 
Acetic Acid 
(19:1 v/v)
(3) Chloroform 
Acetone 
Methanol 
Acetic Acid 
Water
(10:4:2:3:1 v /v /v /v /v )
Figure 6 ; Schematic representation of phospholipid separation bv 
two-dimensional thin layer chromatography.
Phospholipids identified by iodine staining are indicated. 0 - origin;
1. Neutral lipid; 2. phosphatidyl ethanolamine; 3. phosphatidyl choline;
4. sphyngomyelin/lyso-phosphatidyl ethanolamine; 5. phosphatidyl inositol; 
6. phosphatidyl serine; 7. phosphatidic acid; 8. plasmalogen lyso- 
phosphatidyl ethanolamine.
— 110 —
Individual phospholipids were visualised by autoradiography 
(X-Omat S plates, Kodak) and identified using phospholipid 
standards. Phospholipids separated by this method are illustrated 
schematically in Figure 7» Ptdlns(4,5)P2 Ptdlns(4)P migrate 
as discrete bands as does Ptdlns. PtdA migrates with, or just 
behind, the solvent front. The spots corresponding to the 
relevant phospholipids were scraped into polythene scintillation 
vials and counted for radioactivity as before.
2.2.3*4 Metabolism of inositol phospholipids in cells prelabelled 
with L^h ] inositol
Rat platelets, like human platelets, fail to incorporate 
inositol into their phospholipids in a cost-effective manner 
(Section 2.2.9*1*2). However, due to the fact that RPM are 
grown and maintained in culture,L^H^ inositol can be incubated 
with the cells and incorporated into the phospholipids over a 
period of days. RPM, prelabelled with Q^H^ inositol, (0.3 ml, 
containing approximately O.67 mg protein) were dispensed into 
plastic reaction tubes at 37°C. The maximum number of samples 
in any single experiment was 24, whilst within each experiment 
triplicate determinations for each drug/vehicle treatment were 
performed. Reactions were initiated by the additions of agonists 
(usually < 3 p,l) or appropriate control. The design of the 
individual experiments meant that the duration of each experiment 
lasted 20-30 min. Once the reactions had been terminated, 
extraction of inositol phosphates was carried out as detailed 
in Section 2.2.3*5*
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Ptdlns
Figure 7 ; Schematic representation of phospholipids separated 
by one dimensional thin layer chromatography.
Phospholipids identified by iodine staining are indicated.
0 - origin; PtdIns4,5P2 (Phosphatidyl inositol-4,5-bisphosphate; 
PtdIns4P (Phosphatidyl inositol-4-phosphate; Ptdlns (Phosphatidyl 
inositol); PtdA (Phosphatidic Acid); NL - Neutral Lipids;
SF - Solvent Front.
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2*2«3»5 Extraction of inositol phosphates
Extraction of inositol phosphates from RPM was performed 
as follows. The reactions were terminated by adding 0.5 ml of 
20^ (w/v) trichloroacetic acid (ice-cold). After 10 min at O^C, 
precipitated proteins were removed by centrifugation (lOOOg;
10 min; 4°C). The acid soluble fraction was collected and 
analysed immediately or frozen (-20°C) until (pH^ inositol 
phosphates were to be analysed. Unfrozen or thawed aliquots of
inositol phosphates were extracted three times with h volumes 
of water-saturated diethylether. After driving off the residual 
ether in a boiling water bath, the inositol phosphates in
the extracts were then separated on dowex anion-exchange columns.
2.2.3.6 Separation by anion-exchange chromatography of inositol 
phosphates
Samples of inositol phosphates were collected and
distilled water was added (usually < 200 p,l ) to obtain a 1 ml 
aliquot. The 1 ml sample was then applied to columns containing 
approximately 1 ml of Dowex 1 x 8  anion-exchange resin (formate 
form) and the phosphate esters eluted, essentially as described 
by Berridge e_t aT. (1983) by the stepwise addition of solutions 
containing increasing levels of formate. The following procedure 
was routinely followed; inositol eluted by addition of 7 ml
distilled water; glycerophosphoinositol with 8 ml 3mM-
disodiumtetraborate/60mM-sodium formate; L?h1 InslP with 8 ml 
O.IM formicacid/o.2M-ammonium formate; L^hI Ins(l,4)P^ with 
O.IM formic acid/0.4M ammoniumformate and Ins(l,4,3)P^
with O.IM formic acid/lOM ammonium formate. 2 ml samples of each 
fraction was taken for liquid-scintillation counting.
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2.2.4 Measurement of cytosolic free calcium,
^Ca^^^ was measured using the fluorescent calcium indicator 
dye Quin 2 (Tsien, I982). The polycarboxylic anion permeates 
the cell membrane in the form of acetoxymethyl Quin 2 or Quin 2 AM. 
Once it has passed through the cell membrane it readily distributes 
throughout the entire cytoplasm where it is cleaved by non­
specific esterases, generating and trapping the active form of
the dye. Quin 2, in the cytoplasm.
2 + 2+ .Quin 2 binds Ca preferentially, compared to Mg , in a
1:1 stiochiometry with an apparent dissociation constant of 
113 nM. Upon binding Ca^^ the dye exhibits an increase in 
fluorescent intensity which can be calibrated to reveal Lca^ "|^  ^  
(vide infra).
In both cell types, 0.3 ml aliquots together with 1.3 ml 
buffer (modified Hepes buffered tyrodes or HBSS depending upon 
cell type) were placed in a 1 cm square quartz cuvette and 
fluorescence was monitored in a Perkin Elmer - LS3 Fluorescence 
Spectrometer, thermostatted at 37°C, with standard monochromator 
settings of 339 iim - excitation and 492 nm emission. To record 
the development of response a chart recorder (Linseis) was 
linked to the spectrometer. Prior to addition of agonist to 
rat platelet samples, the external free calcium was adjusted 
to 1 mM by addition of CaCl^* For RPM studies, sufficient Ca^* 
was present in the HBSS and no further addition was required. 
Changes in fluorescence consequent upon agonist addition, were 
recorded and calibrated to levels of , using the
following formula:-
= Kd(F - F^.^)
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where F is the fluorescence recorded, F . and F are themin max
fluorescence recordings at very low and very high Ca^ "*" 
respectively* Kd is the dissociation constant = 115 uM.
Fmax determined by saturating Quin 2 with Ca^*. This
was achieved by lysing the cells with digitonin (50 p,M for
rat platelets and 100 p,M for RPM) which exposed the entrapped
dye to the high extracellular calcium concentration. The
addition of EGTA (0.02M, final concentration) to both rat platelet:
and RPM chelated all available Ca^* thus allowing determination
of F . .min
Preliminary investigations were carried out to test the 
validity of this technique, for measuring levels of jca^ "*’J ^  in 
both rat platelets and RPM.
Tsien et al. (l982a) demonstrated that upon hydrolysis of
Quin 2 AM there is a spectral shift and peak fluorescence at 
492 nm (when excited at 430 nm) indicating the formation of 
the active dye Quin 2. Studies following the spectral character­
istics of cells loaded with Quin 2 AM (Figures 8a and b) 
demonstrates a peak in fluorescence at around 492 nm, suggesting 
the presence of Quin 2 in these samples. In addition to being 
present inside the cells, an optimal intracellular concentration 
of Quin 2 - in the millimolar region - is desired in order to 
report accurately concentrations of Cca^tJ^. Reference to 
Sections 2.2.1.3 and-2.2.2.5 demonstrate that this criterion is 
met with, intracellular concentrations of Quin 2 of 2*5 niM and 
0.69 mM being present in rat platelets and RPM respectively.
As already noted. Quin 2 is a Ca^^-chelator (see also Section
2.2.9.2) and may in fact blunt transient increases in or
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Figure BA; Spectral characteristics of rat platelets incubated with Quin 2 AM.
Aliquots (2 ml) of rat platelets incubated in the presence of Quin 2 AM (closed 
symbols) as outlined in Methods (Section 2;2;1:3) or absence of Quin 2 AM (open 
symbols) were excited at 339 nm and their emission spectra followed. Presence 
of Quin 2 is indicated by subtracting (auto) fluorescence detected in platelets 
not incubated with Quin 2 AM (open symbols) from fluorescence detected in Quin 2 
AM loaded platelets (closed symbols) to yield the difference spectrum which is 
attributed to Quin 2 (dotted line). Fluorescence measured in arbitary units.
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Figure 8B» Spectral characteristics of RPM incubated with Quin 2 AM.
Aliquots (2 ml) of RPM preincubated in the presence of Quin 2 AM (closed 
symbols) as outlined in Methods (Section 2:2;2:5) or absence of Quin 2 AM 
(open symbols) were excited at 339 nm and their emission spectra followed. 
Presence of Quin 2 is indicated by subtracting (auto) fluorescence detected 
in RPM not incubated with Quin 2 AM (open symbols) from fluorescence detected 
in Quin 2 AM loaded RPM (closed symbols) to yield the difference spectra 
which is attributed to Quin 2 (dotted line). Fluorescence measured in 
arbitary units.
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slow down rapid increases induced by agonists. This phenomenon 
may be expected to be more pronounced in studies involving rat
platelets compared to those utilizing RPM. Vith hindsight
studies designed to estimate the importance of this phenomenon by 
performing the experiments with a range of intracellular concentr­
ations of Quin 2 should have been performed. However,time did not 
permit this.
Finally, Quin 2 AM has been reported to be non-toxic in lympho­
cytes up to a concentration of 2-3 mM (Tsien ejk a±,j 1982a). In 
order to demonstrate that - at the concentrations used in the 
present experiments - Quin 2 AM was non-toxic — several indices
of cellular viability were recorded. Figures l4 and 31 i%i the
Results Section demonstrate platelet aggregation in the presence 
of Quin 2 AM, the responses obtained suggest no untoward damage 
to the cells has occurred. In the present studies it was 
difficult to demonstrate biological activity of RPM subsequent 
to agonist addition (see Section 3*2.1.1). However, using 
Trypan Blue exclusion, pretreatment with Quin 2 AM routinely 
revealed approximately 90fo viability. Similar degrees of 
viability were reported in the absence of dye.
2.2.5 Platelet Functional Tests
Washed platelets prepared under labelling conditions, but 
with the label P^  ^ or Quin 2 AM excluded, were examined
by platelet aggregometry as an index of functional responsiveness 
under the experimental techniques used. Aliquots (0.4-5 ml) of 
rat platelets prepared as described were placed in plastic 
cuvettes in a thermostatted (37°C) aggregometer. Aggregation, 
measured photometrically using an aggregometer (Malin Electronics) 
was initiated by the addition of agonist or appropriate vehicle,
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usually <5 P-1 volumes were added. The development of aggregatory 
response was followed on a Linseis chart recorder. The extent 
of aggregation was measured by expressing the net maximal 
increase in aggregation induced by an agonist as a percentage 
of maximal aggregation observed using 50 nM (l ^/ml) Thrombin.
2.2.6 Quantification of Radioactivity
After iodine had sublimed, identified spots/bands were 
scraped using a surgical blade and incorporated radioactivity 
quantified by liquid scintillation spectrometry (Packard, Model 
3390)• Scintillant used was either 10 mis toluene:triton-X 100: 
Scintol 2 (1223:667:100, v/v/v) or 5 ml Ecoscint (National 
Diagnostics, N. Jersey). 2 ml aliquots of the separated
inositol phosphates were quantified in a similar manner 
using either 20 ml of toluene:triton-XlOO; scintol 2 or 10 ml 
Ecoscint.
2.2.7 Calculation of Results
Results obtained from the scintillation counter were 
corrected for background radiation then expressed as counts per 
minute (cpm); disintegrations per minute (dpm) or as fold 
stimulation of control levels where a value of 1, by definition, 
is equivalent to basal levels. Simple statistical analyses of 
replicate values within an experiment was carried out to give 
mean values - standard deviation (S.D.) or - Standard error of 
the mean (S.E.M.). Statistical significance between the effect 
of an agonist and the control (vehicle or distilled water or 
saline), or the effect of an agonist and the effect of an 
antagonist, was calculated using Student’s^t-test. Significant
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differences are indicated by probability (p) values;
* = P < 0.05; ** = P < 0.005; *** = P < O.OOO5. The term
EC^q is used to describe the concentration of agonist that 
elicits 509  ^of the maximum response to that agonist.
2.2.8 Other Assays 
Trypan Blue Exclusion
Viability of RPM were monitored before and after each 
labelling procedure by obtaining a 1:100 dilution of RPM with 
trypan blue (0.59^  trypan blue in 0.99^  saline). Cells were 
counted using a haemocytometer (Hawksley, England) and a 
light microscope (Labovent, Leitz).
Protein Determination
Proteins were determined by the method of Lowry et al. 
(1951) using bovine serum albumin (Sigma) as standard.
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2.2.9 Aim of Study and Rationale behind Studies
Besides acting at the level of the platelet, antithrombotic 
drugs, such as aspirin, may also act at the level of the pro­
genitor cell, the megakaryocyte. Studies by Demers e_b al.
(1980) and Worthington and Nakeff (1982) demonstrated a lack of 
cyclooxygenase activity in rat platelets after aspirin treatment 
at times long after the drug would have been removed from the 
animal. They proposed that aspirin, in addition to inhibiting 
platelet cyclooxygenase, may also inhibit cyclooxygenase in 
megakaryocytes. In a separate study, using human tissue.
Bye ejfc al. (1979) demonstrated the inability of arachidonic acid 
to cause platelet aggregation four days after administration 
of aspirin. They also concluded that aspirin may have an effect 
on platelet progenitor cells. Before further studies can be 
undertaken in investigating a possible dual site of action for 
antithrombotic drugs, or even a single action at the level of 
the megakaryocyte, a thorough background knowledge of the 
mechanisms underlying cellular activation in both these cell 
types is required. Such investigations will aid further studies 
into whether or not megakaryocytes are a potential site for 
antithrombotic therapy. However, any such investigation would 
require a ready supply of viable megakaryocytes. The difficulty 
of obtaining human bone-marrow tissue and the paucity of cells 
obtainable from such sources (see Section 1.2) precluded the 
use of human tissue in the present studies. However, to resolve 
this quantitative limitation I used a cell line of rat bone
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marrow derived promegakaryoblasts or RPM. These cells were 
derived from the bone-marrow of a long-Evans female rat by 
Cicoria (Cicoria and Hempling, I98O) and can be grown and 
maintained in culture thus allowing limitless supply of 
tissue for investigation. Having assured myself of the 
similarity between normal rat promegakaryoblasts and the 
RPM line (see Section 2.2.2) I undertook an
— 121 —
investigation into the mechanisms underlying cellular reactivity 
in both rat platelets and RPM. Although the RPM are represent­
ative of a maturational stage occurring early in the sequence 
of rat megakaryocyte development, it would prove interesting to 
observe whether or not the mechanisms (biochemical and/or ionic) 
regulating cellular reactivity were established in these cells 
and to compare them with those occurring in their progeny, rat 
platelets. Mechanisms thought to govern cellular reactivity 
in a number of different cell types, including human platelets, 
include the following: i) generation of cyclic AMP; ii) production 
of arachidonic acid metabolites ; iii) inositol phospholipid 
metabolism and iv) changes in cytosolic free calcium 
Preliminary studies, carried out in this department using RPM, 
demonstrated that these cells could both synthesise cyclic AMP 
after exposure to a suitable stimulus and synthesize icosanoids 
(MacIntyre e_t al. , 1983a,b). Table 1 demonstrates that after 
addition of 0.1-10 p,M agonist, RPM were capable of synthesizing 
significant amounts of cyclic AMP. Interestingly, 1-10 "jiM PGD^ 
failed to elicit significant formation of cyclic AMP suggesting 
that like rat platelets (Hwang, I980), RPM do not possess 
receptors for PGD^. Table 2 demonstrates the ability of RPM 
to synthesize a range of icosanoids when labelled with an 
appropriate marker. Significant amounts of PGE^, TXB^ and 
PGD^ are formed with lesser amounts of 6 keto PGE^^ and PGF^^ 
being detected. Again these results are similar to those 
attainable when using rat platelets.
The present study aims to investigate the nature of the 
remaining two mechanisms, namely inositol phospholipid metabolism 
and changes in cytoplasmic free calcium [ca^ '*’J in both rat 
platelets and RPM, subsequent to agonist addition.
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xcofeftwovo Concentration (pM) Cyclic AMP
(pmoles'10^ ceils)
P G E i 0.1 0.83 + 0.44
PG E i 1.0 1.87 + 0.69
P G E i 10.0 4 .90+  1.30
PGIg 0.1 0.09 + 0.09
PGI2 1.0 0.46 + 0.23
PGI2 10.0 2.39 + 0.30
PGD2 0.1 0
PGD 2 1.0 0.07 + 0.07
PGD2 10.0 0.23 + 0.14
PGP2^ 0.1 0
PGF2^ 1.0 0
PGF^x 10.0 0
6 Keto P G E i 0.1 0 .1 + 0 .1 0
6 Keto PG Ei 1.0 0.53 + 0.50
6 Keto PG E i 10.0 2.3 + 0.83
PG E2 0.1 0.58 + 0.43
FG E 2 1.0 1.33 + 0.44
PG E2 10.0 9.00 + 1.61
Table 1 ; Icosanoid-induced cyclic AMP formulâtion by RPM.
Icosanoids were incubated with RPM for 60 sec, at 37°C and 
reactions terminated by the addition of ethanol. Total cyclic 
AMP was measured by competitive protein binding assay. Results 
are mean values - SEM, above basal levels of cyclic AMP, of 
3-4 experiments each performed in triplicate.
After MacIntyre at al. ,
(1983a)
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icosanoids % Radioacitivity
6 keto PG F-|^
PG F20C 
PG E2
Tx 02 
PG D2
1.73 + 0.16
4.25 + 0.61
9.48 + 0.41
8.34 + 0.36
7.09 + 0.50
Table 2; Icosanoid production by RPM.
3
RPM, or medium alone in control samples, were incubated with H 
arachidonic acid at 37°C for 2 hours. Lipids were then extracted 
from the cell-free supernatent, separated by TLC and identified 
using authentic PG standards. Percentage conversion of -
arachidonate by RPM was estimated by subtracting the corresponding 
control values. The results are the mean values — SEM of 4 
experiments each performed in triplicate and are expressed as 
percentages of the total radioactivity added to the TLC plate.
After MacIntyre ejt ad. (19832
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The methods used were in the first instance gleaned from 
the literature and subsequently modified in order to optimise 
the experimental procedure. To monitor inositol phospholipid 
metabolism the use of radioactive isotope markers was employed; 
changes in cytosolic free calcium were monitored using the 
fluorescent indicator dye Quin 2. A brief discussion on the 
benefits and failings of these techniques now follows.
2.2.9*1 Radioactive markers and inositol phospholipid metabolism
The use of radioactive markers in monitoring agonist- 
induced inositol phospholipid metabolism is widespread. However, 
such a technique inevitably involves a compromise between the 
duration of prelabelling - allowing the radioisotope to be 
incorporated into the molecular species under investigation - 
and the length of time that the tissue has been removed from 
the body to allow such prelabelling. This presents a problem 
when using blood platelets which have a finite lifespan (a few 
hours) outwith the corporeal circulation. However, such 
compromises are obviated when cells that can be maintained in 
culture (such as RPM) are used. Under such conditions, radio­
active isotopes can remain in contact with the cells for long 
periods (up to many days) until they come into isotopic 
equilibrium with radioactive markers.
The metabolic pathways of the inositol phospholipid inter­
conversions are described in Section 1.3*1*5* The following 
lists various methods by which radioactive markers are utilized 
to follow the metabolism of inositol phospholipids.
— 125 —
2. 2. 9 • 1 • 1 Incorporation of
The initial observation by Hokin and Hokin (1933) was 
that in pancreatic slices, acetylcholine caused a rapid and 
apparently specific incorporation of into Ptdlns and
PtdA. Since this initial study many experiments have been 
performed monitoring the incorporation of P^ into inositol
phospholipids following agonist addition. However, this method 
effectively monitors the rate of resynthesis of inositol 
phospholipids rather than the proposed initial event: inositol 
phospholipid metabolism. Additionally, resynthesis of inositol 
phospholipids may be prone to interference thus producing 
artefactual responses. For example Egawa jet al. (198I) demonstrat­
ed that low concentrations of calcium (lO p,M) substantially 
reduced the activity of GDP diglyceride inositol (PtdA) 
transferase thus giving an apparent increase in inositol 
phospholipid metabolism without actually enhancing the rate 
of metabolism. Similar inhibitory effects of calcium have 
been noted in platelets (see Broekman ejt al. , I98O). To over­
come this problem one could label up the inositol phospholipids 
to isotopic equilibrium with cellular t^^pl ATP and monitor 
the metabolism of inositol phospholipids. However, in most 
cells so far examined, Ptdlns by far represents the larger 
proportion of inositol phospholipids, being approximately 
80-85% of the total inositol lipid species. Ptdlns(4)P and 
Ptdlns(4,5)P^ are usually present in approximately equal 
amounts (Downes and Michell, I982). Under resting conditions 
PtdA is present in trace amounts. Given this situation it may 
take several hours (or days) to label Ptdlns to isotopic
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equilibrium. However, given the relatively small amounts of
Ptdlns (4)P and P t d l n s  (4,5)^2 the fact that their 4- and 5— 
phosphate groups turnover extremely rapidly (Hawthorne and 
Pickard, 1979î Downes et al., I982) and derive their phosphates 
directly from ATP via kinase activity, these inositol phospho­
lipids will label up relatively quickly. In human platelets
PtdA is known to be in isotopic equilibrium with cellular 
ATP within 1-2 hrs (Holmsen et al., 1984), an event 
reflecting its presence in exceedin^^ small amounts relative to 
the inositol phospholipids. During agonist-induced metabolism 
of inositol phospholipids, PtdA is derived from 1,2-diacyl- 
glycerol. Using techniques in which L^^pl PtdA is in isotopic 
equilibrium with I?^p] ATP, any changes in levels of 1,2- 
diacyl glycerol will result in a change in levels ofI?^P^ PtdA.
In lymphocytes it has been demonstrated that calcium can activate 
triacylglycerol lipase to produce 1,2-diacylglycerol which in 
turn is then formed into Ptdlns (Allen and Michell, 1978).
Clearly this represents another artefactual response when one 
is monitoring the perturbation of the inositol phospholipid 
signal pathway. However, at least in human platelets, triacyl- 
glycerol lipase is present in negligible amounts (bote and Lowery, 
1979)* Assuming that inositol phospholipids are the only source 
of 1,2-diacylglycerol, then changes in agonist-induced formation 
of IP^pI PtdA reflects an increase in PtdA mass. However, the 
same can not hold true for Ptdlns. Since, under conditions 
where L^^pI PtdA is in isotopic equilibrium with cellular 
ATP, due to its presence in much larger amounts, only a small 
percentage of the Ptdlns pool will be labelled up with L^^P^P^*
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Hence, subsequent to agonist addition, more will be
incorporated into Ptdlns, thus increasing its specific activity, 
ipso facto, changes in t^^p]Ptdlns do not necessarily reflect 
changes in Ptdlns mass. When monitoring changes in L^^P^Ptdlns 
(4)P and Ptdlns (4,5) this complication is relatively
insignificant as a result of the higher degree of labelling 
attained in these lipids by virtue of the rapid turnover of 
their 4- and 5-phosphates.
To date, most studies utilizing L^^p'lp^ are performed 
under non-equilibrium conditions and monitor either disappearance 
of the polyphosphoinositides (the proposed initial event after 
agonist-receptor interaction) or the appearance of C^^^PtdA.
2.2.9.1.2 Incorporation of L^hI inositol
As outlined in Section 1.3.1.6 the initial event occurring 
following occupancy by agonist of receptors known to act 
predominantly through changes in cytosolic free calcium, is a 
decrease in level of Ptdlns(4,5)P2 with a concomitant increase 
in level of Ins(l,4,5)P^• Thus a more realistic approach to 
studying the metabolism of inositol phospholipids would be to 
monitor these two events. The former event has been discussed 
elsewhere. However, one additional drawback in monitoring 
changes in levels of C^^p] P t d l n s ( 4 , 5 ) ^ ^  that the extent 
of agonist induced breakdown of this lipid is minor. Consequently 
a small decrease in radioactivity against a relatively high 
background is difficult to detect. However, against a low, 
if not negligible background of Ins(l,4,5)P^, any increment in 
this compound will be easily detected. As such measurement of
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Ins(lj4,5)P^ formation represents perhaps the most sensitive 
index of inositol phospholipid metabolism.
Unfortunately, a drawback to using inositol in platelets 
appears to be its relatively slow uptake into the cell. Compared 
to other tissues, human platelets require up to ten times as 
much inositol label compared to other cells (compare Watson 
et al., 1984 and Rubin ejfc al., 1984). Rat platelets also fail 
to adequately incorporate inositol into their inositol-containing 
lipids (present study). Due to the prohibitively high cost 
of this label, studies monitoring accumulation of inositol 
phosphates in platelets (human and rat) are limited. Conversely, 
RPM, when incubated with inositol over a period of days,
do incorporate sufficient amounts of label in order for it to 
be used while monitoring agonist-induced accumulation of 
inositol phosphate.
2.2.9*1*3 Incorporation of glycerol and fatty acid labelling
A recent study demonstrated that the inositol phospholipids 
share a common "backbone" namely stearoylarachidonoylglycerol 
(Mauco ejfc al., 1984) from which all inositol phospholipids may 
be formed. Subsequent to its phosphorylation to glycero-3- 
phosphate, glycerol enters the inositol phospholipid
metabolic cycle at PtdA. This label is of use if one wishes to 
monitor changes in mass of the individual inositol phospholipid 
species since incorporation of glycerol into inositol
phospholipids reflects their relative mass. However, one draw­
back of using this label under non-equilibrium conditions is 
that whilst metabolism of inositol phospholipids may be detected.
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the corresponding increase in PtdA may yield an under­
estimate of the actual amounts of PtdA formed.
An alternative^using L HJ glycerol would be to use fatty 
acid labelling techniques. Fatty acids are easily incorporated 
into the phospholipids of blood platelets. In particular
- or - arachidonic acid is often used; arachidonate
being the predominant fatty acid esterified in the 2-position 
of the glycerol backbone in inositol phospholipids (Mahadevappa
and Holub, I982). However, one major drawback to using -
fi4 1
or L CJ - arachidonic acid is that it can be released from 
phospholipids, including inositol phospholipids, either by 
phospholipase A^ attack, by transacylation, or after hydrolysis 
of the inositol phospholipids to 1,2-diacylglycerol, by the 
sequential actions of diglyceride/monoglyceride lipases (see 
Section 1.3.1.4).
2.2.9»1»^ Direct measurement of inositol phospholipid metabolism 
Metabolism of inositol phospholipids may be monitored by 
chemical assays such as a phosphorus assay (Bowyer and King, 
1977)* However the sensitivity of this technique is exceedingly 
low (0.5 - 1 nmole inorganic phosphorus) and would require 
large amounts of freshly drawn blood to perform an average sized 
experiment. This, coupled to the fact that phosphorus assays 
are notoriously laborious, time consuming and prone to artefacts, 
precludes this assay being routinely used. Resolution of the 
mass of inositol-containing metabolites, using gas chromatography 
has recently been reported by Rittenhouse and Sasson (1985)» 
However, such a technique also necessitated large quantities 
of biological tissue and requires sophisticated apparatus.
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not readily available.
2.2.9*2 Measurement of cytosolic free calcium,
In the present studies, the fluorescent indicator dye 
Quin 2 was used to monitor the concentration of cytosolic free 
calcium, [^Ca^^. Other calcium-indicators might also have 
been used; these include the bioluminescent indicator, Aequorin, 
and fluorescent indicators such as Chlortetracycline. A brief 
outline of the properties, advantages and disadvantages of these 
various calcium-indicators including Quin 2 and the newer Fura 2 
derivatives now follows.
2.2.9*2.1 Aequorin
Aequorin is a Ca^^-sensitive photoprotein of 20,000 daltons
obtained from the photocytes of jellyfish, Aequorea aequorea.
Previously aequorin could only be used in cells that were
sufficiently large to allow microinjection of the dye, howeve
the technique has now been modified for use in (human) platelets
(see Johnson et ^ . , 19&5)* Advantages of using aequorin
include rapidity of response (3-10 î great range of
sensitivity with calcium dependent measurable light output over
the entire physiological range of calcium concentration from 
—8 — 410~ - lO” molar and it is relatively nontoxic. Compared to 
Quin 2 (vide infra) whose fluorescence intensity increases only 
twice over its range of useful sensitivity, the light output 
of aequorin increases with > thus aequorin can provide
bright signals from small zones of the cytosol exposed to local 
[ca^^transients. However, this property of aequorin proves 
to be one of its disadvantages in that basal levels of Cca^^
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and agonist-induced elevation of t.Ca^ '*’^^ reported by this 
compound are much higher than those reported by Quin 2 (see 
Johnson ^t al_. , 19^5; Salzman ejb a^. , 1983)» presumably a result 
of aequorin reporting both mean cytosolic levels of ^Ca^^^ 
and predominantly local zones of elevated calcium in the platelet 
In some circumstances, the capacity of aequorin to report local 
zones of calcium may be used to one’s advantage, particularly 
in studies examining the Ca^^-dependency of an agonist. In 
studies utilizing Quin 2, which is distributed homogenously 
throughout the cytoplasm, any localized increase in calcium 
may not be detected. However, using aequorin such localised 
increases would be recorded. Another disadvantage of aequorin 
is that it is consumed during the generation of the calcium 
signal.
2.2.9"2.2 Chlortetracycline
Chlortetracycline was one of the first indicators of 
intracellular {ca^^]i . It can bind Ca^^ in 1:1 stochiometry 
to form a fluorescent complex and has a Kd of 4 x 10 ^(Caswell 
and Hutchinson, 1971a). The fluorescence intensity is very 
much more intense in a non polar than in a polar environment 
(Caswell and Hutchinson, 1971b). This resulted in concept 
that chlortetracycline reported levels of ’membrane bound’ 
calcium. Experiments performed by Thompson and Scrutton (1983) 
confirmed this claim in their studies in human platelets.
However, they were unable to define the membrane site(s) 
monitored by chlortetracycline. Separate studies performed 
by Jy and Haynes (1984) suggest that chlortetracycline may be 
best utilized in monitoring the internal free \_Ca^t3^ in the 
lumen of organelles.
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2.2.9.2.3 Quin 2
Quin 2, a polycarboxylate anion analogue of EGTA, was. 
eustom-synthesized by Tsien in I98O. Properties of Quin 2 
which make it useful as an indicator of . include an
2+ 2+ ability to bind Ca with marked selectivity over Mg and an
indifference to intracellular pH* It binds Ca^^ with a 1:1
stochiometry and has a Kd of II5 nM which is near to resting
values of ^Ca^^ ^  in many cells. Upon binding calcium it
rapidly undergoes an apparent 6 fold increase in fluorescence
intensity with no spectral shift (Tsien ^  , 1982a). One
drawback to the general use of Quin 2 in measuring was
its inability to permeate across the plasma membrane. However,
by esterifying the compound, Tsien (198I) developed a non-
disruptive technique by which one could load population of
suitable cells with the dye. Once the esterified dye has
permeated the plasma membrane, non-specific esterases splice
the ester bond thus regenerating the active quinoline dye.
Although Quin 2 has found much success as a monitor for
it has always had severe and acknowledged limitations 
(Tsien e^ aJL. , 1982a). Firstly, the dye saturates at 
greater than 1 )iM, concentrations observed to occur in activated 
cells. Consequently values reported above 1 p,M are subject to 
error; b) Quin 2 loadings of at least several tenths of milli- 
molar are required to obtain well-calibrated responses. Such 
high concentrations are required to counteract the auto­
fluorescence obtained when the cells are exposed to 339 nm 
wavelength, the optimal wavelength for exciting Quin 2. However,
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at such, high loading concentrations Quin 2 may act to buffer 
any evoked changes in ; c) Quin 2 signals (^Ca^^ ^  only
as a change in the fluorescence intensity, which can be highly 
dependent on illumination intensity or dye concentration. A 
much better situation would be to have an indicator that 
responded to calcium by shifting wavelengths while maintaining 
strong fluorescence; d) finally, several reports of side effects 
during Quin 2 loading have been reported including a lowering 
of ATP concentration, an increase in lactate production, and 
some degree of mitogenic stimulation in murine lymphocytes 
(Tsien ejb al. , 1982; Hesketh aT. , 1983); activation of 
phosphorylase in hepatocytes (Charesk ejfc al., I983) and inhibition 
of glycolysis in human red cells and increased calcium 
permeability (Tiffert e_t al., 1984).
Whilst Quin 2 has been of use in monitoring [ca^t] in 
a variety of different cell types, the above limitations 
dictate that newer and better probes of be designed.
Such probes may be the newly developed stilbene chromophores 
such as fura 2.
2.2.9.2.4 Fura 2
By combining a stilbene fluorophore with the octacoordinate, 
tetracarboxylate pattern of liganding groups characteristic of 
EGTA, Giynkiewicz et al. (1983) have developed new (Zca^^^^ 
indicators with better fluorescence properties than Quin 2.
Typical of these new indicators is Fura-2 which can be incubated 
with and loaded into populations of cells in a manner similar 
to that used with Quin 2.
- 134 -
The salient advantages these new indicators appear to 
have over Quin 2 are a) an approximate 30 fold brighter 
fluorescene; b) major changes in wavelength upon binding Ca^*. 
Consequently calibration of the signal is performed by taking 
the ratio of fluorescence intensities of the dye at two distinct 
excitation wavelengths; c) slightly higher dissociation 
constants, thus improving the resolution of levels
above 1 p,M; d) slightly longer wavelengths of excitation, thus 
decreasing the degree of autofluorescence and finally e) a 
much improved selectivity to Ca^* over other divalent ions.
These properties of fura-2, and like compounds, (e.g.
Indo-1) should prove of great advantage in further elucidating 
the mechanisms underlying calcium homeostasis in platelets 
and other cell types.
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3. RESULTS
The mechanisms underlying cellular reactivity in both rat 
platelets and RPM were investigated. A number of known platelet 
agonists (for human platelets) were screened namely ADP, Thrombin, 
Adrenaline and U44o69 (a TxA^ mimetic). Agonists observed to 
produce a reasonable and measurable response in both cell types — 
namely ADP and Thrombin — were further investigated. Such 
investigations included observing (i) the agonist-induced 
metabolism of inositol phospholipids with respect to both its 
time—course and concentration-dependence. This was assessed 
by (i) monitoring the accumulation of PtdA; disappearance
of C^^p3 Ptdlns (4,3)^2 accumulation of L^ hZI inositol phosphates, 
depending upon the cell type; (ii) the inhibition of such 
agonist-induced responses using agents known to inhibit platelet 
function; (iii) the concentration-response relationship for 
agonist-induced changes in cytosolic free calcium-monitored 
using the quinoline dye Quin 2 - and its inhibition by agents 
known to affect platelet function. Lastly, an attempt was 
made to characterise the nature of the receptor (purinoreceptor) 
recognizing ADP in both rat platelets and RPM.
ADP
A dialysable, heat-stable factor present in acid extracts 
of red cells and platelets was shown to cause platelet adhesion 
to glass (Hellem, I960) and platelet aggregation (011gaard,
1961). This factor was identified as ADP by Gaarder ejb al.
(1961).
When added to platelets ADP causes aggregation which is 
preceded by shape change (Bom, I962, 1970). In human platelets.
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depending upon concentration of ADP, biphasic aggregation and 
platelet release reaction can occur. In rat platelets only 
single phase aggregation and no release reaction is observed 
(Mills, 1970; Sinakos and Caen, 1967)» The reason(s) for 
this species differences is unknown. However, since the release 
of platelet granule constituents can initiate the activation 
of other platelets and hence play an integral role in haemostasis, 
ADP may be more important in haemostasis in man than in the rat. 
Exposure of ADP to human platelets also results in the inhibition 
of platelet adenylate cyclase, a response believed to be 
mediated by the same receptor eliciting platelet aggregation 
(Cusak et al., I983)» The effect of ADP, in human platelets, 
can be inhibited competitively by ATP (Macfarlane and Mills,
1973) and non-competetively by 2-alkylthrs analogues of AMP 
and ATP (Cusack and Hourani, 1982; Cusack ejfc al., 1983)»
Besides platelet dense granules where it is present along 
2+with 3HT, Ca and ATP, other potential sources of ADP include 
damaged erythrocytes or vascular cells. Indeed Born (1962) 
reported that ADP is released from damaged cells into the 
blood at a sufficient rate to account for the aggregation of 
platelets in haemostases.
ADP belongs to the family of compounds known as purines. 
Receptors for the action of purines on different cell types 
were classified in 1978 by Bumstock (Bumstock, 1978) using 
several criteria such as rank order of potency of a range of 
purines in different cell types and the use of selective 
antagonists. Further distinctions were based on activation of 
adenylate cyclase and activation of prostaglandin synthesis. 
Although first established in 1978 the classification has been 
upheld in a range of different tissues (Bumstock and Buckley,
1985 ) .
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Under Bumstock* s classification two receptors are 
identified. P^—purinoreceptors exhibit a rank order of potency 
of Adenosine > AMP > ADP > ATP; they are antagonised by methyl 
xanthines such as theophyline and caffeine; occupation of 
these receptors leads to an activation of adenylate cyclase and 
subsequently increase in intracellular cyclic AMP. The P^- 
purinoreceptors, in contrast, have a rank order of potency of 
ATP > ADP > AMP > Adenosine; no specific antagonists exist 
although quinidine; apamine; 2,2 *-pyridylisatogen and the 
photo affinity compound arylazidoaminopropionyl ATP have all 
been cited as P^-pnrinoreceptor antagonists (Bumstock and 
Buckley, I985); occupation of these receptors have been shown 
to elicit the production of prostaglandins in various tissues.
Both the P^- and P^-purinoreceptor exhibit strict structure- 
activity relationships; the free -NH^ group at position in 
the imidazole ring; the ribose moiety and the steric configuration 
of both purine and ribose rings being essential for activity 
(Hahn and Olsson, 1973)* Like most other receptors which have 
been pharmacologically characterised in detail e.g. adreno- 
receptors (Lands ejt al»j 19&7; Langer, S.Z., 1974; Carlsson,
1979; Langer and Shepperson, 1982; McGrath, J.C. I982) there 
appears to be reason for further subclassification of both 
P^- and P^-purinoreceptors.
The subclassification of P^-purinoreceptors is based on 
the order of potency of a series of adenosine receptor agonists 
and stereospecificity with respect to the diasteromers. L-N^-
phenylisopropropyladenosine(N^—R(—)—L—methyl—2—phenethyT 
adenosine (L-P1A) and D-N^-phenylisopropyladenosine (D-P1A).
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In 1980 Londos and colleagues examined the actions of three
agonists, namely L—PIA; 5*-N-ethyl carboxanudoadenosine (NECA)
and adenosine on the adenylate cyclase system of several cell
types (Londos et al«, I980). He found that for stimulation of
adenylate cyclase the rank order of potency NECA > Adenosine > PIA
was observed while the converse was true for inhibition of
adenylate cyclase i.e. rank order of potency was PIA > Adenosine >
NECA was observed. The terms R and R. were proposed to describea 1
the receptors mediating the stimulatory and inhibitory actions
on adenylate cyclase respectively. Van Calker ejfc aT. (1979)
similarly concluded from studies on cultured glial cells from
mouse brain that adenosine acted at two separate cell surface
receptors, which were termed A^  ^ and A^ representing inhibition
and stimulation of adenylate cyclase respectively. The use of
stereoselectivity in the A^/r . and A_/r classification is a1' 1 2' a
more recent addition. In rats, various workers have demonstrated 
using L-PIA and D-PIA, that the inhibition of lipolysis is an 
A^/R^ receptor mediated action whereas the accumulation of 
cyclic AMP is thought to be an A^/R^ action (Trost and Schwabe, 
I98I; Dunwiddie and Fredholfti, I982). In addition to the 
A^/R£ and A^/R^ sites a "p" site has been proposed (Londos 
et al., 1983)* Unlike the A^/R^ and A^/R^ sites, this *P* 
site is located on the internal surface of the membrane and 
when activated by adenosine leads to the inhibition of adenylate 
cyclase, an effect which is not antagonized by methylxanthines.
The basis for a subclassification of P^-purinoreceptors 
rests, amongst other evidence, upon the divergence of agonist
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potency ranking for purinoreceptors located on different cell 
types e.g. smooth muscle membranes, platelets and mast cells 
(Bumstock, 1981). The purino-receptor on human platelets, 
which promotes aggregation, is highly specific for ADP with 
neither ATP nor AMP being able to activate the receptor. In 
fact, in human platelets, ATP is a competitive antagonist of 
the action of ADP (Macfarlane and Mills, 1973)* In rat mast 
cells ADP is unable to mimic the histamine releasing action 
of ATP (Diamant and Kruger, 1967)* The strict specificity of 
these receptors for either ADP or ATP is in marked contrast 
with the purinoreceptor located on smooth muscle where both 
ADP and ATP are equipotent. This lack of homogeneity amongst 
purinoreceptors recognizing ATP suggests there may be subclasses 
of purinoreceptor.
In a recent review, Gordon (1986) proposed, based on the 
available data, 4 subclasses of purinoreceptor recognizing ATP, 
namely the *T'; *X'; 'Y' and 'Z* purinoreceptor. The P^^
receptor is located on (human) thrombocytes, platelets and 
megakaryocytes. ^2Y P^^i^^^cceptors are located on
smooth muscle cells and elicit respectively contraction or 
relaxation. Finally the P^^ purinoreceptor is apparently 
present on mast cells and lymphocytes.
Attempts to establish the number of ADP receptors on human 
platelets, using radiolabelled analogues of ADP, have revealed 
the existence of one class of receptor with between 400-1200 
sites/plate (Macfarlane e_t al. , 1982; Macfarlane ejfc al. , I983)* 
In an earlier study, using the adenine nucleotide affinity 
analogue 3 *-p-flurosulfonylbenzoal adenosine, Bennett et al.
- l4o -
(1978) identified a polypeptide with molecular weight of
100000 daltons as being a putative ADP receptor in human platelets
A review of the actions of purines on tissues would not be 
complete without considering the possibility of prior metabolism 
of these compounds, by ectonucleotidases, prior to eliciting 
a response. Ectonucleotidases have been found on the surface 
of endothelial cells; blood platelets and leukocytes (see 
Pearson for review, 1985)» The existence of such enzymes can 
complicate the interpretation of data using for example ATP 
as an agonist, since any effect observed with ATP may be due 
to a direct action of ATP or due to the actions of one of its 
metabolites. Such possibilities may explain discrepancies 
in the literature concerning classification of purinoreceptors. 
Indeed, in guinea pig ileum, ATP has been shown to exert an 
inhibitory response, partly mediated by its metabolites and 
partly due to a direct action (Moody et al., 1984). Clearly 
caution is required when interpreting data obtained while 
studying the effects of purines on tissues.
Thrombin
Thrombin, a serine protease, has a substantial degree 
of structural homology with other known serine proteases such 
as trypsin and chymotrypsin, but differs in its side chain 
specification (Blow, 1971; Keil, 1971; Magnusson, I971).
Thrombin is formed by the enzymatic cleavage of prothrombin, 
a component present in plasma, and is one of the most important 
endogenous stimuli involved in haemostasis - its most important 
role being the initiation of clot formation by cleaving
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fibrinogen into fibrin monomer which may then be converted 
by factor Xllla into fibrin polymer. As a platelet agonist, 
Thrombin is one of the most efficacious agents known, capable 
of evoking platelet shape change, aggregation, release of 
dense granule, a granule and lysosomal enzymes and tGo^&zioid 
synthesis at very low (nM) concentrations. Platelets themselves 
can catalyse the production of Thrombin in several ways (Walsh,
1974), and it is possible that sufficient Thrombin may be 
generated within platelet aggregates to trigger the release of 
platelet granule contents without formation of fibrin. The 
effects of Thrombin on platelets can be inhibited by Hirudin, 
an anticoagulant substance derived from leech salivary glands 
(Markwardt, I96O; Holmsen ejb aJL. , I98I) and by other serine 
protease inhibitors such as Leupeptin (Holmsen et al., 1984; 
Ruggiero and Lapetina, 1983)* The interaction of Thrombin with 
platelets is unusual in that it exhibits properties of both 
an agonist-receptor equilibrium reaction and an enzyme catalysed 
reaction (Tollefsen ^  al*> 1974; Detwiler and Feinman, 1973; 
McGowan and Detwiler, I983; Shuman aJL. , 1978; Martin i^b al. , 
1973; Detwiler, I98I; Davey and Luscher, I967).
Thus concentration-response and time-course curves are 
more consistent with an agonist-receptor equilibrium model 
(Detwiler and Feinman, 1973; Martin et al., 1973)» The catalytic 
activity of Thrombin has been demonstrated to be essential for 
platelet activation i.e. blocking the active site serine inhibits 
Thrombin-induced platelet activation (Davey and Luscher, I967). 
However, the finding that active site blocked Thrombin competes 
with native Thrombin for binding sites to platelets, but does
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not inhibit Thrombin-induced aggregation of platelets (Philips, 
1974; Tollefsen ejt al. , 1974) suggests that all attempts to 
gain insight into the Thrombin receptor through analysis of 
such receptor binding data is compromised by the fact that the 
detected binding sites may not be identical with the functional 
receptor.
The exact mechanism of action of Thrombin in inducing 
platelet activation thus remains enigmatic. However a model 
of Thrombin-induced activation of platelets incorporating 
elements of both an agonist-receptor equilibration and enzyme- 
catalysed event seems most likely (Martin ejfc al. , 1975;
Tollefsen ejfc al. , 1974; Detwiler, I98I).
Putative "receptors" or more accurately "binding sites" 
for Thrombin have been identified. Phillips and Poh Agin (l977) 
presented evidence that the proteolytic substrate for Thrombin 
was glycoprotein V, since following addition of Thrombin to 
platelets only glycoprotein V was hydrolysed.
Subsequent studies have shown that the complete removal 
of glycoprotein V from the platelet surface by chymotrypsin 
revealed no inhibition of platelet activation (McGowan et al., 
1983). While this suggests that hydrolysis of glycoprotein V 
alone does not constitute the signal event in Thrombin-induced 
platelet activation, some role for glycoprotein V hydrolysis 
may exi s t.
Radioligand binding studies have revealed a high degree of 
heterogeneous binding, interpreted as evidence for three distinct 
classes of binding sites; a high affinity, low capacity site 
(Kd 1 nM, 500 sites/cell); a low affinity, high capacity site
— l43 “
(Kd 100 nM, 5000-50,000 sites/cell and a non-saturable site 
(Detwiler and McGowan, 19&5))* In a separate study, Harmon and 
Jamieson (1985) estimated that the high affinity site approached 
a size of approximately 90 K Daltons and suggested, due to its 
size, that this binding site for thrombin may involve a multi- 
molecular complex of membrane components somewhat analogous 
to the adenylate cyclase system.
Although no identifiable receptor (substrate) for Thrombin 
has yet been identified on the platelet surface, it appears that 
the response to Thrombin, in human platelets, may involve more 
than one such binding site. Studies by Holmsen e_t al. (198I)
have shown a requirement for the continued presence of active 
Thrombin for such events as acid hydrolase secretion, arachidonic 
acid metabolism and phosphatidic acid formation. Other 
consequences of Thrombin-induced platelet activation such as 
aggregation, dense-granule secretion and phosphatidyl inositol. 
metabolism do not have this requirement. These results have 
been interpreted as being the consequence of either separate 
receptors or separate effectors mediating the response of Thrombin 
It is interesting to note that McGowan and Detwiler (1986) have 
recently presented results suggesting the existence of two 
separate receptors. Whether they correspond to the observations 
of Holmsen ^  al. is, at present, unknown. Finally, perhaps the 
most convincing evidence for a true receptor for Thrombin on 
platelets stems from the studies of Ruda and colleagues (1985) 
who showed that the tripeptide 5^40476 exhibits properties of 
a partial agonist at the putative Thrombin receptor.
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3.1 Rat Platelets
3*1*1 Agonist-induced metabolism of inositol phospholipids
The metabolism of inositol phospholipids in rat platelets 
was monitored using (30 liCi/ml) prelabelled rat platelets.
Within approximately 90 min incorporation of into PtdA
was approaching steady-state conditions, whereas incorporation 
of into Ptdlns was still increasing at this stage
(Figure 3 in Section 2). Due to the relatively high turnover 
of the 4- and 5-phosphate moieties of Ptdlns(4)P and Ptdlns(4,5)P2» 
incorporation of L^^pl P^ into these lipids was assumed to 
approach steady state by 90 mins. Thus a time point of 90 min 
was used to prelabel rat platelets with P^ in all subsequent
experiments monitoring the metabolism of inositol phospholipids. 
Under these labelling conditions, the basal levels of L^^pjj f  i 
prelabelled inositol phospholipids routinely monitored were 
112 993 - 32 248 dpm; 36 378 ± 6384 dpm, 81 439 - 4o 272 dpm 
and 3648 - 468 dpm (mean - SD) for Ptdlns (4,3 )P2 » fZ^^pl
Ptdlns(4)P; (^^P^ Ptdlns and PtdA respectively. The following 
sections outline the effects of ADP on inositol phospholipid 
metabolism in rat platelets. The effects of Thrombin on inositol 
phospholipid metabolism are discussed in Section 3*1*^*
3*1.1.1 ADP-induced platelet aggregation
In order to establish that rat platelets prepared under 
radiolabelling conditions are still responsive, agonist-induced 
platelet aggregation was monitored. Figure 9 depicts the response 
obtained while monitoring platelet aggregation induced by 
ADP(l-100 p,M). Aggregation is preceded by shape change - lasting 
approximately 10-13s - followed by a concentration-dependent
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Figure 9; Aggregation of washed rat platelets in response to ADP.
Plasma free suspensions of platelets (0.45 ml) prepared as described 
in the Methods were exposed to.ADP at the concentrations indicated 
and aggregation was monitored photometrically with continuous stirring.
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primary aggregation response. The addition of CaCl^ (extra­
cellular calcium concentration 3: 1 mM) 60s before ADP addition 
facilitated aggregation.
3.1.1.2 Effect of ADP on platelet inositol phospholipid metabolism 
; Time course
If the metabolism of inositol phospholipids following 
agonist-receptor interaction is a determinant of cellular 
activation in rat platelets then the time-course of such an 
effect should be consistent with the rapidity of the cellular 
response. Figure 10 depicts the time-course of ADP-induced
PtdA formation. In the absence of agonist the levels of 
L^^pl PtdA do not change significantly throughout the course of 
the experiment. No changes in levels of Ptdlns were
observed, either in the presence of absence of agonist (results 
not shown). ADP (lO pM) induced a rapid increase in L^^l^PtdA 
which was maximal (43^ above basal levels in experiment shown) 
within 10 sec of agonist addition. The percentage increase, 
above basal levels, in a number of experiments ranged from 
43 - ZkOfo, After the initial peak, levels in L?^P^ PtdA 
declined towards basal. The lack of change in levels of t-^^p3 
Ptdlns relative to changes observed in levels of LP^p3 PtdA 
may be explained by the presence of a large metabolic pool of 
Ptdlns, changes in the size of which - consequent of agonist- 
receptor interaction - would be difficult to detect. Conversely, 
under resting conditions, the size of the PtdA metabolic pool 
is very small and thus any changes to its size, consequent upon 
agonist-receptor interaction, would be readily detectable.
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Figure 10; Time-course of ADP-induced changes in PtdA in rat platelets.
0.5 ml samples of P- prelabelled platelets prepared as described
(Section 2;2:1:2) in Methods were exposed to 10/y\M ADP. Results measured 
in terms of fold stimulation, under which nomenclature basal levels are 
represented by a value of 1. The levels of L p] PtdA were measured at the 
times indicated after agonist addition. The experiment shown is typical of 
3 similar experiments.
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3»1«1*3 Effect of ADP on platelet inositol phospholipid 
metabolism; Concentration-response relationship 
Having established the time-course of ADP-induced inositol 
phospholipid metabolism, the concentration-response relationship 
for ADP-induced changes in PtdA was examined# The time-
point of 30 sec was used since it proved more convenient to 
use and u ^ pj PtdA levels were still elevated at this time 
point. Figure 11 depicts a typical example of the concentration- 
response relationship of ADP-induced PtdA formation. The
threshold for stimulation of PtdA formation was < 0.1 ^M;
th maximal stimulation of G^^p3 PtdA formation occurring atwi
approximately 10 ixM. In this experiment the maximal stimulation 
of L^^P^ PtdA formation was approximately 2» 3 fold of control, 
the levels varying between 2-3 fold in different experiments.
The EC^Q value was O.9 - 0.2 ]xM (mean - SEM, n = 4). Similar 
experiments have been performed using both rabbit (Lloyd ejt al. , 
1972; 1973a) and human (Lloyd ^t al., 1973%; MacMillan et a^. , 
1984; MacIntyre ejfc al. , 1983c; Fisher e^ al. , I983) platelets. 
However, whereas similar results as those obtained here are 
found in experiments using rabbit platelets, several workers 
(MacMillan ejt al. , 1984; MacIntyre ejk a^. , 1983c; Fisher ejfc al. , 
1983) have been unable to confirm the findings of Lloyd e_fc al. 
(1973%) who reported that ADP could elicit changes in PtdA
in human platelets. The reason(s) for these paradoxical findings 
is unknown but may merely reflect the insensitivity of the 
assay techniques available to monitor changes in inositol 
phospholipid metabolism in human platelets. However, of the 
techniques available to monitor inositol phospholipid metabolism.
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Figure 11; Concentration-response relationship for ADP-induced stimulation 
of L^-P3 PtdA formation in rat plateletsi
0.5 ml samples of P^ prelabelled platelets prepared as described
(Section 2;2:1:2) in Methods were exposed to ADP at the concentrations 
indicated. Results measured in terms of fold stimulation - basal levels 
equal to 1. PtdA levels were measured at 30s after agonist addition.
The results are mean - SEM of triplicate determinations. The experiment 
shown is typical of 4 similar experiments.
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measurement of PtdA (Irvine et , I983), in addition
to measurement of inositol phosphates (Fisher ejb , I983), 
appear to be the most sensitive.
3.1.1.4 Inhibition of ADP-induced changes in phosphatidate
The most obvious site at which to inhibit an agonist effect 
is at its receptor. Several receptor antagonists acting 
specifically at the human platelet ADP receptor are known e.g. 
2-methylthio-AMPj 2-methylthio ATP and 2-chloro—ATP (Cusack 
et al.9 1983). However these were not available in sufficient 
quantity to test their specificity and use as potential antagonist: 
at receptors recognizing ADP in rat platelets. An alternative 
mechanism by which one can inhibit agonist-induced platelet 
activation is to elevate cytoplasmic levels of cyclic AMP 
(see Section 1.3.1.2). Consequently, where no specific receptor 
antagonist was available, agents elevating cytoplasmic cyclic AMP 
levels were used throughout this study to demonstrate inhibition 
of agonist-induced platelet activation.
3.1.1.4.1 Effect of PGE^
PGE^ has been demonstrated to elevate rat platelet cyclic 
AMP levels and is a potent inhibitor of platelet (aggregation) 
activation (Michel et al., 1976). The effect of PGE^ on ADP- 
induced inositol phospholipid metabolism was examined. Figure 
12 demonstrates the effect of PGE^  ^ on submaximal stimulation 
of [p^P^ PtdA by ADP. Prior exposure to PGE^ (lO p,M) inhibited 
the subsequent response to ADP (l liM) by 30 - 39^  (mean - range, 
n = 2). It appears therefore that in rat platelets cyclic AMP 
dependent processes exist which can inhibit ADP-induced 
metabolism of inositol phospholipids.
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Figure 12; Effect of PGE^ on ADP-induced PtdA formation in rat platelets.
0.5 ml samples of L^^pl prelabelled platelets prepared as described 
(Section 2;2;1;2) in Methods were exposed to lp.M ADP in the absence or 
presence of PGE^ as indicated. PGE^ was added 60s prior to ADP and the 
levels of PtdA measured 30s thereafter. Results measured in terms
of fold stimulation - basal levels equal to 1. The experiment shown is 
typical of 2 similar experiments.
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3«1»1«5 Effect of ADP on the polyphosphoinositides
In Section 3»1*1*3 It was demonstrated that ADP stimulates 
inositol phospholipid metabolism as indicated by the accumulation 
of PtdA. Although agonist—induced accumulation of
PtdA remains a sensitive index of agonist—induced metabolism 
of inositol phospholipids (irvine ^  , I983) t^^P^ PtdA
could, theoretically, be derived from the phosphorylation of 
1>2-diacylglycerol formed as a consequence of phospholipase C 
activity on any one of the inositol phospholipids i.e. Ptdlns 
(4,5 )^2» PtdIns(4)P or Ptdlns,1,2-diacylglycerol may also arise 
from the déacylation of triglyceride. Consequently agonist- 
induced accumulation of L^^p3 PtdA gives no indication of the 
initial event occurring subsequent to agonist-receptor inter­
action. Michell's original hypothesis (1975) was that cell 
surface receptors were coupled to calcium gating via stimulation 
of Ptdlns turnover and that agonist induced metabolism of Ptdlns 
was amongst the initial events triggered by agonist-receptor 
interaction. However, Kirk ejt ad. (l98la) demonstrated, in 
rat hepatocytes, that the metabolism of Ptdlns(4,5)?2 preceded
that of Ptdlns and was the event initiated by agonist occupation 
2+of Ca -mobilizing receptors, such as the vasopressin, 
receptor in hepatocytes. Consequently they proposed that the 
initial consequence of receptor occupation was in fact the 
metabolism of Ptdlns(4,5)?2 (Michell ejfc a^., I98I). Data is now 
available from a variety of different cell types, including 
human platelets, indicating that the initial events occurring 
subsequent to agonist-receptor interaction 'do in fact include 
a rapid decrease in levels of Ptdlns(4,5)^2 ^ parallel
- -L5J -
increase in its water soluble metabolite, Ins(l,4,3)P^ (see 
Berridge, 1984; Berridge and Irvine, 1984; Farese, 1984; 
for reviews and section 1«3«1«5)« Thus in addition to monitoring 
the accumulation of 'PtdA* as an indice of agonist-receptor 
interaction, one could also monitor the decrease in levels of 
Ptdlns(4,3)^2 the accumulation of Ins(l,4,3)P^ (see Section 
2.2*9»l)« However, a limitation to the use of the latter 
technique in platelets (see Section 2.2.9*1.2) lies in the 
apparent slow uptake of C^H*1 inositol into the inositol phospho­
lipids of platelets including human and rat platelets.
Preliminary results for the latter cell type indicated that 
when incubated with \^ h^] inositol (20 pCi/lO^ cells), basal 
levels of inositol phosphates measured were 111 - ICj dpm/
2 X  10^ cells, 37 - 8 dpm/2 x 10^ cells and 2 1 - 6  dpm/2 x 10^ 
cells for Ins(l,4,5)P ; [^h1 Ins(l,4)P and Ins IP
l3 1respectively. Due to this inadequate rate of L Hj inositol 
incorporation into rat platelets and the prohibitively high
cost of this label, studies designed to monitor the accumulation 
of C^H^ inositol phosphates, in rat platelets prelabelled with 
L^h3 inositol, subsequent to agonist addition were not performed. 
However, studies designed to monitor the metabolism of the 
polyphosphoinositides - in rat platelets prelabelled with 
^ ^ p 3 Pj^  - subsequent to agonist addition did prove successful 
and the results are discussed below.
3.2.1.3.1 Effect of ADP on rat platelet polyphoinositide 
metabolism; Time course
Figure I3 depicts the time-course of ADP-induced metabolism
of ^^P^ Ptdlns(4,3)P. Within 3 sec ADP (lO pM) induced an
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Figure 13: Time-course of ADP-induced changes in ^ pJ PtdIns(4,5)P_ in rat platelet
0.5 ml samples of t?^p] P. prelabelled platelets prepared as described 
(Sectian 2;2:1:2) in Methods were exposed to 10 P-M ADP and the levels of 
[32p^ PtdIns(4,5)P2 measured^at the times indicated after agonist addition.
The results are mean values - SO of triplicata determinations expressed as 
a percentage of zero time control; 100% L PJ PtdIns(4,5)P2 112 995 - 52 248 
dpm. The experiment shown is typical of 3 similar experiments.
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approximate 12^  ^loss in Ptdlns(4,5)P2 (l0.8 - 1.5,
mean - range, n = 3)« No changes in either L^^pJ PtdIns(4)P 
or Q^^p] Ptdlns are observed throughout the course of the 
experiment (data not shown). At the longer time points (> 60s) 
there is a slight, but insignificant, increase in 
Ptdlns(4,5)^2 levels above basal. These results are similar 
to those obtained in rabbit platelets using ADP (Vickers ejt af. , 
confirming the concept that amongst the initial events initiated 
by agonist-receptor interaction is the metabolism of poly­
phosphoinositides.
5.1.2 ADP-induced changes in cytosolic free calcium, [Ca^^ ^  
5.1*2.1 ADP-induced platelet aggregation
To ensure that platelets prepared under Quin 2 loading 
conditions maintained their functional responsiveness, platelet 
aggregation in Quin 2 loaded cells was monitored. Quin 2 loaded 
cells retain their characteristic disc shape, as monitored by 
the swirling (schlieren) observed when the cells are shaken 
in bright light prior to stimulation. Figure l4 demonstrates 
the aggregatory response obtained with ADP (l-lOO p,M).
Comparison with unloaded or vehicle (DMSO) treated platelets 
reveals that Quin 2-loaded platelets exhibit pronounced shape 
change only at the lower agonist concentration (l p,M) tested. 
Additionally the aggregatory response observed at this 
concentration appears to be somewhat enhanced compared to the 
response obtained using the same agonist concentration in
2+unloaded or vehicle treated platelets. Disruption of the Ca 
homeostasis by Quin 2 may, in some manner, account for this 
response.
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Figure 14; Aggregation of washed rat platelets in response to ADP.
Plasma free suspensions of platelets (0.45 ml) preincubated with either 
Quin 2 AM (extreme right) vehicle (DMSG) (middle) or unloaded (extreme left) 
were exposed to ADP at the concentrations indicated and aggregation was 
monitored photometrically with continuous stirring.
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3.1.2.2 Effect of ADP on rat platelet cytosolic free calcium, 
Subsequent to agonist-receptor interaction, changes in 
cytosolic free calcium are believed to mediate cellular 
activation in a number of different cell types (Sections 1.3.1.3 - 
1*3'1*8)* For this to be true of rat platelets such changes in 
should be consistent with the time-course of known 
platelet functional responses. Figure 13a depicts the observed 
changes in C Ca^^, ; (monitored as changes in Quin 2 fluorescence) 
in rat platelets following exposure to ADP (0.03 - 10 p,M). A 
rapid and concentration—dependent elevation in  ^ is
evident. Significant elevation above basal levels being detected 
within 10 sec - in keeping with the time-course of platelet- 
functional responses. With increasing agonist concentration, 
the rate of increase and decline of response is visibly quicker. 
Such responses may represent a mechanism by which the cell 
regulates its function - by terminating its response more quickly 
in the presence of a large concentration of stimulant. The 
processes responsible for terminating the elevation of [ca^^i 
under normal conditions are not fully understood, but may involve 
the action of protein kinase C (see Section 1.3*1*8.3 plus 
Drummond and MacIntyre, I983)* Figure 13b depicts the cumulative 
concentration-response curve for ADP-induced elevation in 
From basal levels of approximately 70 nM, maximal elevation 
in of approximately 1200 nM above basal levels is
detected at a concentration of 3 I^ M. The EC^^ value was 
0.63 - 0.21 liM ( mec - SEM, n = 3-7)* Similar studies carried 
out in human platelets (Hallam at al•, I983; Hallam and Rink*
1983) also show a concentration-dependent elevation in Lca^’*Q .
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Figure 15a; ADP-induced elevation of cytosolic free calcium Lca^^i in rat platelet
Aliquots (2 ml) of Quin 2-labelled platelets prepared as described in 
Section 2:2:1:3 were incubated with ADP at the concentrations indicated.
Changes in Ca were estimated from the observed changes in dye
fluorescence (Section 2:2:4). The traces above are from a single 
representative experiment typical of 5 others.
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Figure 15b; Concentration-response relationship for ADP-induced elevation 
"of cytosolic free calcium LCa^t)%in rat platelets.
Aliquots (2 ml) of Quin 2-labelled platelets prepared as described (Section 
2:2:1;3) were incubated with ADP at the concentrations indicated. Results 
shown are cumulative observations from several experiments (n = 7) and are 
expressed as mean values - SEM, above basal levels.
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after exposure to ADP. The unusual phenomenon of ADP eliciting 
the elevation of ^Ca^t] in human platelets in the absence of 
effects on inositol phospholipid metabolism suggests that, 
unlike the situation in rat platelets, the link between 
metabolism of inositol phospholipids and calcium gating in human 
platelets, using this particular agonist, is more tenuous.
Studies carried out in calcium free buffer in the presence 
of 2mM EGTA (to chelate residual Ca^^) showed that the majority 
of the rise inLca^^H^ detected after ADP addition could be 
attributed to an influx of extracellular Ca^*, Figure l6.
This is similar to the situation observed in human platelets 
where it has been demonstrated that approximately 80^ of the 
increase in[jCa^^3^ is due to Ca^* influx (Rink _et a^. , 1982; 
MacIntyre ^t al•, 1983c).
Observations in other tissues of the rat e.g. hepatocytes 
have shown a similar concentration-dependent increase in Lca^'0 ^  
when exposed to ADP. The for ADP-induced elevation of
in hepatocytes was O.3 “pM which is lower than that 
observed for the same event in rat platelets (Charest ejfc al., 
1985a). This indicates that ADP either has a lower affinity 
for the platelet receptor than hepatocyte ADP receptors or 
that there are different efficiencies in receptor/effector 
coupling in different cell types.
3.1.2.3 Inhibition of ADP-induced changes in Loa^t]^
Use of agents elevating cytoplasmic levels of cyclic AMP 
were examined in an attempt to demonstrate inhibition of ADP-
induced tca^t] ^  elevation in rat platelets. Figure 17 demonstrate
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Figure 16; ADP-induced elevation of cytosolic free calcium in the presence 
and absence of extracellular free calcium in rat platelets»
Aliquots (2 ml) of Quin 2-labelled platelets prepared as described (Section 
2;2;1;3) were incubated with ADP at the concentrations indicated, eithgr in 
the presence or absence of extracellular free calcium. Changes in Lca 31 
were estimated from the observed changes in dye fluorescence. Above represents 
typical responses from a single experiment, representative of 3 others.
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Figure 17; Effect of PGE^ on ADP-induced elevation of cytosolic free calcium 
Ca%+ i in rat platelets.
Aliquots (2 ml) of Quin 2-labelled platelets prepared as described (Section 
2:2:1;3) were exposed to ADP, at the indicated concentrations, in the presence 
or absence of PGE^ as indicated. PGE^ (lO^M) was added 60s prior to ADP and2^ 
changes in fluorescence monitored thereafter were converted to changes in LCa J*|. 
The above responses are obtained from a single experiment and are representative 
of 2 similar experiments.
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that, in the presence of PGE^ (lO p,M) responses to a maximal
(3 liM) and submaximal (0.3 p.M) concentration of ADP were
inhibited by 73 — 6^ and 100 — 0^ (mean - range, n = 2)
respectively. In the presence of PGE^ ,^ the response to ADP
(3 I^ M) was notably slowed as well as attenuated. These results
are suggestive of a cyclic AMP-dependent process, existing in
rat platelets, acting to inhibit agonist-induced changes in 
2+Ca ^. Kaser-Glanzman ejfc a^. (l977; 1979) have demonstrated 
that cyclic AMP stimulates the active sequestration of Ca^* 
into purified platelet intracellular membranes corresponding to 
the dense tubular system. However, Menashi ejb al. (1982) 
reported that they were unable to demonstrate any effect of 
dibutyrlcyclic AMP on Ca^* accumulation into the dense tubular 
system. Nevertheless, this effect of cyclic AMP may represent 
one of the possible mechanisms by which it can inhibit agonist- 
induced platelet activation (see Section 1.3»1*2).
3«1«3 Characterization of the receptors recognizing ADP in 
rat platelets
Having demonstrated that ADP is capable of elicting the 
formation of PtdA and elevating Lca^^^ in rat platelets,
I next attempted to characterise the nature of the receptor 
recognizing ADP in this cell.
Receptors may be characterised by several pharmacological 
techniques; - 1) Comparison of the rank order of potency of 
a series of similar chemical compounds, tested in a range of 
tissues; 2) The use of selective antagonists. (Tallarida and 
Jacob, 1979); 3) Radioligand binding studies, where only the
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binding shown to be saturable, reversible and pharmacologically 
specific as well as consistent with the time-course and 
concentration-dependency of the response under investigation, 
is deemed to reflect receptor occupancy (Birnbaumer et ad.,
1974) and 4) Analyses of transduction processes. Transduction 
processes exist to transfer information received on the external 
surface of the cell to the inside of the cell in order to elicit 
a cellular response. Receptors may then be classified on the 
nature of this transduction process (see Section 1.3*1 plus 
Berridge, I98O; I98I).
From previous sections the nature of the transduction 
process in rat platelets, activated by ADP-receptor occupancy, 
would appear to involve the inositol phospholipid signal 
pathway (ergo metabolism of inositol phospholipids and 
elevation of [ca^^ ^ . The possibility exists, but is not 
proven, that these effects may be causally interrelated.
The aim of this section was to further characterise the 
nature of the receptor(s) recognizing ADP in rat platelets by 
comparing the rank order of potency of a range of purines namely 
ATP, ADP, AMP and Adenosine on inositol phospholipid metabolism 
(monitored as accumulation of PtdL^ and elevation of [ca^^ ^
3*1.3*1 Effect of ATP, ADP, AMP and Adenosine on rat platelet
inositol phospholipid metabolism; Concentration-response 
relationship
Figure 18 depicts the effects of ATP-, ADP-, AMP- and 
Adenosine-induced tp^pJptdA formation in rat platelets. Both 
ADP(10 nM - 100 p,M) and ATP (l p,M — 1 mM) but not AMP or 
Adenosine when tested at a single concentration of 100 p,M
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Figure 18; Concentration-response relationship for agonist-induced 
stimulation oft^^P^PtdA formation in rat platelets.
0.5 ml samples of P. prelabelled platelets prepared as described
(Section 2:2;1:2) were exposed to ADP (A )• ATP (O); AMP (D ) or Adenosine (■ ) 
at the concentrations indicated. Results are measured in terms of fold 
stimulation - basal levels equal to 1. L^^PJ PtdA levels were measured 30s 
after agonist addition. The results are means - SO of triplicate determinations. 
The data shown for ATP and ADP is taken from individual experiments representative 
of 3-4 similar experiments.
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elicited» in a concentration-dependent manner, the formation of
p3 PtdA. The threshold concentration for stimulation of
PtdA formation, using ADP as the agonist, was < 0.1 )iM
and < 1 p,M using ATP. In the results shown, the maximal extent 
P32 1of L pj PtdA formation was approximately 2«3 fold of control 
(range 2-3 fold in different experiments) using ADP as the 
agonist and 1.6 fold of control (range 1.4—2.0 in different 
experiments) using ATP as the agonist. The values for
ADP and ATP are 0.9 - 0 . and 3*8 - 1 p,M (mean - SEM, 
n = 3“ )^ respectively. In rat platelets it appears that ADP 
is more potent and efficacious, when compared to ATP, at 
eliciting the formation of E^^p] PtdA. In contrast AMP and 
Adenosine are inactive.
Numerous studies have shown the presence of ectonucleo- 
tidases, capable of metabolising purines, on the surface of 
various cells, including platelets (Pearson, 1983)» In order 
to negate the possibility, that the observed responses of ATP 
are a result of the actions of its metabolites - subsequent to 
its hydrolyses - rather than due to a direct action of ATP, 
studies were carried out comparing the effects of ATP and the 
non-hydrolysable ATP analogue, Adenosine-3 *-3 -thiotriphosphate 
in the same experiment. Figure 19 demonstrates the results 
obtained from a single experiment of the effects of ATP and 
Adenosine 3 *-3-thiotriphosphate , ATP^S, on inositol phospholipid 
metabolism in rat platelets. Both ATP and ATP^S (l )iM — 1 mM) 
elicit, in a concentration-dependent manner, the formation of 
Î?^p3 PtdA. Maximal fold stimulation of ATP-induced L^^pI PtdA 
formation is 2 (range 1.4 - 2 in different experiments) and for
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ATP^S—induced PtdA formation it is 1*75 (range 1.6 — 1.75
in different experiments). Calculated values are
3.1 i 0.98 ]iU and 3.1 i 0.92 p-M (mean ± SEM, n = 3) for ATP 
and ATPVs respectively. No statistical difference exists 
between these two values and from the degree of fold stimulation 
of [?^pl PtdA formation detected using either ATP or ATPYS, 
it appears that ATpVs may be slightly less efficacious when 
compared to ATP at eliciting the formation of PtdA.
These results are suggestive that, when exposed to rat platelets, 
both ATP and ATP^S behave in a similar manner and lends credence 
to the suggestion that responses elicited by ATP on rat platelets 
are primarily a result of ATP interacting at given receptor(s) 
and not due to the products of its metabolism.
3«1*3«2 Effect of ATP, ADP, AMP and Adenosine on rat platelet 
cytosolic free calcium, Cca^t] ^
Figure 20 depicts the effects of ATP-; ADP-, AMP- and 
Adenosine-induced elevation in cytosolic free calcium. Both 
ADP (30 nM - 10 ]j,M) and ATP (3 P<M - 1 mM) but not AMP or Adenosin 
(1 p,M - 100 p,M) elicited, in a concentration-dependent manner, 
the elevation of from a basal value of approximately
70 nM to approximately I3OO nM and 550 nM for ADP and ATP 
respectively. The EC^^ values are O.63 - 0.2 )iM and 23 - 5 P-M 
(mean - SEM), n = 3-7) for ADP and ATP respectively. Comparison 
of Figure 15a, using ADP as the agonist, with Figure 21, 
demonstrating the effects of ATP on cytoplasmic calcium levels, 
will reveal no discernible difference in the nature of the 
response to either of the two agonists - suggestive that the 
observed response to ATP in rat platelets is primarily due to
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Figure 19; Concentration-response relationship for ATP- and ATPY S-induced 
"stimulation of PtdA formation in rat platelets.
0.5 ml samples of prelabelled platelets prepared as described
(Section 2;2;1:2) were exposed to ATP (open symbols) or ATP S^(closed 
symbols) at the concentrations indicated. Results are measured in terms 
of fold stimulation - basal levels equal to 1. C^^ pU PtdA levels were 
measured 30s after agonist addition. The results are means - SEM of 
triplicate determinations. The experiment shown is typical of 3 similar 
experiments.
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Figure 20; Concentration-response relationship for agonist-induced changes 
in cytosolic free calcium FCa^+j ^ in rat platelets.
Aliquots (2 ml) of Quin 2-labelled platelets prepared as described (Section 
2:2:1;3) were incubated with ADP (A  ); ATP (O); AMP(D ) or Adenosine (# ) 
at the concentrations indicated. Results measured in terms of increase in [ca 
above basal levels (means - SEM). The data shown are cumulative results 
from 3-7 experiments.
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Figure 21; ATP-induced elevation of cytosolic free calcium in rat platele
Aliquots (2 ml) of Quin 2-labelled platelets prepared as described 
(Section 2;2;1;3) were incubated with ATP at the concentrations 
indicated. Changes in Cca t]. were estimated from the observed 
changes in dye fluorescence (Section 2;2;4). Above depicts typical 
responses from a single experiment representative of 4 others.
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a direct effect of ATP itself and not as a result of its 
metabolites subsequent to its hydrolysis. To substantiate 
this point, studies were performed to compare the effects of 
ATP and ATP^S, in the same experiment, at eliciting the elevation 
of Cca t] . The results are depicted in Figure 22. values
are 22 — 2 p,M and 17 - 1.6 p,M (mean - SEM, n = 2 ) for ATP and 
ATI^S respectively. There was no statistical difference between 
EC^q values or maximal response when either ATP or ATpV s was 
used as the agonist. These results extend those obtained while 
monitoring changes in t?^p3 PtdA induced by ATP/ATI^S and 
indicate that ATP^S behaves in a similar fashion to ATP with 
respect to elevating . Hence responses elicited by
addition of ATP appear to be due primarily to the direct action 
of ATP and not to metabolites generated following ATP hydrolysis. 
Figure 23 depicts the actual responses obtained in a représentatif 
experiment; they demonstrate the similarity in response of 
ATP and ATP)fs.
Figure 24 demonstrates the lack of response to AMP and 
Adenosine in rat platelets with respect to changes in cytosolic 
free calcium.
In conclusion, with regard to the characterisation of the 
nature of the receptor recognizing purines on rat platelets, 
the data obtained while monitoring tP^P^ PtdA formation and 
elevation of ^Ca^t]  ^indicate that rat platelets contain 
receptors acted upon by ADP and ATP but not AMP or Adenosine.
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Figure 22; Concentration-response relationship for ATP-_and ATpY 5 induced 
of cytosolic free calcium CCa^tl^ rat"platelets.
Aliquots (2 ml) of Quin 2-labelled platelets prepared as described (Section 
2:2:1;3) were incubated with ATP (open symbols) or AIP^S (closed symbols) 
at the concentrations indicated. Results are expressed in terms of increase 
in tca^'^3 . above basal levels, (means - SEM). The data shown is typical of 
that obtained in 2 other experiments.
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Figure 23; ATP- and ATPîTS-induced elevation of cytosolic free calcium, Cca^'3 ^  
in rat platelets.
Aliquots ("2 ml) of Quin 2-labelled platelets prepared as described (Section 
2:2:1:3) were incubated with ATP (upper tracel or ATPYs (lower trace) at 
the concentrations indicated. Changes in Lca "3. were estimated from the 
observed changes in dye fluorescence (Section 2:2:4). The responses shown 
are from a single experiment representative of 2 others.
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Figure 24; AMPn^and Adenosine-induced elevation of cytosolic free calcium, 
CCa , in rat platelets.
Aliquots (2 ml) of Quin 2-labelled platelets prepared as described (Section 
2:2:1:3) were incubated with Adenosine (upper trace) or AMP (lower trace) 
at the concentrations indicated. Above represents typical responses from 
one of four similar experiments.
- 175 -
3»1«4 Thrombin-induced metabolism of inositol phospholipids
The effect of Thrombin on inositol phospholipid metabolism 
in rat platelets was monitored in cells prelabelled with
* The basal levels of each of the inositol phospholipid 
species routinely monitored are as described in Section 3,1.1.
3«1»4.1 Thrombin—induced platelet aggregation
Platelets prepared under radiolabelling conditions were 
still functional with respect to aggregation induced by 
Thrombin (5-50 ^ M) as demonstrated in Figure 25» The aggregation 
response to Thrombin is concentration—dependent and irreversible 
and is preceded by a shape change lasting 10-15s. Unlike ADP- 
induced platelet aggregation, Thrombin-induced platelet 
aggregation was evident in the absence of added Ca ions.
3«1«4.2 Effect of Thrombin on platelet inositol phospholipid 
metabolism; Time course
In rat platelets Thrombin (50 nM, 1 u/ml) induced a rapid
increase in t?^pl PtdA formation (Figure 26). The peak response,
which represented a 770^ increase above basal levels in this
experiment (range 770-890 °^ in other experiments) occurred
within 3O-6OS of agonist addition. Compared to ADP-induced
formation of PtdA "tüiese results suggest that Thrombin
is far more efficacious at stimulating the formation of G^^p] PtdA.
In the absence of agonist, the levels of Q^^p2 PtdA did not
change significantly throughout the course of the experiment.
After the initial peak, levels of [p^p3 PtdA returned slowly
towards basal levels. However, unlike ADP-induced formation of
PtdA, levels of L"^ p^3 PtdA remain elevated - 4^9^ above
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Figure 25; Aggregation of washed rat platelets in response to Thrombin,
Plasma free suspensions of platelets (0.45 ml) prepared as described 
in Methods were exposed to Thrombin at the concentrations indicated 
and aggregation was monitored photometrically with continuous stirring.
- 177 -
9-1
co
iS 7 -
co
T3
0 »*-1
C
o
6-
5 -
T 3■M
o_ 3 -
-  2-
1J
**•
•••
#  *•«
T "
60
— I-----
120
Time (s)
180
—T-
240
— I
300
p32 1
Figure 26; Time-course of Thrombin-induced changes in L pJ PtdA in rat
P22 platelets.
0.5 ml samples of L pjp^  prelabelled platelets prepared as described 
(Section 2;2:1;2) were exposed to Thrombin. Results are expressed in^^._ 
terms of fold stimulation of the basal levels (= l). The levels of C  pJ 
PtdA were measured at the times indicated after agonist addition. The 
experiment shown is typical of three similar experiments.
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basal in this particular experiment by h min. This effect 
may be reflective of the more efficacious nature of Thrombin
i.e.j being able to elicit and maintain the formation of 
PtdA over a longer period of time compared to ADP. Throughout 
the course of the experiment no significant changes in Cp^plPtdlns 
were observed (data not shown). The lack of changes in t^^p] 
Ptdlns relative to changes in [^ ^^ p3 PtdA is unusual in that, 
compared to ADP-induced changes in inositol phospholipid 
metabolism, Thrombin is much more efficacious and one may have 
expected Thrombin to have an effect on the -labelled
pool of Ptdlns.
3.1.4.3 Effect of Thrombin on platelet inositol phospholipid 
metabolism; Concentration-response relationship
Having established the time course of Thrombin-induced 
inositol phospholipid metabolism, the concentration-response 
relationship for Thrombin-induced PtdA formation at 30s
was investigated. Figure 27* The threshold concentration for 
stimulation of [?^P^ PtdA formation was <15 nM and maximal 
effects were observed at I50 The calculated EC^^ is
31 - 0.25 nM (mean - SEM, n = 2-3)» In the experiment shown, 
the maximal stimulation of [P^p[l PtdA formation was approximately 
13 fold of control (the levels ranged between 7 and I3 fold in 
different experiments). When similar experiments are performed 
using either horse (Lapetina ejt al. , I98I), rabbit (Lloyd and 
Mustard, 1974) or human platelets (Broekman ejk aT. , I98O;
Holmsen e_t aT. , I98I) similar results are observed. The present 
findings confirm and extend those of Koutouzov ejt (1985)
and Kito et al (1985) who showed a comparable increase in
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Figure 27; Concentration-response relationship for Thrombin-induced 
stimulation of PtdA formation in rat platelets.
0.5 ml samples of prelabelled platelets prepared as described
(Section 2:2;1;2) were exposed to ADP at the concentrations indicated. 
Results measured in terms of fold stimulation - basal levels equal to 1. 
L^2pJ PtdA levels were measured at 30s after agonist addition. The 
results are means - SEM of triplicate determinations. The experiment 
shown is typical of 3 similar experiments.
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PtdA formation in rat platelets following Thrombin 
addition. Like the studies of Kito et al. (l975)> no changes 
in levels of Ptdlns, following exposure of platelets to
Thrombin were observed.
3.1.4.4 Inhibition of Thrombin-induced changes in ___
Phosphatidate
Thrombin-induced platelet activation exhibits properties 
of both a receptor operated and enzyme-catalysed reaction (see 
Section 3 ) and methods designed to inhibit its response
in platelets are complicated by this fact. However, there are 
compounds known to antagonise (although not at the receptor level) 
the response to Thrombin in platelets. Hirudin, an anticoagulant 
substance derived from leech salivary glands (Markwardt, I960) 
is known as a high affinity inhibitor of Thrombin and can 
inhibit both the stimulation of platelets by Thrombin and the 
binding of Thrombin to platelets (Detwiler and Peinman, 1973; 
Ganguly and Sonnichsen, 1976; Tam and Detwiler, 1978). In 
human platelets, Holmsen e_t al. (198I) demonstrated that in the 
presence of Thrombin, excess (approximately 20 fold) jiirudin, 
added 10s before Thrombin, can inhibit acid hydrolase secretion, 
Arachidonic acid metabolism and phosphatidic acid formation.
The effects of excess ^irudin on Thrombin-induced changes in
PtdA formation in rat platelets were examined. Figure 28 
depicts the effects of excess Hirudin added 10s before a sub- 
maximal concentration of Thrombin. Hirudin (8 0|/ml) inhibited 
Thrombin-induced PtdA formation by 75 - 7• 59^  (mean -
range, n = 2) .
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Figure 28: Effect of Hirudin on Thrombin-induced L^^pJptdA formation in rat platelet
0.5 ml samples of P ^ r Jp prelabelled platelets prepared as described 
(Section 2;2:1;2) were exposed to Thrombin (20 nM) in the absence or 
presence of Hirudin as indicated. Hirudin was added IDs prior to Thrombin 
and the levels of p] PtdA measured 30s thereafter. Results are expressed 
as fold stimulation of the basal level (= l). The experiment shown is 
typical of 2 similar experiments.
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3.1.4.4.1 Effect of PGE^
The effects of PGE^^ on Thrombin-induced formation of 
C?^P^ PtdA was examined. Figure 29 depicts the results obtained 
against 30 nM Thrombin, PGE^ (lO p,M) inhibited the agonist 
response by 26 - 2.6^ (mean - range, n = 2). Thus, as for 
ADP-induced formation of L^^p]l PtdA, PGE^ can also attenuate 
Thrombin-induced formation of L^^p3  PtdA in rat platelets, 
presumably as a result of activating a cyclic AMP-dependent 
process.
3#1«4.5 Effect of Thrombin on polyphosphoinositide metabolism;
Time course
The effect of Thrombin on polyphosphoinositide metabolism 
was examined in an attempt to discern which inositol phospho­
lipids is(are) metabolised following receptor occupancy by 
agonist. As with studies using ADP as the agonist (Figure 13) 
it appears that the metabolism of L?^p3 Ptdlns(4,5)P2 Is one 
of the first events occurring subsequent to agonist-receptor 
interaction. Figure 30 depicts the time-course of Thrombin- 
induced metabolism of L?^P^ PtdTns(4,3)P2*Within 5s of agonist 
addition there is a significant loss in \^^pl Ptdlns(4,5)?2 
(21^ in experiment shown, 22 - 1.4, mean - range, n = 3)« The 
maximal loss of Ptdlns (4,5 )^2’ 34^  ^in experiment shown
(33 - 1.4^, mean - range, n = 3 ) occurs at 15s. When compared 
to ADP-induced metabolism of Ptdlns(4,5)?2 (figure 13);
Thrombin evokes, by far, a greater decrease in L^^pl Ptdlns(4,5)^2 
- again reflective of the more efficacious nature of Thrombin 
in rat platelets. Throughout the course of the experiment no 
significant changes in either Ptdlns (4)P or fp^p3 Ptdlns
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Figure 29; Effect of PGE., on Thrombin-induced PtdA formation in rat platelet
0.5 ml samples of prelabelled platelets prepared as described
(Section 2:2;1:2) were exposed to Thrombin (50 nM) in the absence or 
presence of PGE.. as indicated. PGE.. was added 60s prior to Thrombin 
and the levels of L^^p3 PtdA measured 30s thereafter. Results are 
expressed as fold stimulation of the basal level (= l) and are typical 
of 2 similar experiments.
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Figure 30: Time-course of Thrombin-induced changes in PtdIns(4,5)P^
r^2 1 in rat platelets,
0.5 ml samples of L pJ P prelabelled platelets prepared as described 
(Section 2:2;1;2) were exposed to Thrombin (50 nM) and the levels of L pj 
PtdIns(4,5)P measured at th^ times indicated after agonist addition.
The results are mean values - SD of triplicate determinations expressed as 
a percentage of the zero time control; 100^ L?^P^ PtdIns(4,5)P^ =
112 995 - 52 248 dpm. The experiment shown is typical of 3 similar 
experiments.
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were observed (data not shown). After 15s there is a slow 
return towards basal levels of Ptdlns(4,5)P2* Similar
results are obtained using human platelets (Rendu ejfc ad.> I983; 
Agranoff et al.9 I983) suggesting that metabolism of CP^p3 Ptdlns 
(4,5)^2 of the earliest events occurring after agonist-
receptor interaction in a variety of different cell types 
including rat platelets.
3»1"5 Thrombin-induced changes in cytosolic free calcium [ca^^^ 
3«1«5»1 Thrombin-induced platelet aggregation
Platelet aggregation was examined, under Quin 2 loading 
conditions, in order to demonstrate maintenance of platelet 
functional responsiveness during Thrombin-induced changes in
r 2+1(_Ca Figure 31 demonstrates the aggregatory response
obtained with Thrombin (5-30 nM). When compared to unloaded 
or vehicle treated platelets. Thrombin-induced platelet 
aggregation was markedly enhanced in Quin 2 loaded platelets. 
Shape change was only evident at the lowest Thrombin concen­
trations tested, possibly being masked at the higher concen­
trations of Thrombin due to the potentiated aggregatory responses 
However, the results serve to illustrate that Quin 2 loaded 
platelets, stimulated with Thrombin, exhibit a concentration- 
dependent response.
3.1.5.2 Effect of Thrombin on rat platelet cytosolic free 
calcium Cca^t] ^
The changes in L c a ^ 3 i n  rat platelets subsequent to
Thrombin exposure were investigated, in order to elucidate
whether or not they were contemporaneous with known platelet
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Figure 31: Aggregation of washed rat platelets in response to Thrombin.
Plasma free suspensions of platelets (0.45 ml) preincubated with either 
Quin 2 AM (extreme right) vehicle (DMSO) (middle) or unloaded (extreme 
left) were exposed to Thrombin at the concentrations indicated and 
aggregation was monitored photometrically with continuous stirring.
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ftinctioTial responses and hence may be involved in platelet 
activation. Figure 32a depicts the changes in [,Ca^^ ^  in rat 
platelets Following addition of Thrombin (0.3 — 13 nM). A rapid 
and concentration-dependent elevation in is observed.
Maximal elevation in occurs within 10 sec and as with
ADP—induced changes in with increasing agonist
concentration, the rate and decline of response is greater.
These results indicate that changes in ^Ca^^^ occur within 
the same time scale as platelet functional responsiveness.
Figure 32b depicts the cumulative concentration-responsiveness 
for Thrombin-induced elevation of ' It is apparent
that Thrombin is much more potent and efficacious compared to 
ADP (Figure 13b) at elevating ^ a ^ ^  . Maximal elevation in
[ca^^(above basal level of approximately 70 nM) of approxi­
mately 4000 nM is observed at Thrombin concentrations of 13—30 nM. 
The value is 7 - P.23 nM (mean - SEM, n = 3)« The extent
of Thrombin-induced elevation of (^Ca^^was greatly reduced
in the absence of external Ca^* (i.e. using cells suspended in
Ca^*-free buffers containing EGTA (2 mM), Figure 33« This
indicates that, as with ADP, the majority of the Thrombin-induced
elevation of Tca^^ . derives via influx of external Ca^ '*’.1
Similar concentration-dependent elevation in platelet 
evoked by ihrombin are obtained when human platelets 
are used (Zavoico and Feinstein, 1984; Brydon ejfc al., 1984).
3.1.3.3 Inhibition of Thrombin-induced changes inLca^'O^
The inhibition of Thrombin-induced changes in [ca^'^3  ^
was investigated using Hirudin and PGE^.
— 188 —
g  2209- 
_  645-
+
CM
CDO
190-
8 4 1 -  
[Thrombin] f
RFI
f 5nM t 1 .5nM O.SnM
CO-T
CDtnO
CD3O
CD
1 min
Figure 32a: Thrombin-induced elevation of cytosolic free calcium Lca ^3 .
in rat platelet
Aliquots (2 ml) of Quin 2-labelled platelets prepared as described (Section 
2î2îl;3) were incubated with Thrombin at the indicated concentrations.
Changes in LCa were estimated from the observed changes in dye fluorescence 
(Section 2:2:4). Above responses are from a single experiment representative 
of 4 others.
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Figure 32b: Concentration-response relationship for Thrombin-induced elevation 
of cytosolic free calcium LCa^t]^ in rat platelets*
Aliquots (2 ml) of Quin 2-labelled platelets prepared as described (Section 
2:2;1;3) were incubated with Thrombin at the concentrations indicated.
Results are cumulative observations from several experiments (means - SCM) 
and are expressed as the increase in above basal.
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Figure 33; Thrombin-induced elevation of cytosolic free calcium in the
presence and absence of extracellular free calcium in rat platelets.
Aliquots (2 ml) of Quin 2-labelled platelets prepared as described (Section 
2;2:1:3) were incubated at the concentrations indicated, either in the 
presence or absence of extracellular free calcium. Changes in were
estimated from the observed changes in dye fluorescence. Above represents 
typical responses from a representative experiment.
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Effect of Hinrudin
Wlien added to platelets before Tbrombin, ^irudin inhibited 
the resultant elevation of (Figure 34). In the example
shown, 1.25 u/ml Hirudin inhibits the elevation of ^Ca^^^ 
induced by a maximal (13 nM) and submaximal (l»3 t]M) 
concentration of Ihrombin by 38 — 12^ and 100 — 0% (mean — range» 
n = 2) respectively. As well as attenuating the response to 
13 TiM Thrombin, the presence of ^irudin also severely slows 
its development. These results indicate that in addition to 
inhibiting Thrombin-induced PtdA formation in rat platelets,
Hirudin can also inhibit Thrombin-induced elevation of
3.1.3.3.2 Effect of PGE^
The effects of PGE^ were examined on Thrombin-induced 
changes in Q]a^t]« After prior exposure to 10 PGE^, the 
response to a maximal (13 nM) and submaximal (l«3 nM) 
concentration of Thrombin was reduced to 76 - 0.9^ and 100 
- Ofo (mean - range, n = 2-3) respectively (Figure 33)* In 
addition to attenuating the response to Thrombin, PGE^ also 
severely slowed the development of the response to I3 nM 
Thrombin. These results indicate that PGE^-induced elevation 
of cyclic AMP can result in the inhibition of agonist-induced 
elevation of ^ a ^ ^  ^  in rat platelets.
3.2 RPM
3.2.1 Agonist-induced metabolism of inositol phospholipids
Metabolism of inositol phospholipids in RPM were monitored 
in cells prelabelled with either t?^p3 P. (3 ]iC±/6 x 10^ cells)
or [pH^ inositol (lO pCi/lO^ cells). Within approximately 24 hrs,
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Figure 34; Effect of Hirudin on Thrombin-induced elevation of cytosolic 
free calcium in rat platelets.
Aliquots (2 ml) of Quin 2-labelled platelets prepared as described (Section 
2:2:1:3) were exposed to Thrombin, at the concentrations indicated, in the 
presence or absence of Hirudin (1.25 p-/ml) (H) as indicated. Hirudin was 
added prior to Thrombin and changes in fluorescence monitored thereafter 
were converted to changes in Lca J.» Traces shown are from a single experiment 
representative of 2 others.
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Figure 35; Effect of PGEj^ on Thrombin-induced elevation of cytosolic 
free calcium LCa^tl^ in rat platelets.
Aliquots (2 ml) of Quin 2-labelled platelets prepared as described 
(Section 2;2;1;3) were exposed to Thrombin, at the concentrations 
indicated, in the presence or absence of PGE^ as indicated. PGE^
(10 Tifl) was added 60s prior to Thrombin and changes in fluorescence 
monitored thereafter and converted to yield changes in Cca^t].. The 
above responses are from a single experiment, typical of 3 otAers.
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incorporation of into PtdA was approaching steady-state
conditions, incoirporation of L^ p^'l P^ into Ptdlns was still
increasing at this time point (Figure 3 Section 2). Due to
the relatively high turnover of the 4— and 3—phosphate moieties
in Ptdlns (4)P and Ptdlns(4,3)P^ (Section 2.2.9«l*l)> incorporatioi
of tp^pl P^ into these lipids is assumed to approach steady state
conditions by 24 hrs. Thus, a preincubation period of 24 hrs
was chosen for all experiments utilizing the radiolabel C^^P^ P^.
Under the conditions of radiolabelling the basal levels of [j ^^ p3
prelabelled inositol phospholipids routinely measured, were
63 306 - 4383 dpm; 88312 - 6678 dpm; 46 733 - 2721 dpm and
384 - 48 dpm (mean - SD) for [P^p3 P t d l n s (4,3)^2» Ptdlns
(4)P; [?^p3 Ptdlns and C?^p3 PtdA respectively. Time course
studies following the rate of incorporation of L^h J inositol
into the inositol phospholipids in RPM were not performed.
Instead a period of preincubation with inositol lasting
three days was chosen. This duration of preincubation compares
favourably with those used with other cultured cells (see
Drummond ejk al. , 1984; Berridge ejfc al. , 1984; Rebecchi e_t al. ,
1983)* After the three day incubation period, incorporation
of inositol into the inositol phospholipids was 370 I76 -
33 416 dpm, 49 940 - 19 708 dpm and 10 092 - 3460 dpm (mean -
SEM) for [?^p] PtdIns(4,3)P25 PtdIns(4)P and Ptdlns
respectively. These values are indicative that any inositol
phosphates formed, consequent upon agonist addition, could be
derived from the parent compounds. Basal levels of the inositol
+ +phosphates monitored were routinely 332 - 10 dpm; 332 - 10 dpm 
and 2332 - 20 dpm (mean - SD) for Ins(l,4,3)P^; Ins
(l,4)P and L^h3 Ins IP respectively.
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3*2«1«1 Functional Responsiveness in RPM
In any biological study, the demonstration of an agonist- 
induced functional response helps to validate biochemical 
responsiveness (e.g. inositol phospholipid metabolism‘and changes 
in induced by the same agonist. Possible parameters
which could be monitored in RPM include agonist-induced release 
of 3HT or adenine nucleotides or morphological changes. Although, 
in the present studies, I could demonstrate both C^h3 3HT 
(10024 - 1384 dpm/4 X  10^ cells) and Adenine (ll 192 -
304 dpm/4 X  10^ cells) to be associated with the RPM in experiment 
designed to monitor agonist-induced release of radiolabel 
marker from RPM, no radioactivity was found in the high speed 
supernatant fraction in such studies (results not shown). This 
would suggest that in RPM, incubated with either 3HT or
Adenine, that ADP and Thrombin failed to elicit a functional 
response. Studies using mature megakaryocytes have shown both 
release of 3HT and ATP from storage granules (Fedorko,1977?
Miller, I983) suggesting that in these immature cells the 
transduction processes - transferring information to the inside 
of the cell - may not be fully functional or developed. Studies 
designed to monitor morphological changes in RPM subsequent to 
agonist addition were beyond the scope of the present study.
Although no index of functional responsiveness in RPM 
could be demonstrated, to establish whether or not similar 
mechanisms possibly underlying cellular reactivity in rat 
platelets exist in RPM, the effects of agonists on inositol 
phospholipid metabolism and changes in Q]a^^^ were investigated.
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The following sections outline the effect of ADP on inositol 
phospholipid metabolism in RPM. The effects of Thrombin on 
inositol phospholipid metabolism are discussed in Section 3.2.4.
3*2.1.2 Effect of ADP on RPM inositol phospholipid metabolism; 
Time-course
The time course of agonist-induced metabolism of inositol 
phospholipids was monitored initially. Figure 36 depicts the
results obtained from ADP-induced L_/^ P_j PtdA formation in RPM.
In the absence of agonist the levels of PtdA did not
change significantly throughout the duration of the experiment. 
ADP (3 P-M) induced a rapid increase in L^^pl PtdA formation 
representing a 3^^ increase above basal levels in the example 
shown (36 - 0%, mean - SEM, n = 2) within 60s of agonist addition. 
Thereafter levels in PtdA decline slightly reaching a
plateau level of approximately 3IJ0 above basal levels in this 
particular experiment. No changes in Ptdlns levels were
detected throughout the duration of the experiment (results not
shown ).
3*2.1.3 Effect of ADP on RPM inositol phospholipid metabolism;
Concentration-response relationship
Having established the time-course of ADP-induced PtdA
formation the next parameter to be investigated was the 
concentration-dependence of this response. Figure 37 depicts
the results obtained for ADP-induced formation of LP^P~1 PtdA 
monitored 60s after agonist addition to cells. ADP was tested 
over the concentration range 1-1000 p,M. At 1 p,M ADP no 
significant formation of t-^^p3 PtdA was observed; a 1.3 fold 
stimulation occurred at 3 P-M (range 1.23 - 1*3 fold in different 
experiments) which apparently was maximal * The estimated EC^^
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F jours 36; Time-course of ADP-induced changes in ptdA in RPH.
0.4 ml samples of P prelabelled RPM, prepared as described
(Section 2:2;2:3) were exposed to ADP (3V'l''l). Results are expressed 
as fold stimulation (basal levels =1). The levels of L32p3 ptdA were
measured at the times indicated after agonist addition, 
shown is typical of 2 similar experiments.
The experiment
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Figure 37; Concentration-response relationship for ADP-induced 
stimulation of C^^P3 PtdA formation in RPM.
0.4 ml samples of p. prelabelled RPM prepared as described
(Section 2;2:2;3) were exposed to ADP at the concentrations 
indicated for 60s. Results are expressed in terms of fold 
stimulation of the basal levels (equal to l). The results are 
means - SEM of triplicate determinations. The experiment shown 
is typical of 3 similar experiments.
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value was 1.6 - 0.07 liM (mean - SEM, n = 2-3). These results 
indicate that, like rat platelets, RPM are capable of metabolis­
ing inositol phospholipids, resulting in the formation of PtdA, 
subsequent to agonist-receptor interaction.
3*2.1.4 Inhibition of ADP-induced changes in C^^pl Phosphatidate
As in studies with rat platelets, availability of known 
antagonists of the effects of ADP in human platelets were 
restricted. However, PGE^ has been shown to elevate levels 
of cyclic AMP in RPM (Section 2.2.9) and studies were carried out 
using this compound to discern whether or not if a qualitatively 
similar cyclic AMP-dependent mechanism that acts to inhibit 
[^^^l^PtdA formation in rat platelets also exists in RPM.
Figure 38 depicts the effect of PGE^ on submaximal stimulation 
of C?^p3 PtdA by ADP. Prior exposure to PGE^ (lO ]iM) inhibited 
ADP-induced formation of PtdA by 36 - 39^  (mean - range,
n = 2). These results indicate that, as in rat platelets, 
cyclic AMP-dependent mechanisms exist in RPM to inhibit agonist 
induced metabolism of inositol phospholipids.
3*2.1.3 Effect of ADP on polypho sphano si tide metabolism; Time 
course
Studies in rat platelets (Section 3*1*1*5*1 and 3*1*4.3) 
demonstrates that one of the earliest events initiated by 
receptor occupation by agonist is the metabolism of L^^p3 Ptdlns 
(4,3)P^ resulting in an apparent reduction in the level of this 
inositol phospholipid. Similar studies were performed using
prelabelled RPM in an attempt to discern whether or not 
a qualitatively similar rapid metabolism of Ptdlns(4,3)Pp
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Figure 38; Effect of PGE^ on ADP-induced PtdA formation in RPM.
0.4 ml samples of P prelabelled RPM prepared as described
(Section 2:2:2:3) were exposed to ADP (2 P-M) in the presence or 
absence of PGE^ as indicated. PGE, was added 60s prior to ADP 
and the levels of L^^pH PtdA measured 60s thereafter. Results 
are expressed in terms of fold stimulation of the basal (equal 
to l). The experiment shown is typical of 2 similar experiments.
- 201 -
is evident. The results are summarised in Table 3«
I n  contrast to the situation in rat platelets (Section 
3*1.1.3*l) ADP (3 IxM) does not appear to induce the metabolism 
of L? p 3  P t d l n s (4,3)^2 RPM. No significant changes in the
levels of either Ptdlns(4,3)P^, PtdIns(4)P or Ptdlns are 
observed at any time during the experiment; however significant 
stimulation of "PtdA" formation at 10, 30, 60 and 300s suggests 
that the inositol phospholipid cycle has been perturbed. This 
lack of effect on metabolism of polyphosphoinositides may be 
a reflection of the low efficacy exhibited by A D P  in RPM. 
Reference to Sections 3*2.1.2 and 3*2.1.3 will demonstrate that 
in this cell the maximal stimulation of L?^p3 PtdA formation, 
induced by A D P ,  ranges from between 3 0 - 4 0 %  above basal levels. 
Such a weak effect may stimulate the metabolism of only a small 
*pool' of P t d l n s (4,3) P2 which may be rapidly replenished. 
Additionally, the errors inherent in using this techniqu'e mean 
that small changes in levels of any of the inositol phospholipids 
monitored will be difficult to detect. However, an interesting 
point to note is that significant amounts of Cp^p"3 PtdA are 
formed at very early time points during these experiments.
This at variance with those results obtained while monitoring 
agonist-induced changes in L?^P^ PtdA formation (Section 3*2.1.2), 
Different, and more thorough, phospholipid extraction procedures 
compared to those utilized to obtain results in Section 3*2.1.2 
are utilized in the present experiments. It is quite possible 
that any slight formation of (?^p3 PtdA will be more readily 
detected using the present extraction procedure compared to any 
other method of extraction.
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Table 3: Time-course of ADP-induced changes in the polyphosphoinositides in RPM,
5
ADP incubation period (s)
10 50 50 300
1.04 + 0.05 0.99 1 0.18 1.02 + 0.04 1.06 + 0.06 0.97 + 0.02
0.98 + 0.05 0.95 + 0.02 0.98 + 0.04 1.03 1 0.05 1.03 + 0.08
1.05 + 0.02 1.01 + 0.06 0.89 + 0.01 0.94 + 0.09 1.02 + 0.03
1.20 + 0.44 1.25 + 0.005 1.42 + 0.37 1.31 + 0.27 1.18 + 0.07
[32p] P. prelabelled RPM prepared as indicated
Phospholipid
Ptd Ins 4,5P2 
Ptd Ins 4P 
Ptd Ins 
PtdA
0.5 ml samples of
(Section 2.2.2.3) were exposed t o  __ __ ____  _________
The results shown are mean values - SD of triplicate determination; 
calculated as fold stimulation of basal (= 1). The experiment 
shown is typical of 2 similar experiments.
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These results confirm the ability of ADP to induce the 
formation of LP^p3 PtdA in RPM. However, unlike rat platelets, 
no demonstrable ADP-induced metabolism of P t d l n s  (4,3 )1*2 could 
be produced. This may simply imply the lack of sensitivity of 
this technique in detecting extremely small changes in the 
levels of inositol phospholipids or indicate that one of the 
initial events occurring subsequent to agonist-receptor inter­
action in RPM does not include metabolism of P t d l n s  (4, 3 )l*2* T T  
the latter were true, then the formation of PtdA, previously
assumed to be solely derived from inositol phospholipid metabolism, 
may be a coincidental event occurring in RPM upon agonist 
exposure.
To resolve this dilemma I thus attempted to monitor the 
effects of ADP on RPM inositol phosphate formation. Since these 
compounds are the water soluble products of inositol phospholipid 
metabolism, an accumulation of these compounds in particular 
Ins(1 , 4 , 3 >  would be suggestive that the metabolism of Ptdlns 
(4,3 ^ ) 2  is one of the first events occurring following agonist- 
receptor interaction.
3*2.1.6 Effect of ADP on inositol phosphate formation in RPM
As outlined in Section 2.2.9*1» the metabolism of inositol 
phospholipids can be monitored either by measuring the dis­
appearance of radioactive labelled inositol phospholipids e.g. 
disappearance of L?^p3 Ptdlns(4,3)P^; by measuring the accumulation 
of radioactive labelled intermediaries in the inositol phospho­
lipid metabolic cycle e.g. t?^P^ PtdA or by measuring the 
accumulation of the water soluble products of inositol phospho­
lipid metabolism e.g. the inositol phosphates. Unlike rat
-  20k  -
platelets, RPM are capable of incorporating Inositol into
their phospholipids (Section 2.2.9.1.2) and hence the metabolism 
of inositol phospholipids can be monitored in RPM by following 
the accumulation of inositol phosphates subsequent to agonist 
addition. Figure 39 depicts the time-course of ADP (3 P-M)- 
induced accumulation of -inositol phosphates in RPM from
a typical experiment. The following values represent ,the 
increase in the individual inositol phosphate species, expressed 
as a percentage above basal levels, for the example shown 
followed by the range in brackets.
Accumulation of Ins IP was observed after a lag period
of approximately 60s, at which point levels of Ins IP had
accumulated to 20^ above basal (20 - 0.7?^ > mean - range = 2). 
Thereafter Ins IP continued to accumulate, until by 3 min,
levels were 30?^ above basal (33 - 20fo, mean - range, n = 2).
Rapid accumulation of Ins (l, 4)P^ was observed. Within
3 sec of agonist addition levels of L?hQ Ins(l,4)P2 were kO^ o 
above basal (66 - 36%, mean - range, n = 2). Thereafter
Ins(l,4)P2 continued to accumulate, until by 60s levels 
were 2Z0?Qabove basal (19I - 40%, mean - range, n = 2).
Ins(1,4, 3 accumulated more rapidly than Ins(l,4)l
or Ins IP. Within 3s, Ins(l,4,3)P^ levels were 120%
above basal (79 - 57%> mean - range, n = 2) and the peak 
response of 190% above basal (l44 - 63%» mean - range, n = 2) 
occurred within 30s. Thereafter levels in this triphosphate 
declined, until by 3 min, levels were reduced to 100% above 
basal (38 - 39%» mean - range, n = 2).
The fact that C?El1 Ins(l,4,3)P^ and D h 3  Ins(l,4)P^ 
do not continue to accumulate suggests that both are hydrolysed.
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Figure 39: Time-course of ADP-induced formation of inositol
polyphosphates in RPM.
0.5 ml samples of L^H3 inositol prelabelled RPM prepared as described 
(Section 2;2;2;4) were exposed to ADP (3 um). The levels of LxHJ Ins. 
(1,4,5)P (0): Lpnllns (l,4)P (D ) and L?hI\ Ins IP (^ ) were 
measured at the times indicated after agonist addition. The experiment 
shown is typical of 2 similar experiments.
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by specific phosphomonesterases> to yield C?h3 Ins(l>4^)P2 and 
subsequently [^h 1 Ins IP and inositol in the case of
Ins (l, 4 > 5 )P^ > and Ins IP and inositol in the
case of [^h 3 Ins(l,4)P2* This probably explains the lag period 
observed before significant accumulation of tplîl Ins IP is 
observed — since, theoretically, in addition to being formed by 
the action of phospholipase C on Ptdlns, L^h 3 Ins IP could also 
be formed by the sequential hydrolyses of L?h 3 Ins(l,4,5)P^ to 
[pH^ Ins(l,4)P2 and thence to i^pT] Ins IP. The other water 
soluble metabolites of inositol phospholipid metabolism, namely 
inositol and glycerophosphoinositol, were not routinely monitored 
as preliminary experiments demonstrated no significant changes 
in levels of glycerophosphoinositol and only a late increase
in levels of IlPh ^  inositol.
These results argue that one of the earliest events 
following agonist-receptor interaction in RPM is the metabolism
of Ptdlns(4,5)P2 with consequent formation of Ins(lA,5)P^ - 
assuming that Ptdlns(4,3)P2 the sole source of Ins(l,4,3)P^ 
(see Section 1.3.1.3)» That agonist-induced accumulation of
Ins(l,4,3)P^ could be demonstrated, whereas the metabolism 
of C^^p3 Ptdlns(4,3)^2 could not (Section 3»2.1.3) indicates
that monitoring the accumulation of the water soluble metabolites 
of inositol phospholipid metabolism, as well as being more 
direct, may be a more sensitive assay by which to demonstrate 
agonist-induced metabolism of inositol phospholipids.
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3*2*2 ADP—induced changes in cytosolic free calcium E Ca^t]^
3*2.2,1. Effect of ADP on RPM cytosolic free calcium
Having established that, as in rat platelets, ADP elicits 
inositol phospholipid metabolism in RPM, I next investigated 
the effect of ADP on cytosolic free calcium in RPM. Basal levels 
of [ c a ^ ^ a r e  approximately I30 nM. ADP (0.03 - 30 p-M) elicits 
a rapid and concentration—dependent elevation in ^Ca^^^
(Figure 40a). As with rat platelets, as the agonist concentration 
increases, the rate of rise and decline in response also increases 
Figure 40b depicts the cumulative concentration-response curve 
for ADP-induced elevation in (^Ca^^in RPM. The maximal extent 
of the elevation in [^Oa^^ ^  above basal levels (approximately 
600 nM) occurs at approximately 3 pM ADP and the calculated EC^^ 
value is 0.22 - O.O7 pM (mean - SEM, n = 3)* When ADP-induced 
changes in ^ a ^ ^ ^  were monitored in calcium-free buffers in 
the presence of EGTA (2 mM) a small, but reproducible response 
was observed in the absence of extracellular free calcium 
(Figure 4l). This response amounts to approximately 30-^0^ 
degree of Ca^^ mobilization and is in contrast with the 
situation observed in rat platelets where, in the absence of 
extracellular calcium, the agonist-induced response is completely 
abolished.
3.2.2.2 Inhihibition of ADP-induced changes in Cca^~^ ^
The effects of PGE^ on agonist-induced changes in (jCa^ '^ J  ^
in RPM, were investigated. Figure 42 depicts the effects of 
prior exposure to PGE^ (lO pM; 60s) on the elevation of [ca^^^ 
in RPM induced by maximal (3 pM) and submaximal (0.3 pM) 
concentrations of ADP. PGE^ inhibited the response induced
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Figure 40a; ADP-induced elevation of cytosolic free calcium Cca^^ . in RPM,
Aliquots (2 ml) of Quin 2-labelled RPM prepared as described (Section 
2;2;2;5) were ^ncubated with ADP at the concentrations indicated. 
Changes in [jCa 3. were estimated from the observed changes in dye 
fluorescence (Section 2:2:4). Above represents typical responses from 
a single experiment representative of 2 others.
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Figure 40b; Concentration—response relationship for ADP—induced elevation 
in cytosolic free calcium l.Ca^ '*'3^  in RPM.
Aliquots (2 ml) of Quin 2 labelled RPM prepared as described (Section 2;2:2;5) 
were incubated with ADP at the concentrations indicated. Results (mean values 
- SEM) are cumulative observations from several experiments and are expressed 
as the increase in [_Ca (nM) above basal levels.
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Figure 41; ADP-induced elevation of cytosolic free calcium in the oresence and 
absence o f  extracellular free calcium in R O M .
Aliquots (2 ml) of Quin 2-labelled platelets prepared as described 
(Section 2:2;2:5) were incubated with ADP at the concentrations 
indicated either in the |resence or absence of extracellular free 
calcium. Changes in L c a  J. were estimated from the observed changes 
in dye fluorescence (Section 2:2:4). Responses shown are from a 
single experiment typical of 3 others.
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Figure 42: Effect of PGE  ^ on ADP-induced elevation of cytosolic free
calcium [Ca^+3 RPM.
Aliquots (2 ml) of Quin 2-labelled RPM prepared as described (Section 
2:2:2:5) were exposed to ADP, at the concentrations indicated, in the 
presence or absence of PGE^ as indicated. PGE^ (lGp,M) was added 60s 
prior to ADP and changes in fluorescence monitored thereafter and 
converted to yield changes in .. Above are typical responses
from a single experiment representative of 2 others.
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by 3 "pM ADP by 4o — 4^, and that evoked by 0.3 p.M ADP by 
43 - 4% (mean values - range, n = 2-3)• Both the rate and 
extent of ADP-induced elevation of Loa^tl were impaired by 
PGE^. These results indicate that, like rat platelets, RPM 
possess a cyclic AMP-dependent mechanism which acts to oppose 
evoked increments in [,Ca^ t] *
3*2.3 Characterisation of receptors recognizing ADP in RPM
Having established that ADP elicits inositol phospholipid 
metabolism and elevation of ^Ca^^ ^  in RPM, as in rat platelets,
1 attempted to characterise the nature of the receptor(s) 
recognizing ADP in RPM by comparing the rank order of potency 
of a series of purines on their ability to induce the formation 
of L^^p3 PtdA and elevate Lca^^J^.
3.2.3*1 Effect of ATP, ADP, AMP and Adenosine on RPM inositol
phospholipid metabolism; Concentration-response relation­
ship
Figure 43 depicts the ëffects of ATP, ADP, AMP and Adenosine 
on the accumulation of L^^P^ PtdA in RPM. Both ADP (I-30 p,M) 
and ATP (l p,M - 1 mM) but not AMP or Adenosine, when tested at 
a single concentration of 100 )iM, elicited, in a concentration- 
dependent manner, the formation of PtdA. The threshold
concentration for stimulation of t?^p3 PtdA formation was <3 p-M 
using ADP and <100 pM using ATP. For the examples shown, the 
maximal stimulation of P^p3 PtdA formation using ADP as the 
agonist is 1.3 fold of control (range 1.23 - 1*30) and 1.2 fold 
of control using ATP as the agonist (range 1.2 - 1.4). The 
estimated EC^^ values for ADP and ATP are respectively I.60 - 
0.03 pM and 22 - 3 pM (mean - SEM, n = 2-3). In RPM it appears
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Figure 43; Concentration-response relationship for agonist-induced stimulation 
of* L^-P3 PtdA formation jn RPM.
0.4 ml samples of Pi prelabelled RPM prepared as described (Section
2:2;2;3) were exposed to ADP ); ATP (O); AMP (Q ) or Adenosine ( # )  at 
the concentrations indicated. Results are measured in terms of fold 
stimulation, basal levels equal to 1. C^^p3-PtdA levels were measured 30s 
after agonist addition. The results are means - SO of triplicate determinations 
The data shown for ATP and ADP is from separate experiments representative of 
2-3 similar experiments.
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that ADP is more potent than ATP at eliciting the formation 
of [?^p] PtdA.
As in rat platelets, the possibility existed that the 
effects observed with ATP may result from the action of metabolites 
produced by hydrolysis of ATP rather than a direct effect of 
ATP. Consequently, the effects of the non-hydrolysable ATP 
analogue, ATP^S, on PtdA formation was monitored (Figure
44). Both ATP and ATf^S (O.l p,M - 1 mM) elicit, in a concentratioi 
dependent manner, the formation of D^P^ PtdA. Maximal fold 
stimulation of 1P^p3 PtdA formation induced by ATPKS is 
1.26(1.24 - 1.26 in different experiments). Calculated EC^^ 
values are I7 - 5» 7 }iM and I7.I - 5*6 jiM (mean - SEM, n = 3) 
for ATP and ATI^ )(% respectively. No statistical difference 
exists between these two values or in the extent of maximal 
response elicited by either agonist. Thus ATP and ATP^S exert 
similar effects indicating that responses elicited by ATP in 
RPM most probably can be attributed to a direct effect of 
this agonist and not to a hydrolysis product that also acts 
upon the receptor recognizing purines.
3*2.3*2 Effect of ATP, ADP, AMP and Adenosine on RPM cytosolic 
free calcium, Cca^tl ^
Figure 45 depicts the effects of ATP, ADP, AMP and Adenosine 
on changes in y, * Both ADP (0.03 - 30 pM) and ATP (0.03 -
100 ixM) but not AMP or Adenosine (l - lOO^M) elicit, in a 
concentration dependent manner, the elevation of (jOa^tl* The 
maximal elevation in was approximately 60O nM using
ADP as the agonist and approximately 550 nM using ATP as the 
agonist. The calculated EC^^ values are 0.22 - 0.07 P-M and
—  215  —
co
(C
3E
CO
•O
0 
4—
1
CO.
4-*
G3
*o
4->
o_
I
Q .CvlhO
1.5
1.4
1.3
1. 2
1.1
1.0
0.1
— T"
1.0
-T
10 100 1000
[Agonist]
Figure 44; Concentration-response relationship for ATP- amd ATP S induced.formation 
of L3^P3 PtdA in RPFL
0.5 ml samples of prelabelled RPM prepared as described (Section
2:2:2:3) were exposed to At P (open symbols) or ATP^fS (Closed symbols) at 
the concentrations indicated. Results are measured in terms of fold 
stimulation - basal levels equal to 1. L?^p3 PtdA levels were measured 30s 
after agonist addition. The results are means - SEM of triplicate 
determinations. The experiment shown is typical of 3 similar experiments.
- 216 -
700-,
6 0 0 -
5  5 0 0 -
CNI 4 0 0 -
o
500 -
200 -
100 -
0
3000.03
[Agonist] |iM
Figure 45; Concentration-response relationship for agonist-induced changes 
in cytosolic free calcium LCa 3 ^ in RPM.
Aliquots (2 ml) of Quin 2-labelled RPM prepared as described (Section 
2:2;2:5) were incubated with ADP (A. ); ATP ( o ) ;  AMP ( Q ) or Adenosine )
at thegConcentrations indicated. Results measured in terms of increase 
in (_Ca 3, above basal levels (means - SEM). The data shown are the 
cumulative results from 3-4 experiments.
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3*3 — 1»55 "P-M (mean - SEM, n = 3-4) for ADP and ATP respectively* 
ATP—induced changes in are rapid in onset (Figure 46)
and comparable in rate to those evoked by ADP (Figure 40a).
This could imply that ATP exerts a direct effect on RPM 
without prior metabolism to ADP* To substantiate this point, 
the effects of ATP and ATP^S on RPM  ^were then compared
(Figure 4?)* The estimated EC^^ values for agonist-induced 
elevation in were 1*45 - 0*09 "P-M for ATP and 0*26 - 0*02^M
for ATP^S (mean - SEM, n = 2)*
Figure 48 illustrates the effects of ATP and ATP*)(^ S on 
changes in in RPM; no major difference in the nature
of the evoked response is evident* Although ATP'5s appears to 
be more potent than ATP, there is but a marginal difference 
in the maximal response (increase in (^Oa^^ i ) elicited by the 
two agonists* Thus, ATP-induced elevation of Lpa^ "*^  ^  in RPM 
results primarily from a direct action of ATP* Lastly,
Figure 49 illustrates the total lack of effect of AMP and 
Adenosine on ia RPM*
In conclusion, from the data presented in this section 
it appears that RPM possess a receptor, at which ADP is the 
most potent agonist, which is coupled to inositol phospholipid 
metabolism and elevation of j c a ^ ^ *
3*2.4 Thrombin-induced metabolism of inositol phospholipids
The effect of Thrombin on inositol phospholipid metabolism
\ 3 2  ^in RPM was monitored in cells prelabelled with either L PJ P^ 
or Inositol* The basal levels of each of the inositol
phospholipid species was routinely monitored, using either 
or Inositol radiolabels, in addition to basal levels of
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Figure 46; ATP-induced elevation of cytosolic free calcium €ca2-0. in RPM,
Aliquots (2 ml) of Quin 2-labelled RPM prepared as described (Section 
2:2:2:5) were incubated with ATP at the concentrations indicated.
Changes in [Ca^‘3.  were estimated from the observed changes in dye 
fluorescence (Section 2:2:4). Traces shown are from a single experiment 
representative of 2 others*
- 219 -
500-n
400-
300
O)
v>
coO)
200-
100-
0 0.1 1.0
[Agonist] pM
10 100
Figure 47; Concentration-response relationship for ATP- and ATPXS .induced elevatio 
ïn cytosolic free calcium LCa^+]. in RPM.
Aliquots (2 ml) of Quin 2-labelled RPM prepared as described (Section 
2:2:2:5) were incubated with ATP (open symbols) or ATPVS (closed symbols) 
at the concentrations indicated. Results are measured in terms of increase 
in LCa J. above basal levels (mean - SEM). The experiment shown is typical 
of 2 others.
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Figure 48; ATP- and ATP)^ Sr-induced elevation of cvtoeolic free calcium Cca^^. ^  
RPM. ^
Aliquots (2 ml) of Quin 2-labelled RPM prepared as described (Section 
2;2:2:5) were incubated with ATP (upper trace) or ATPfs (lower trace) 
at the concentrations indicated. Changes in Cca^'til. were estimated 
from the observed changes in dye fluorescence (Section 2:2:4). Those 
shown are typical responses from a single experiment representative of 
at least 2-3 others.
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Figure 49; AMP- and Adenosine-induced elevation of cytosolic free calcium Cca^lj. 
in RPM. 1
Aliquots (2 ml) of Quin 2-labelled RPM prepared as described (Section 
2;2;2;5) were incubated with Adenosine (upper trace) or AMP (lower trace) 
at the concentrations indicated. Above represents typical responses of 
a single experiment, representative of 2-3 others.
D h ] inositol phosphates are as described in Section 3»2.1.
3«2.4.1 Effect of Thrombin on RPM inositol phospholipid 
metabolism; Time-course
Using a relatively high concentration of agonist, the 
time-course of Thrombin-induced metabolism of inositol phospho­
lipids in RPM was examined. The time-course of Thrombin (200 nM)- 
induced PtdA formation is shown in Figure 30» The peak
response, representing a 2h^ o increase above basal levels in the 
experiment shown (24 - 0^, mean - SEM, n = 2) was observed at 
60s. Thereafter levels of PtdA declined, reaching basal
levels by approximately 3 min. No changes in D^p3 Ptdlns were 
observed either in the presence or absence of agonist. These 
results suggest that, like ADP, Thrombin is capable of eliciting 
the formation of Q^^P^ PtdA in RPM.
3*2.4.2 Effect of Thrombin on RPM inositol phospholipid metabolism 
Concentration-response relationship
Using a duration of agonist exposure of 60s, the 
concentration-response relationship for Thrombin-induced 
stimulation of L^^P^ PtdA formation was next investigated 
(Figure 31 ). It is clear, that in RPM, Thrombin is a ver}^  weak 
stimulant of inositol phospholipid metabolism eliciting an 
increase in t?^P^ PtdA of approximately 12^  ^above basal in 
the experiment shown. Due to the errors inherent in the 
system it is difficult to detect small changes in C^^p] PtdA 
of <10^. The observed changes with Thrombin fall close to 
this limit and thus difficulties arose in attempting to obtain 
consistent and measurable responses to Thrombin in this cell.
From the available data, an estimate of the EC^^ value is
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Figure 50; Time-course of Thrombin-induced changes in PtdA in RPM.
0.4 ml samples of P, prelabelled RPM prepared as described (Section
2s2:2;3) were exposed to Thrombin (200 nM) and the levels of L  Pi PtdA 
were measured at the times indicated after agonist addition. Results are 
expressed as fold stimulation of the basal level (equal to l). The 
experiment shown is typical of 2 similar experiments.
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Figure 51; Concentration-response relationship for Thrombin-induced 
stimulation of PtdA formation in RPM.
0.4 ml samples of [32p] P pre-labelled RPM prepared as described
(Section 2;2;2:3) were exposed to Thrombin at the concentrations 
indicated and PÜ PtdA levels were measured 60s after agonist 
addition. Results are expressed in terms of fold stimulation 
(basal level = 1). The results are means - SEM of triplicate 
determinations. The experiment shown is typical of 3 similar 
experiments.
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< 150 nM. Due to the high cost of Thrombin and the weak 
responses evoked by this agonist, studies designed to monitor 
the inhibition of Thrombin-induced PtdA formation were
not performed#
3.2.4.3 Effect of Thrombin on polyphosphoinosotide metabolism;
Time-course
The effect of Thrombin on the metabolism of the polyphospho­
inositides was next examined using L?^P^ P^  ^prelabelled RPM.
The results are summarised in Table 4.
No demonstrable effect on levels of P t d l n s (4,5)^2»
(^^p3 Ptdlns (4)P or l^^p3 Ptdlns was observed subsequent to 
thrombin addition. However, the appearance of PtdA
(significant at 5s) suggests, but does not necessarily prove, 
that metabolism of inositol phospholipids had occurred, 
(incidentally these results, like those obtained with ADP 
(Section 3*2.1.5) are at variance with those obtained when 
monitoring Lp^P ^ PtdA formation using a different extraction 
procedure (Section 3*2.4.1) again demonstrating that the present 
extraction procedure may be more effective). As outlined in 
Section 2.2.9.1.1, 1,2-diacylglycerol (the precursor of PtdA) 
can be derived from triacylglycerol. It is quite possible 
that production of PtdA is concurrent, but coincidental, with 
agonist addition. However, if one assumes that inositol 
phospholipids are the sole source of PtdA formation in RPM, 
then one possible explanation to describe the effect of Thrombin 
on the metabolism of polyphosphoinositides in R P M  may be that, 
like ADP, Thrombin - due to its weak effect - is able to 
metabolise only a small ’pool* of Ptdlns(4,5)Pq> one which is
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Table 4: Time-course of Thrombin-induced chang as in the polyphosphoinositides
in RPM.
.
Phospholipid
5
Thrombin
10
Incubation period (s) 
30 60 300
Ptd Ins A/SPg 1.04 + 0.08 1.04 + 0.08 1.03 + 0.07 1.01 + 0.08 1.08 1 0.05
Ptd Ins 4P 1.01 + 0.02 0.99 + 0.03 0.99 + 0.01 1.02 + 0.01 1.05 1 0.01
Ptd Ins 0.95 + 0.02 0.87 + 0.08 0.86 + 0.06 0.95 + 0.04 0.91 1 0.10
PtdA 1.23 + 0.12 1.26 + 0.007 1.39 1 0.10 1.28 + 0.10 1.26 + 0.05
Legend to Table 4
0.5 ml samples of L?^p3 prelabelled RPM prepared as indicated 
(Section 2;2;2:3) were exposed to Jhrombin for the times indicated. 
The results shown are mean values - SO of triplicate determinations 
calculated as fold stimulation of basal ( = l). The experiment 
shown is typical of 2 similar experiments.
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rapidly replenished* Alternatively, metabolism of P t d l n s (4,5)P2 
may play no part in the receptor-operated mechanisms for 
cellular reactivity in RPM, in which case, as already stated, 
formation of 1!P^p3 PtdA may in fact be a coincidental event.
To resolve this situation, of whether or not Pt d l n s(4,5)P2 
is metabolised in RPM following agonist addition, I attempted 
to monitor the accumulation of inositol phosphates in RPM.
An early accumulation of Ins(l,4,5)P^, the water soluble 
metabolite Ptdlns(4,5)P2> would be indicative of the metabolism 
of Ptdlns(4,5)f2 in fact one of the earliest events
occurring after agonist-receptor interaction in RPM.
3*2.4.4 Effect of Thrombin on inositol phosphate formation in RPM 
The effect of Thrombin on inositol phosphate accumulation 
in RPM prelabelled with CpPll Inositol was examined. Thrombin 
( 2 5 0 nM) induced the formation of Ins (l, 4, 3 )P^; Ins
(l,4)P^ and Ins IP; the time-course of such a formation,
from a typical experiment, is depicted in Figure 32. The 
following values represent the increase in appearance of the 
individual inositol phosphates expressed as a percentage above 
basal levels, for the example shown, followed by the range in 
brackets.
Thrombin induced a significant increase in the level of 
Ins IP only at the longest time point studied (3 min).
At this point, Ins IP had accumulated to 60^ above basal
( 6 0 - 6%, mean - range, n = 2).
A rapid accumulation of Ins(l,4)P2 was observed.
By 3s levels had accumulated to 21^ above basal (21 - 2^, 
mean - range, n = 2). Thereafter levels of Ins(l,4)P2
continued to increase and were still increasing by 6 0 s.
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Figure 52; Time-course of Thrombin-induced formation of inositol
polyphosphates in RPM.
0.5 ml aliquots of inositol prelabelled RPM prepared as described
(Section 2;2;2:4) were exposed to Thrombin (250 nM). The levels of 
Ins(l,4,5)R (O); L^h 3 Ins(l,4)P2 ( D )  and C?h 3  Ins IP ( A )  were measured
at the times indicated after agonist addition. The experiment shown is 
typical of 2 similar experiments.
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Thrombin also induced a rapid accumulation of Ins(l>4>5)
and by 5s levels were 6^ above basal (6 — 1^, mean - range, 
n = 2). Peak response representing a 100^ increase above basal 
(lOO - 10^, mean - range, n = 2) was observed at 30s. Thereafter 
levels declined slightly reaching a plateau value of 'Jh^o above 
basal (74 - mean - range, n = 2) by 30-60s.
The continued presence of the diphosphate, in the example 
shown, is unlike the situation observed with ADP (Figure 39) 
where by 60s levels ofC^Iki Ins(l,4)P2 began to decrease.
However, like ADP-induced accumulation of CPh3 Ins(l,4)P2> 
levels of this bisphosphate incurred the greatest degree of 
accumulation compared to either Ins (l, 4 , 5 or Ins IP.
The lag period before any accumulation of 1^ h3 Ins IP occurs 
may be partly explained by the prolonged accumulation of
Ins(l,4)P2» since, in addition to being formed from Ptdlns 
by the action of phospholipase C, Ins IP can also be
produced by the sequential hydrolysis of Ins(l,4,5)P2
Ins(l,4)P2 and hence to Ins IP. However these
results demonstrate that, like ADP, Thrombin is capable of 
inducing the rapid formation of \^H^ Ins(l,4,5)F^ and hence 
the metabolism of P t d l n s (4,5)P2* ^^an compared to ADP however, 
Thrombin appears less efficacious at stimulating the formation 
of inositol phosphates, since at the peak response for each 
of the phosphates measured, greater accumulation was observed 
when ADP was used as the agonist. The ability of Thrombin to 
induce the accumulation of inositol phosphates in RPM, in the 
absence of a well defined effect on the metabolism of Ptdlns(4,5)P. 
and accumulation of |^^p3 PtdA (Sections 3»2.4.2 and 3*2.4.3)
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indicates that monitoring the production of* inositol phosphates 
is a more sensitive technique by which to monitor agonist- 
induced metabolism of inositol phospholipids in RPM.
3*2.5 Thrombin-induced changes in cytosolic free calcium Cca^^
2+3*2.5*1 Effect of Thrombin on RPM cytosolic free calcium Ca ^
Having investigated the effects of Thrombin on inositol
phospholipid metabolism in RPM, I next investigated its effects
on changes in . Thrombin is a poor stimulatn of elevation
of in RPM (Figure 53)* The maximum elevation of
observed (using 500 nM Thrombin) was approximately 200 nM above
basal. Due to the high concentrations of thrombin required to
construct full concentrât!on-response curves — and the
prohibitively high cost of such experiments - only a partial
investigation into the effects of Thrombin on [ c a ^ i n  RPM
was viable. From the available data an estimated EC__ value50
2+ +for Thrombin-induced elevation in Ca  ^is I50 — 100 nM 
(n = 2-3) and like experiments using ADP as the agonist 
approximately 30-40^ change in  ^is due to mobilization
of intracellular calcium (results not shown). Thus Thrombin, 
while inducing the elevation of cytosolic free calcium, appears 
to be less efficacious at evoking the increase in 
RPM, as was the case with inositol phospholipid metabolism.
in
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Figure 53; Thrombin-induced elevation of cytosolic free calcium Cca^t] ^ in RPM
Aliquots (2 ml) of Quin 2-labelled RPM prepared as described (Section 
2:2;2:5) were ^ncubated with Thrombin at the concentrations indicated.
Changes in [Ca "*3. ware estimated from the observed changes in the dye 
fluorescence (Section 2:2:4). The responses shown above are from a 
single experiment representative of 2-3 others.
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DISCUSSION
An early but historically vexy intuitive hypothesis by
Michell (1973)» concerned the role of agonist-induced phospha-
tidylinositoi metabolism and resynthesis (the so-called "PI
cycle") as a common receptor—mediated event for Ca^* mobilization
in many tissues. This concept was later modified (Michell et al.,
1981) to include the possibility that metabolism of phospha-
tidylinositol-(4,3)-bisphosphate, rather than phosphatidylinositol,
was the primary receptor-linked event. The major characteristics
of this "Pl-response" include the rapid agonist-induced metabolism
of inositol phospholipids involving only those specific receptors
known to act predominantly through calcium mobilization and
occurring independently of extracellular calcium levels. In
addition, a close coupling between inositol phospholipid metabolisr
receptor occupation, mobilization of calcium and the physiological
response is often observed (Berridge, I98O; Michell and Kirk,
1981,• Michell et , I98I; Gill, I983). More definitive
evidence associating metabolism of inositol phospholipids and
subsequent changes in cytoplasmic calcium levels has been
reported by Berridge and colleagues (Berridge and Fain, 1979;
Fain and Berridge, 1979)* In blowfly salivary glands they
demonstrated that in the continuous presence of agonist, the
2+ability to mobilize Ca gradually decreased. Upon incubation
with inositol (and presumably subsequent inositol phospholipid
2+metabolism) the ability of agonist to induce Ca mobilization 
returned. In the present study as a preliminary to elucidating 
the mechanism(s) underlying stimulus-response coupling in both 
rat platelets and RPM, I decided to investigate the nature of
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inositol phospholipid metabolism and calcium mobilization in 
both cell types. Such an investigation was designed to elucidate 
firstly whether or not common transduction processes exist in 
each cell type; secondly, whether such processes were capable 
of being manipulated pharmacologically; and thirdly revealing 
whether or not the megakaryocyte could be a potential site for 
novel antithrombolic therapy.
4.1 Pharmacology
4.1.1 Metabolism of inositol phospholipids
From the results (Section 3) it is clear that in both rat 
platelets and RPM, both Thrombin and ADP receptors are coupled 
to the metabolism of inositol phospholipids; monitored in rat 
platelets, either as the accumulation of C?^p3 PtdA or dis­
appearance of Ü2^p3 P t d l n s ( 4 ,5)^2 in the RPM as the
accumulation of {^^P^ PtdA or 0 h3 inositol phosphates.
The time-courses of agonist-induced stimulation of 
^^p3 PtdA formation differed slightly between the two agonists 
and cell types. In rat platelets, ADP (Figure 10) attained its 
maximum stimulation within 10s, whereas using Ihrombin (Figure 
26) maximum stimulation was attained within 30s. The slower 
time to peak using Thrombin as the agonist may be explained 
by the fact that Thrombin evokes a response of greater magnitude 
than ADP. In RPM, both ADP (Figure 36) and Thrombin (Figure 50) 
attained maximal stimulation within 60s. The longer time to 
peak in RPM compared to rat platelets may reflect a difference 
in the balance of enzymes required for the metabolism of inositol 
phospholipids in each cell type. Additionally, it is possible
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that the tramsduction processes in RPM are not as fully 
developed compared to rat platelets. The observation that 
stimulated levels of PtdA sometimes remain elevated above
basal levels probably indicates some unique feature of that 
particular agonist in that particular cell type. When dis­
appearance of L ^ ^ P ^  P t d l n s (4j5 )?£ monitored; in rat platelets, 
a significant decrease is observed within 3s of agonist addition 
using either ADP (Figure 13) or Thrombin (Figure 30) confirming 
that, like so many other systems, in rat platelets, metabolism 
of P t d l n s (4,5 )?2 one of the first events occuring subsequent 
to agonist-receptor interaction. No significant change in 
levels of inositol phospholipids, including P t d l n s (4,3 ) F2* is 
observed in RPM when ADP (Table 3) or Thrombin (Table 4) is 
used. These results may suggest that metabolism of P t d l n s (4,5)^2 
is not one of the first events to occur soon after agonist- 
receptor interaction in RPM or that agonist-induced metabolism 
of P t d l n s (4,3 ) ^ 2  RFM triggers the metabolism of a small pool 
of P t d l n s (4,3)^2• which is rapidly replenished such that
no net decrease in levels of l^^P^ P t d l n s (4,3) P2 occurs. The 
significant accumulation of L^^p3 PtdA using ADP and Thrombin 
in these studies (Tables 3 and 4) suggests that metabolism of 
inositol phospholipids did occur and favours the latter suggestion. 
When accumulation of inositol phosphates were monitored in
RPM, both ADP (Figure 39) and Thrombin (Figure 3 2 ) elicited 
significant accumulation of Ins(l,4,3)P^ within 3s of
agonist addition. Assuming that P t d l n s (4,3 )P2 the sole source 
of Ins(1 ,4 ,3)P^ formation, this data would suggest that in RPM, 
exposed to either ADP or thrombin, metabolism of Ptdlns(4,3 )Pp
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is in fact one of the first events initiated as a consequence 
of receptor occupancy. The fact that appearance of Ins(l,4,3)P^ 
was observed, but not disappearance of PtdIns(4,3)P2* 
substantiates the claim made previously - that A D P  - and 
Thrombin—receptor occupation triggers the metabolism of a small 
pool of P t d l n s (4,3)P2 that is rapidly replenished - and suggests 
that, in RPM, monitoring accumulation of inositol phosphates 
may prove a more sensitive assay of inositol phospholipid 
metabolism rather than measuring the disappearance of Ptdlns(4,3)
^2-
The construction of concentration-response curves allows a 
comparison of the potency of agonist examined, as well as 
indicating their efficacy. In rat platelets, the calculated
indicate a rank order of potency of Thrombin » A D P  (Figures 
27 and ll). In addition, the maximum stimulation of PtdA 
formation evoked by Thrombin is far greater compared to that 
evoked by ADP. Hence, in rat platelets, it appears that Thrombin 
is by far more potent and efficacious compared to ADP. Similar 
studies performed in RPM suggest that ADP is more efficacious 
compared to Thrombin (Figures 37 and 31)• However, in RPM, 
the extent of PtdA formation evoked by each agonist is low 
and approximates the limits of sensitivity of the phospholipid 
assay. Consequently, interpretation of the data frequently 
is difficult.
Nevertheless, these results suggest that, like so many 
other cell types, the rapid metabolism of inositol phospholipids, 
in particular Ptdlns(4,3)P2> is one of the first events occurring
—  C. _J)U —
soon after agonist addition to either rat platelets or RPM 
(see Berridge, 1984). In rat platelets, at least, such rapid 
metabolism is contemporaneous with known platelet functional 
responses.
4.1.2 Changes in cytosolic free calcium [Ca^^^
Inherent in the hypothesis of the inositol phospholipid 
signal pathway being involved in cellular activation, is that 
the metabolism of inositol phospholipids somehow is coupled 
to changes in cytosolic free calcium. Changes in in
rat platelets and RPM were monitored using the fluorescent 
quinoline dye Quin 2. As in phospholipid studies, both ADP 
and Thrombin when added to samples of rat platelets or RPM, 
elicited in a concentration-dependent manner, the elevation of 
Ca^*  ^ (see Figures 15a,b; 32a,b; 40a,b; 53)«
In rat platelets (Figures 32b and 15b) the calculated EC^^ 
values indicate a rank order of potency of Thrombin »ADP with 
respect to elevation of . Additionally, maximal elevation
in Q)a^^^ above basal reflects a value of approximately 1200 nM 
when ADP is used as the agonist and approximately 4000 nM when 
Thrombin is used. Hence in rat platelets. Thrombin is more 
potent and efficacious compared to ADP. When similar studies 
are performed in RPM (Figures 40b and 53)> it appears that ADP 
is more efficacious compared to Thrombin. As with the analysis 
of Thrombin-induced metabolism of inositol phospholipids in RPM, 
large and prohibitively expensive amounts of Thrombin were 
necessary to perform these studies. Hence, as in the phospho­
lipid studies, no EC^^ values can be quoted for Thrombin-induced 
effects in RPM. Nevertheless, it appears that in both rat 
platelets and RPM, subsequent to the addition of ADP or Thrombin,
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a rapid and concentration—dependent elevation in [jCa^^ is 
observed. In rat platelets, at least, such rapid responses 
are contemporaneous with platelet functional, responses 
(aggregation)•
2+One prominent feature of the evoked Ca -signal, in both
cell types, is the rapid decline in fluorescence (and hence in
cytoplasmic free calcium concentration) towards basal values
once the maximal elevation of Q)a^^^ has been attained. The
decline is generally more rapid at higher agonist concentrations.
Although this probably represents a mechanism by which the cell
can limit its response after agonist addition, the exact
mechanism(s) underlying this effect is unknown. Nevertheless,
recent evidence suggests that the activation of protein kinase C -
by 1,2-diacylglycerol produced as a result of inositol phospho-
2+lipid metabolism - besides acting synergistically with Ca ions 
(Section 1.3*1*8*3) can actually exert a negative feedback role 
in agonist-induced Ca^^-mobilization (Dxnmmond, I985; Drummond 
and MacIntyre, I985; MacIntyre ejb al. , 1985a; MacIntyre ejk al. , 
1985b). In human platelets, MacIntyre ejfc al. (1985a) demonstrated 
that prior addition of active phorbol esters e.g. PMA, inhibited 
the platelet activating factor (PAP)-induced elevation in 
cytoplasmic free calcium. More importantly, addition of PMA 
at the peak of the response, accelerated the decline in Ca^*- 
signal generated by PAF. These results would tend to suggest 
a role for activated protein kinase C in the regulation of 
calcium homeostasis after agonist addition. Similar effects are 
obtained in GH^ cells (Drummond, I985). Indeed Drummond and 
MacIntyre (1985) have proposed that activated protein kinase C
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may serve as a bidirectional regulator of cellular function -
both stimulating and inhibiting cellular activation. Other
compounds such as membrane permeant derivatives of cyclic AMP
2+and cyclic GMP, when added at the peak of the Ca -si^al, 
are also known to rapidly reduce the Ca^^-signal in human 
platelets (MacIntyre e^ al. , 1985a; MacIntyre jet a^. , 1985b). 
However, no changes in levels of either cyclic AMP or cyclic 
GMP are detected following agonist addition (MacIntyre et al., 
1985a; MacIntyre _ejfc al. , 1985b) and hence presumably have little 
or no physiological role in calcium homeostasis.
Markedly different responses in agonist-induced changes 
in [ c a ^ ^ a r e  obsenrved in rat platelets and RPM when extra­
cellular Ca^* is removed from the suspension medium (Figures I6,
33 and 4l). In rat platelets, the complete abolition of the 
response to ADP and Thrombin is observed when extracellular Ca^* 
is removed. The simplest interpretation of this is that the
change in [ca^^^ observed after agonist addition, in rat
2+platelets, is entirely due to influx of extracellular Ca . An 
alternative explanation for this apparent dependency on extra­
cellular calcium however could be that (extracellular) calcium 
is required to fill a trigger pool of calcium which is released 
into the cytosol following agonist addition. Nevertheless, the 
results observed in rat platelets, in the absence of extra­
cellular calcium, are similar to those observed in human platelets 
where approximately 80-90^ of the observed increase in 
is due to influx, the remaining 10-20^^ derived via mobilization 
of Ca^* from (intra)-cellular compartments (MacIntyre ejfc al., 
1985c). In RPM a small, but reproducible, response is observed
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in the absence of extracellular Ca^*, indicating a small
degree of Ca^*—mobilization is involved in agonist—induced
elevation of . The reason for the differences in
requirement for extracellular Ca^* for agonist-induced response
between the two cell types is unknown. That the elevation of
[ca^t3  ^induced by ADP and Thrombin in rat platelets is lost
2+in the absence of extracellular Ca may suggest an obligatory 
requirement for an influx of calcium in the activation (e.g. 
metabolism of inositol phospholipids and ancillary sequelae) of 
rat platelets by these agonists. However, it has been demonstratec 
(Simon ejb al. , 1984) that metabolism of inositol phospholipids 
can occur at basal levels of [ca^^^.
The observed agonist-induced changes in and inositol
phospholipid metabolism in rat platelets and RPM exhibit many 
similarities with responses evoked by a variety of agonists in 
different cell types (see Berridge, 1984; MacIntyre et al.,
1985c) and suggests that the receptor-initiated transduction 
processes in both rat platelets and RPM involve the metabolism 
of inositol phospholipids and changes in Uca^^^.
The major defect in the use of RPM as a surrogate to probe 
receptor-mediated events (ergo inositol phospholipid metabolism 
and Ca^* flux) in megakaryocytes is the lack of a functional 
response to which the observed biochemical effects could be 
correlated. Although this is a disadvantage, it should be 
noted that a similar scenario pertains in rat brain slices, 
where, eilthough ndWcopious studies have been presented on the 
ability of various agonists to perturb the metabolism of 
inositol phospholipids (Jacobson et al., 1985; Batty et al.,
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1985) no functional correlate can be demonstrated in these 
preparations. The possibility of measuring heparin neutralising 
activity in RPM, as an index of functional responsiveness, 
was considered, however due to lack of time no studies were 
performed.
4.1.3 Specificity of agonist effects
One means of ensuring that stimulation of inositol 
phospholipid metabolism is a consequence of the specific 
interaction between an agonist and its specific receptors, and 
not just a non-specific effect occurring at the plasma membrane, 
would be to use selective receptor antagonists and demonstrate 
selective inhibition of agonist—induced phospholipid metabolism 
in the presence of these compounds. In the present study ADP 
and Thrombin were used to probe the transduction mechanisms 
in both rat platelets and RPM. Specific antagonists of the 
actions of ADP on human platelets e.g. 2 alkyl derivatives of 
AMP and ATP (Cusack _et al. , I985) are known. However, such 
compounds were not available in substantial quantities to allow 
a study of their suitability as antagonists at the ADP receptor 
on rat platelets or RPM. Another method by which one can 
inactivate or inhibit platelet reactivity is to increase 
cytosolic levels of cyclic AMP (see Section 1.3«1*2). This can 
be performed by using agents such as PGE^. Although levels of 
cytoplasmic cytoplasmic cyclic AMP were not measured in the 
present study, earlier studies have demonstrated PGE^-induced 
elevation of cyclic AMP in rat platelets (Michel _et al,t 1976). 
The effects of PGE^ on inositol phospholipid metabolism and 
changes in cytosolic free calcium in rat platelets induced by 
ADP and Thrombin are demonstrated in Figures 12, 17; 29 and 33*
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It is clear from these results that an increase in cytoplasmic 
levels of cyclic AMP is capable of inhibiting agonist-induced 
responses in rat platelets. Similar effects of PGE^ on ADP- 
induced metabolism of inositol phospholipids and changes in 
were observed in RPM (Figures 38 and 42). Again, 
levels of cyclic AMP in RPM subsequent to addition of PGE^ 
were not measured in the present study. However, preliminary 
experiments carried out in this department did demonstrate 
PGE^-induced elevation of cyclic AMP in RPM (MacIntyre e^jfc al. , 
1983a and Section 2.2.9)* la studies where Thrombin was used 
as the agonist, the effects of Hirudin were examined. Hirudin 
is known as a high affinity inhibitor of Thrombin and can inhibit 
both the stimulation of platelets by Thrombin and the binding 
of Thrombin to platelets (Detwiler and Feinman, 1973; Ganguly 
and Sonnichsen, 1976; Tam and Detwiler, 1978). Figures 28 and 
34 demonstrate that, in rat platelets, ^irudin is capable of 
reducing both the metabolism of inositol phospholipids and 
changes in [ca^f^^ induced by Thrombin.
Whilst these results demonstrate the reversal or inhibition 
of ADP- or Thrombin-induced metabolism of inositol phospholipids 
and changes in [Ca^t] in either cell type, conclusive proof 
of these effects being a receptor-mediated event await the 
development of specific receptor antagonists.
4.2 Classification of ADP receptor in rat platelets and RPM
Having established that the receptors recognizing ADP 
in both rat platelets and RPM, when activated, are coupled 
to the inositol phospholipid signal pathway (ergo metabolism
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of inositol phospholipids and sequelae of events including 
elevation of cytoplasmic free calcium), I next attempted to 
characterise the nature of this "ADP" receptor in both cell 
types. This study involved a comparison of the rank order of 
potency of a range of purines e.g. ATP, ADP, AMP and fl^enosine) 
on metabolism of inositol phospholipids (monitored as an 
accumulation of tp^pl PtdA) and elevation of cytoplasmic free 
calcium. From the results obtained it appears that the same 
rank order of potency (ADP > ATP »  AMP = Adenosine = O) is 
obtained regardless of the nature of experiment or the tissue 
used. This suggests that a similar type of receptor exists 
on both cell types. This receptor has been characterised 
initially as an "ADP" receptor, since ADP is a full agonist 
in RPM at eliciting formation of PtdA and elevating
cytoplasmic free calcium (Figures 43 and 45) whereas in rat 
platelets ADP is more potent compared to ATP, the latter 
acting as a partial agonist with respect to eliciting the 
formation of PtdA and elevating cytoplasmic free calcium
(Figures 18 and 20). These results would tend to suggest 
that perhaps a separate and distinct receptor exists on rat 
platelets and RPM for ADP. As the potency ratios for ADP- 
and ATP-induced inositol phospholipid metabolism:elevation of 
differ, in rat platelets, (Table 5) the possibility 
exists that both effects are not mediated by a single receptor 
and thus heterogeneity of purinoreceptors must be invoked.
In RPM it appears that only one "ADP" receptor exists, since 
the above mentioned ratio is the same irrespective of whether 
ADP or ATP is used as the agonist (Table 6). In view of the
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Table 5 : Comparison of potency (eC^q ) values for agonist-
induced PtdA formation and elevation of C.Ca^ 'G ^
in rat platelets.
EC50 (pM)
Agoni s t ATP ADP
Response
Formation
of D ^ pD PtdA 3* 8 - 1 . 0  0 * 9 - 0 . 2
Elevation of
[_Ca2+]^ 23.5 -  34. 0.7 - 0.2
Aliquots of CP p3 P. pre-labelled or Quin 2 labelled platelets 
prepared as described (Sections 2.2.1.2 and 2.2.1.3) were 
exposed to either ATP or ADP and the concentration-response 
relationship for both agonist induced formation of C32p3 PtdA 
and elevation in CCa^ 't) . was examined. From these curves the 
estimated EC _ values were calculated. The results represent 
the EC__ values (mean ± SEM, n = 2-6) obtained, using either 
ADP or ATP as the agonist, in such experiments.
v i ii/tûhd iZcdtok. oj
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Table 6; Comparison of potency (EC__) values for agonist-
T32 T ^induced pj ptdA formation and elevation of
[Ca^fl in RPM.
EC50 (MWO
Agoni s t ATP ADP
Response
Formation
of C32p3
PtdA 22 - 5.00 1.57 - 0.05
Elevation 
of [Ca^+.] 3*3 - 1.55 0.22 - 0.071"
Aliquots of L p3 P. prelabelled or Quin 2 labelled RPM 
prepared as described (Sections 2. 2. 2.3 2. 2. 2.5) were
exposed to either ATP or ADP and the concentration-response 
relationship for both agonist-induced formation of L32p] ptdA 
and elevation in CCa^tl . was examined. From these curves the 
EC_Q values for both agonists were estimated. The results 
represent the EC__ values (mean - SEM, n = 2-4) obtained, 
using either ADP or ATP as the agonist, in such experiments.
hêki/âiA
O^cL UAôhk7cfJf0L-J g f M
o ‘5
Pc6'O5X0Ol 5
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possibility that the response observed with ATP may be secondary 
to its conversion to ADP, or due to the presence of a 
contaminant in the ATP preparation used during the studies,
I decided to investigate the nature of the response obtained 
with ATP in greater detail, ^ere the responses observed with 
ATP were due to a contaminant, one may expect a "constant" 
level of contamination and hence any differences observed 
between ATP and ADP may be expected to be constant. Clearly 
from Figures 18, 20, 43 and 43 this is not the case and argues 
against contamination explaining the results obtained with ATP. 
Prior conversion of ATP to the di- and monophosphate compounds 
or Adenosine is a distinct possibility. However, studies 
investigating the nature of the ATP response in rat platelets 
were performed using washed platelets and, in studies with RPM, 
a balnanced salt solution was used to resuspend the cells, hence 
reducing the contribution of possible plasma/serum nucleotidase 
activity on nucleotides. The possibility of ectonucleotidases 
residing on the surface of these cells, capable of metabolising 
ATP remained a possibility. Hence, experiments were performed 
using the non-hydrolysable ATP analog ATP^S in an attempt to 
establish whether the observed response was due to ATP per se
or to the metabolites of ATP. Figures 19, 22, 44 and 4?
in the Results Section demonstrate that ATP^S, without exception,
is capable of inducing the formation of tP^P^ PtdA and elevating
cytoplasmic free calcium in both rat platelets and RPM. In
most experiments similar EC^^ values for both ATP and ADP were
reported. These results argue for a direct action of ATP on
receptors recognizing purines in rat platelets and RPM.
Additional evidence includes i) the observation that regardless
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of whether ADP, ATP or ATf^S was used, no lag period before 
the onset of agonist-induced response (at least with respect 
to changes in cytosolic free calcium) was observed. Figures 
15a, 23, 40a and 4%; ii) reference to Figures 24 and 49 
demonstrate a total lack of effect of AMP and Adenosine at 
eliciting elevation of cytoplasmic free calcium. If the 
response to ATP was due to its metabolites (ergo ADP, AMP and 
Adenosine) then one may expect to observe a greater response 
than is actually observed with AMP or Adenosine. Due to the 
lack of effect of exogenous AMP and Adenosine, if the response 
to ATP is in fact due to a metabolite, then the primary 
candidate would be ADP. Of course, the possibility that part 
of the response elicited by ATP being due to ATP metabolites - 
as observed in guinea pig atria and ileum by Moody ejfc al.
(1984) - cannot be ruled out and awaits further study. Nevertheles 
several workers have demonstrated the ability of ATP to elicit 
the formation of C?^p3 PtdA and elevate cytoplasmic free 
calcium in a variety of tissues including rat hepatocytes 
(Charest al. , 1985; Haynes al. , I985); arterial smooth 
muscle (Watts and Borovey, I983) and Ehrlich ascites tumor cells 
(Dubyak, I986) underscoring the ability of ATP to elicit 
direct effects independently of any subsequent conversion.
Studies by Agarwal ejfc al. (1980) suggested that ATP responses 
(aggregation) in rat platelets occurred as a result of its prior 
conversion to ADP. Clearly these results are at variance with 
those presented here and may be explained by methodological 
differences in experimental techniques employed in the respective 
studies. In conclusion, while attempting to classify the nature 
of the receptor(s) recognizing purines in both rat platelets 
and RPM, it appears that at least two of the four criteria used
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to characterise any given receptor has been satisfied (see 
Section 3.1.3), namely a demonstration of the structure activity 
relationship, for a range of purines, has been made for the 
* ADP * receptor and the nature of the transduction processes 
coupled to these receptors has been alluded to. Further 
investigations involving radioligand binding studies and the 
use of specific "ADP" receptor antagonists will aid in the 
further characterisation of the receptor(s) present on both 
cell types. Nevertheless, the available data suggests that 
there exists receptor(s) on both rat platelets and RPM which 
recognize both ADP and ATP. The data is inconsistent with other 
possible mechanisms, such as the membrane permeabilising effect 
of ATP known to occur at high ( ^  10 p,M) concentrations (G omperts, 
1983; Heppel ejfc ad., 1985). Of interest is the possibility that 
the receptor(s) recognizing purines on rat platelets may be 
different from those receptors recognizing purines on human 
platelets, since at these receptors, ADP is an agonist whereas 
ATP is an antagonist (Macfarlane and Mills, 1974). A recent 
review by Gordon (1986) has proposed the designation of P^^ for 
the receptor recognizing purines on human platelets (and 
megakaryocytes). Whether an additional subtype of receptor is 
now required to accommodate the present data awaits further 
study.
—  2 4 - 8  —
4*3 Correlation with metabolism of inositol phospholipids and 
elevation of Lca^tl^
The hypothesis presented by Michell (l975) stated that 
the metabolism of phosphatidylinositoi was somehow coupled to 
the increase in cytoplasmic free calcium. Although this 
hypothesis has been updated to incorporate new data, the nature 
of the link between the two events is still unknown. However, 
two pieces of evidence (albeit circumstantial) obtained from 
the present study suggest a correlation between the metabolism 
of inositol phospholipids and changes in cytosolic free calcium 
in both rat platelets and RPM. Firstly, the rank order of 
activity at eliciting elevation of Lca^'Q^^ is the same as that 
inducing the metabolism of inositol phospholipids (measured as 
accumulation of PtdA) whether ATP, ADP, AMP, Adenosine or 
Thrombin is used as the agonist. Secondly, a contemporaneous 
relationship exists between changes in PtdA and elevation of
in each cell type. Perhaps the most definitive evidence 
coupling these two events is the marked stiochiometry exhibited 
between receptor occupation, metabolism of inositol phospho­
lipids, changes in and the Ca^”*^-dependent physiological
response - a close correlation between the concentration- 
response curves for these events is suggestive that the same 
receptor is responsible for mediating all the above mentioned 
responses. However, a general feature of receptors which are 
coupled to the inositol phospholipid signalling system is that 
the agonist concentrations required to maximally activate 
inositol phospholipid metabolism (and Ins(l,3>5)P^ accumulation) 
are invariably higher than those required for maximal stimulation
o 1 2+
of Ca -mobilization and Ca -dependent cellular functions
— 24-9 ~
(Kirk ejk af. , I98I; Charest ejb a^. » I985; Lynch e_t al. , I985; 
Creba et al., 1983)* Using the formation of PtdA as an index 
of inositol phospholipid metabolism, such a discrepancy between 
agonist concentration inducing maximal elevation of j^Ca^^3^ and 
formation of PtdA is observed for Thrombin in rat platelets 
and ATP and ADP in RPM (Figures 34a,b). In rat platelets no 
such difference exists when ADP is used as the agonist. Such 
a phenomenon, whereby a discrepancy does exist in the agonist 
concentration-range over which maximum PtdA formation and 
elevation in  ^ occurs, may be explained by the concept
of receptor reserve (Michell e_fc al., I98I) whereby occupancy of 
a few receptors evokes maximal elevation of \jCa^^^ but only 
a small degree of inositol phospholipid metabolism. However, 
formation of PtdA occurs distal to receptor occupancy and is 
preceded by metabolism of Ptdlns(4,3)F2 accumulation of
Ins(1, 4 , 3 •  Perhaps a more valid correlation would be to 
compare the concentration-response curves for accumulation of 
Ins(l,4,3)P^ and elevation of When this is performed
in rat hepatocytes, using a range of agonists (Lynch ejfc al., 
1983)» a similar discrepancy between the concentration of agonist 
required to elicit maximal response for both effects is observed. 
Given these results, and the existence of spare receptors 
(receptor reserve) the present studies probably do reflect a 
receptor reserve for Thrombin, but not ADP, in rat platelets 
and for both ADP and ATP in RPM. However, further studies, 
most notably radioligand binding analysis would be required 
to substantiate this hypothesis in rat platelets and RPM.
When ATP is used as the agonist in rat platelets, the
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Figure 54a: Concentration-response relationship for agonist induced 
stimulation of PtdA formation and elevation of Cca
Aliquots of P. prelabelled or Quin 2 labelled platelets prepared
as described (Sections 2.2.1.2 and 2.2.1.3) were exposed to agonist at 
the concentrations indicated. L^^pl PtdA levels (O) were measured 30s 
after agonist addition and elevation of CCa^t]. (D  ) was calculated 
from the observed changes in dye fluorescence. Results are the cumulative 
data from 2-5 experiments. For ease of comparison, data are expressed 
as percentage of maximum response.
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Figure 54b : Concentration-response relationship for agonist induced 
stimulation of PtdA formation and elevation of Lca ..
Aliquots of L P-* p. prelabelled or Quin 2 labelled RPM prepared as 
described (Sections 2.2.2.3 and 2«2.2.5) were exposed to agonist at 
the concentrations indicated. L  P^ PtdA levels (O) were measured 60s
after agonist addition and elevation of ^ a  J .. (D ) was calculated
from the observed changes in dye fluorescence. Results are the cumulative 
data from 2-5 experiments. For ease'of comparison, data are expressed 
as percentage of maximum response.
 ^ appears
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concentration-response curve for elevation of
to lie to the right of that for PtdA formation. This is a
different phenomenon compared to that noted above and could
suggest that transduction processes other than inositol phospho-
2+lipid metabolism are involved in Ca -signalling. However,
the exact mechanism(s) underlying its manifestation are not known.
The major unanswered question in cells utilizing the inositol
phospholipid signal pathway still remains as to how metabolism
of inositol phospholipids is coupled to elevation of
Sources of Ca^^ used during cellular activation can be either
intracellular or extracellular in origin. The missing link
2+between mobilization of intracellular Ca and metabolism of 
inositol phospholipids appears to be the water soluble metabolite 
of Ptdlns(4,3)?2 metabolism, Ins(l, 4 , 3 Studies have shown 
its rapid formation subsequent to agonist addition, in a variety 
of different cell types including human platelets (Rittenhouse- 
Sasson, I983); hepatocytes (Thomas e_t ad., 1984) and GH^ 
clonal pituitary tumor cells (Drummond ejfc al., I983; see 
Berridge, 1984). It appears to bind to specific sites (receptors) 
(probably the endoplasmic reticulum or dense tubular system 
in platelets (Spat et al., I986). Moreover, it is capable of 
eliciting the release of Ca^ "*" from intracellular, non-mitochondria 
stores in various cell types (Streb ejfc aT., 1983; Burgess ^  al., 
1984; Joseph ^  , 1984; Gershengom ejb aT. , 1984; O'Rourke
et al., 1983; Authi and Crawford, 1983)» Studies to examine 
whether or not Ins(l,4,3)P^ is formed sufficiently rapidly 
in rat platelets following receptor occupancy by agonist to 
be utilized to mobilize intracellular calcium were hampered
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and effectively precluded by the fact that these platelets do
not appear to incorporate inositol to any great extent.
However, due to the fact that RPM are grown and maintained in
culture, it is feasible to label these cells with L^H^inositoi
over a period of days allowing it to incorporate into the
inositol phospholipid pool. The results presented here
demonstrate that upon exposure to ADP (Figure 39) or Thrombin
(Figure 52) RPM are capable of fonning significant amounts of
inositol triphosphate within 5s of agonist addition. This rapid
formation of inositol trisphosphate is consistent with an
action as a second messenger to mobilize intracellular calcium.
The exact isomeric form of inositol trisphosphate accumulated
in RPM was not determined. Irvine al. (1985) demonstrated
in rat parotid glands, that the 1,4,5-isomer was the predominant
species accumulating at early time points. Thereafter the
1>3>4-isomer of inositol trisphosphate accumulated. Given that
only the 1,4,5-isomer has definitively been demonstrated to
induce release of Ca^ "*” from intracellular stores (Streb et al. ,
1983; Irvine ejfc aJL. , 1984b; Burgess ^  al. , I985; Burgess e;t al. ,
1984a) the nature of the isomer of inositol trisphosphate
produced, in any system, is of utmost importance if one is to
correlate its appearance with Ca^^-mobilization from internal
stores. A possible additional source of intracellular calcium -
other than that mobilized from the endoplasmic reticulum/dense
tubular system - could be that associated with Ptdlns(4,5)P2*
2+ 2 +This inositol phospholipid is known to bind Ca and Mg with 
high affinity (Dawson and Hauser, I970) and it is possible that 
upon its metabolism it may release this bound Ca^* (Billah and
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Lapetina» I982). However» under normal conditions, the 
concentration of ion is thought to exceed that of the Ca^ "*"
ion by at least 1000 fold (see Downes and Michell, I982) 
suggesting that the Mg^* ion will bind preferentially^to Ptdlns 
(4, 5)^2* that P t d l n s  (4, 5)?2 not be a physiologically 
important source of Ca^’*’.
While there appears little doubt as to how metabolism of 
inositol phospholipids is coupled to the mobilization of intra­
cellular calcium, the method by which metabolism of inositol 
phospholipids is coupled to Ca^^-influx, in those cells 
predominantly using this source for cellular reactivity, is 
unknown. Extracellular calcium may enter cells through, at 
least, two types of calcium-channel, either voltage-operated or 
receptor-operated. Human platelets lack the former type of 
channel (MacIntyre and Rink, I982; Doyle and Rttegg, I983) and 
there is no reason to assume that rat platelets, possess them. 
Considering the receptor-operated Ca^* channels, the mechanism(s) 
governing its opening are unclear, however several hypotheses 
have been proposed (Berridge, I98O). For instance agonist- 
receptor interaction itself may perturb the plasma membrane 
opening a calcium channel; it is envisaged in this scenario 
that metabolism of inositol phospholipids could regulate the 
length of time the channel remains open. An alternative mechanism 
involves the proposed ionophoric properties of PtdA and its 
derivative lyso PtdA, both formed (rather indirectly) as a 
result of agonist-induced metabolism of inositol phospholipids. 
Both PtdA and LysoPtdA have been demonstrated to act as calcium 
ionophores (Putney ejt al. , I98O; Lapetina ejt al. , 1981a).
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However, the inability of PtdA to translocate Ca^* across
membranes of purified phosphatidylcholine vesicles (Holmes and
Yoss, 1983) suggested that it may not represent an important
mechanism for regulating Ca^*-fTux. Recently, Watson et al.
(1985) have proposed that, rather than acting as an intracellular
2+messenger in mediating the mobilization of Ca , LysoPtdA may 
act directly through cell surface, high affinity receptor sites, 
coupled directly or indirectly to mechanisms regulating Ca^*- 
influx. Other workers have proposed the existence of specific 
calcium channels in platelets (see Section 1*3»1*3) whether 
these channels are also regulated by the metabolism of inositol 
phospholipids is unknown.
Clearly there are many possible mechanisms of increasing 
levels of l ^ a ^ ^ i n  cells which act predominantly through the 
inositol phospholipid signal pathway. One recent report has 
added a further dimension to the role of inositol phospholipid 
metabolism in Ca^^-flux. Putney (1986) proposes, that besides 
mobilizing Ca^ "*" from intracellular stores, Ins(l,4,5)P^ may also
act at the plasma membrane to increase the permeability to
2+ 2+Ca and thus allow an influx of Ca into the cell. His
proposal, based on a "capacitance model" allows for both the
2+ 2+ mobilization of Ca from internal stores and Ca influx to
be governed by a single messenger, namely Ins(l,4,5)P^* Recently
several workers have demonstrated the existence of a higher
phosphorylated derivative of inositol phosphates, designated
Inositol (1, 3 > 4, 5)Pji^  (inositol tetrakisphosphate) (Batty al. ,
1985; Hansen ejk al. , I986; Heslop _et al. , I986; Michell, I986;
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Nahorski and Batty, I986). Whilst a biological/physiological 
role has yet to be attributed to Inositol(l, 3 > 4 , 3 Hansen 
et al. (1986) have suggested that it may also serve to integrate 
plasma membrane calcium fluxes with intracellular calcium 
mobilization.
4.4 Alternatives to inositol phospholipid metabolism in rat 
platelet/RPM activation
Having proposed that the inositol phospholipid signal
pathway operates in both rat platelets and RPM, it is important
to consider other possible mechanisms of activation in these
two cell types. Hirata and Axelrod (198O) proposed that the
méthylation of membrane phospholipids plays an important role
in receptor-mediated signal transduction in many cells. Platelets
contain the necessary enzymes required for the méthylation of
phosphatidylethanolamine to phosphatidylcholine (Shattel et al.,
1981). In the present study, no significant changes in either
[P^P^ Phosphatidylethanolamine or L^^p3 phosphatidylcholine
were recorded subsequent to agonist addition in either rat
platelets or RPM (results not shown). Additionally, other
workers have demonstrated that inhibitors of these enzymes
(e.g. methyltransferases and 3-adenosylhomocysteine hydrolase)
do not affect platelet activation (Hotchkiss et al., I98I;
Shattel ^  ^ . , 1982). It would thus appear that phospholipid
méthylation, while of possible importance in signal transduction
in other cell types, is of minor importance in rat platelets
and RPM. Although dogma suggests that inositol phospholipid
2+metabolism and Ca flux are intimately involved in platelet 
activation, it is still possible that other transduction
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mechanisms are involved in the sequence of events that link 
agonist—receptor interaction to cellular response (Huang and 
Detwiler, I986). Clearly further studies are necessary to 
evaluate the importance of these additional processes.
CONCLUDING REMARKS
The present study was undertaken to investigate the nature 
of. the transduction processes in both rat platelets and RPM cells 
From my results it appears that the inositol phospholipid 
signalling pathway (ergo agonist-induced metabolism of inositol 
phospholipids and the associated sequelae of events, including 
elevation of C^a^ "*[^ )^ operates in both cell types. Upon agonist 
addition it appears that ADP, ATP and Thrombin all are capable 
of eliciting inositol phospholipid metabolism and elevation of 
|ca^ "J^  ^ in both rat platelets and RPM, although in RPM Thrombin 
is very much less efficacious compared to the other agonists.
One possible explanation could be that, in RPM, receptors for 
Thrombin are poorly coupled to the transduction process. 
Additionally, given that the transit time from immature mega­
karyocytes to megakaryocytes capable of releasing platelets 
can be as short as 43 hours (Ebbe and Stohlman, I963) the full 
expression of various receptors, destined for platelets, may 
occur at different periods in megakaryocyte development. In 
which case one may suggest that receptors for Thrombin are 
expressed later in development compared to receptors for purines. 
Future studies, involving more differentiated stages of RPM 
development may resolve this proposition.
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Various workers, using mature megakaryocytes, have 
demonstrated, often to a striking degree, a similarity in the 
response obtained in these cells to known platelet agonists 
and those obtained in platelets using similar compounds (see 
Section 1.2.3)» Whilst the present studies have confirmed and 
extended this similarity between the two types of cell we must 
consider other possible effects of the agonists used in the 
present study whilst investigating the pharmacology of the RPM.
Such considerations extend to the possibility that, besides 
being agonists in platelets, the compounds used in the present 
study (e.g. Thrombin and purines) could possibly act as agents 
of cellular proliferation and growth in these immature cells.
The two major ionic events that contribute to the onset of 
proliferation are changes in the level of calcium and the 
activation of a neutral Na^/H^ exchange carrier (Durham and 
Walton, 1982; Moolenaar ejfc al., 19&3)» The methods by which 
metabolism of inositol phospholipids are coupled to elevation 
of [ca^^^ have already been alluded to. Phorbol esters, 
acting presumably through protein kinase C (See Section 1.3»1»8.3), 
have been demonstrated to increase cellular pH in Swiss 3T3 
cells (Burns and Rozengurt, I983) suggesting that 1,2-diacyl- 
glycerol^ produced from inositol phospholipid metabolism, may 
be responsible for activating the Na*/H^ carrier system involved 
in regulating cellular pH.Changes in inositol phospholipid 
metabolism have been described upon activation of a variety of 
cultured cells (Ristow ^  ad., I98O; Sawyer and Cohen, I98I; 
Habenicht ^  ^ . , I98I) by a variety of mitogens. Thus, whilst 
I have demonstrated the agonist-induced perturbation of the
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inositol phospholipid signal pathway in RPM, the consequence 
of such effects, in RPM, may be quite different to those in 
rat platelets and may actually involve the promotion of growth 
and proliferation of these cells. Unfortunately, microscopic 
examination of the RPM before and after agonist addition were 
beyond the scope of the present study. However, this is one 
particular area that would be of interest to investigate 
further.
An attempt was made to characterise the nature of the 
receptor recognizing ADP in both rat platelets and RPM. It 
appears that the results obtained from this study do not fulfil 
entirely, any of the established criteria for either a P^- or 
P^- purinoreceptor or their subtypes (see Section 3). This 
suggests that a new subtype of purinoreceptor may be required 
to designate the receptor recognizing ADP on each cell type. 
Clearly further studies, including an analysis of the ability/ 
inability of ATP to elicit the elevation of cyclic AMP and/or 
production of icosanoids (see Section 3) will aid in the 
further characterisation of these receptors.
The products resulting from the action of phospholipase C 
on inositol phospholipids have been demonstrated to an integral 
role in cellular reactivity in many cell types, including 
platelets, subsequent upon agonist addition. It is conceivable 
that selective inhibition of this enzyme may represent a means 
by which to inhibit cellular (platelet) reactivity. Clearly 
such agents, if they were to exert similar effects in the 
progenitor cell, would represent a novel addition to anti-
- 260 -
thrombotic therapy.
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